ES $ METHODS OF DIAGNOSIS OF CANCER AND METHODS FOR TRACING OVARIAN MODULATORS FIELD OF THE INVENTION The invention relates to the identification of expression profiles of nucleic acids and to acids and antibodies for them that are involved in cancer and to the use of These expression profiles and compositions in cancer prognosis and therapy The invention further relates to methods for identifying and utilizing objective agents that inhibit cancer. BACKGROUND OF THE INVENTION Ovarian cancer is the sixth most common cancer in counting percent of all female cancers occupies the fifth part of death in the American Cancer Society predicts that there will be approximately new cases of ovarian cancer in this country in the year and approximately women will die from it Because many ovarian cancers do not can be detected timely in your account by a disproportionate number of cancers being r Responsible for almost half of deaths from cancer of the genital tract more deaths than with any other cancer of the reproductive organs The majority of patients with ovarian cancer the form are asymptomatic in the disease in early stage and present with the disease in stage III or Its five-year survival is less than 25 per cent with a lower survival among women. The smaller part of the patients in whom the disease is discovered in the early stage have a five-year survival rate of 80 to 90 per See Parker and collaborators CA Cancer In the absence of a family history of cancer the risk of ovarian cancer in the lifetime is of The risk factors include familial cancer syndromes up to 82 percent at the age of 70 years in women with hereditary syndrome of family history of the percent in the life span without relatives of 5 percent with a relative of 7 percent with two relatives Kerlikowske et al. Obstet Gynecol age personal history of cancer or few or mature age in the first Without 95 percent of all ovarian cancers occur in women without factors The use of contraceptives and tubal sterilization reduce the risk of cancer Ovarian and collaborators Hankinson and JAMA collaborators without even the bilateral may not be completely effective in preventing cancer The ovarian cancer treatment consists largely of coforectomy therapy Although many ovarian cancer patients are indeed current therapies they can all induce serious side effects that decrease the quality of The decision on a particular course of treatment is usually based on a variety of parameters and prognostic markers and collaborators Pathol Hamilton and Piccart Ann Oncol including markers of genetic predisposition and 18 The identification of novel therapeutic targets and bookmarks Diagnosis is essential to improve the current treatment of cancer patients. Recent advances in molecular medicine have increased the interest in tumor-specific cell surface antigens that could serve as targets for different immunotherapeutic or small molecule strategies. The right antigens for the strategies should be expressed highly in cancer tissues and ideally not expressed in adult tissues. Sin can not tolerate expression in tissues that are dispensable for the. Examples of these antigens include and the antigen of humanized monoclonal antibodies directed to the are currently used for the treatment of breast cancer Ross and Fletcher Stem Cells Monoclonal antibodies are used in a way to effectively treat the non-Maloney lymphoma and collaborators Blood Leget and Oncol. Potential immunotherapeutic targets for cancer have been identified. d e these objectives is the epithelial mucin The MÜC1 is a protein present on the surface Apical epithelial cells are often overexpressed in cancer and typically exhibit a glycosylation pattern that results in an antigenic molecule and is in the first clinical studies as a goal of Gilewski et al. Cancer Scholl et al. The protein expressed by the tumor often dissociates in the one where it is detectable as the CA marker by Bon et al. Without many patients they have tumors that do not express or because it is clear that other targets need to be identified to manage localized disease and mutations in both BRCA1 and in BRCA2 are associated with increased cancer susceptibility Mutations in BRCA1 occur at approximately 5 percent confidence of 95 percent by 3 to 8 percent of women diagnosed with ovarian cancer before the age of 70 See Stratton and collaborators in the genetic carriers of the risk of developing ovarian cancer is of Seeing Easton and Elit Physician It has been reported that other markers such as are associated with cancer but are not absolute indicators of the Although approximately 85 percent of women with clinically apparent ovarian cancer have higher levels of also increases CA125 during the first trimester of during the in the presence of non-diseases and in cancers of others Although industry and academia have identified genetic sequences has not exerted an equal effort to identify the function of these sequences It is essential to elucidate a role for proteins and novel compounds in disease states for the identification of therapeutic targets and markers in order to improve the current treatment of cancer patients. In accordance with the present are provided molecular targets for therapeutic intervention in cancer of ovary and in others in the present methods are provided In addition there are provided methods that can be used to screen candidate bioactive agents for their ability to modulate cancer. SUMMARY OF THE INVENTION By the present invention it provides nucleotide sequences of genes that are increased and are reduced in cancer cells These genes are useful for purposes of and also as targets for screening therapeutic compounds that modulate cancer such as hormones or methods for detecting nucleic acids of the or their proteins can be used for many. example, the timely detection of cancers from monitoring and timely detection of recurrence following the monitoring of the response to the selection of patients for chemotherapy or for therapy by the selection of the determination of or response to the treatment of the tumors, primary or metastatic tumors and the timely detection of Precancerous Ions Other aspects of the invention will become apparent to the skilled person by means of the following description of the invention. In the present invention, it provides a method for detecting a transcription associated with ovarian cancer in a cell of one comprising the method of contacting a sample. of the patient with a polynucleotide that selectively hybridizes to a sequence at least 80 percent identical to a sequence as shown in Tables 1a. In one the present invention provides a method for determining the level of a transcription associated with cancer. The invention provides a method for detecting a transcription associated with ovarian cancer in a cell of one comprising the method of contacting a biological sample of the patient with a polynucleotide that selectively hybridizes to a sequence at least 80 percent identical to one sequence as shown in Tables 1 a In one the polynucleotide is selectively hybridized to a sequence at least 95 percent identical to a sequence as shown in Tables 1 a In a biological sample is a sample In another the biological sample comprises nucleic acids for example In a polynucleotide for example with a label In one the polynucleotide is immobilized on a surface In one the patient is undergoing a therapeutic regimen to treat cancer In another one is suspected that the patient has metastatic ovarian cancer In one the patient is a being In a the transcription associated with cancer of ovary is In one the method comprises the step of amplifying nucleic acids before the step of contacting the biological sample with the In another the present invention provides a method for monitoring the effectiveness of a therapeutic cancer treatment comprising the steps method provide a biological sample of a patient who is undergoing treatment and determine the level of a transcript associated with ovarian cancer in the sample by contacting the biological sample with a polynucleotide that selectively hybridizes to a sequence at least 80 percent identical to a sequence shown in Tables 1 to thus the efficacy of the a modality the patient has ovarian cancer In a modality the patient has a form of ovarian cancer resistant to In a the method further comprises the step comparing the level of transcription associated with cancer with a level of transcription associated with cancer of ovary in a biological sample of the patient sooner or earlier the treatment herein provides a method to evaluate the effect of a cancer candidate drug of which comprises administering the drug to one and removing a cell sample from the The expression profile of the method can also include comparing the expression profile with a profile of expression of an individual In one embodiment, this expression profile includes a gene from Tables 1 to. In one embodiment, the present invention provides a nucleic acid molecule which consists of a polynucleotide sequence as shown in Tables 1 through expression vector or cell comprises the nucleic acid In a present invention provides an isolated polypeptide that is encoded by a nucleic acid molecule having the polynucleotide sequence as shown in Tables 1 a In another the present invention provides an antibody that specifically binds to an isolated polypeptide that is encoded by a nucleic acid molecule having the polynucleotide sequence as shown in Tables 1 to. In one the antibody is conjugated to a component for example a one or a chemical label. the antibody is a fragment of In another the antibody is humanized In a the present invention provides a The method of detecting an ovarian cancer cell in a biological sample of a method comprising contacting the biological sample with an antibody as described in. In another embodiment, the present invention provides a method for detecting ovarian cancer-specific antibodies in a The method comprising contacting a biological sample of the patient with a polypeptide encoded by a nucleic acid comprising a sequence of Tables 1 to. In another the present invention provides a method for identifying a compound that modulates a polypeptide associated with cancer comprising the method steps contacting the compound with a cancer-associated polypeptide of the polypeptide being encoded by a polynucleotide that selectively hybridizes to a sequence at least 80 percent identical to a sequence as shown in Tables 1 a and determining the functional effect of the compound on the In the the functional effect is an effect an effect or an effect In a the polypeptide is expressed in a cell eukaryotic host or on a membrane In another the polypeptide is In one the functional effect is determined by measuring the binding of the ligand to In another the present invention provides a method to inhibit the proliferation of a cell associated with ovarian cancer to treat ovarian cancer in one the method comprises the step of administering to the subject a therapeutically effective amount of a compound identified as described in In one the compound is an In another the present invention provides a screening assay of which comprises the steps of administering a compound of test a mammal having cancer or a cellular sample isolated by comparing the level of genetic expression of a polynucleotide that selectively hybridizes to a sequence at least 80 percent identical to a sequence shown in Tables 1 to 26 in a cell or mammal with the level of genetic expression of the polynucleotide in a cellular sample or mammal Where a test compound that modulates the expression level of the polynucleotide is a candidate for the treatment of cancer In a the control is a mammal with ovarian cancer or a cell sample that has not been treated with the compound of another the control is a cell or mammal or is not tissue In a the test compound is administered in amounts or concentrations In another the test compound is administered during different periods of In another the comparison can be made after the addition or removal of the In one, the levels of a plurality of polynucleotides that selectively hybridize to a sequence at least 80 percent identical to a sequence as shown in Tables 1a with their respective levels in a cellular or mammalian sample are compared individually. one embodiment the plurality of polynucleotides is from three to ten In another the present invention provides a method for the treatment of a mammal having cancer of which comprises administering a compound identified by the assay described in the In another the present invention provides a pharmaceutical composition for the treatment of a mammal having cancer of the composition comprising a compound identified by the assay described in and a physiologically excipient In a the present invention provides a method for screening candidate drugs by providing a cell that expresses a gene that increases and decreases as in a cancer of a gene is selected from Tables 1 to it also includes adding a candidate drug to and determining the effect of the candidate drug on the expression of the profile gene. In one the method of screening candidate drugs includes comparing the level of expression in the absence of the drug with the level of expression in the presence of the drug where the concentration of the candidate drug can vary when it is and where the comparison can be made after the addition or removal of the drug In a modality the cell expresses at least two genes of the profile of the genes of the profile can show an increase or A method is also provided to evaluate the effect of a cancer candidate drug of which comprises administering the drug to a transgenic animal that expresses or overexpresses the cancer protein of or an animal lacking the cancer modulator protein of eg as a result of a deletion More herein a biochip comprising one or more nucleic acid segments of Tables 1 a is provided wherein the biochip comprises less than 1000 acid probes De at least two acid segments are included In a further manner at least three acid segments are included A method is provided to diagnose a disorder associated with cancer. The method involves determining the expression of a gene from Tables 1 to 26 in a first tissue type of a primer and compare the distribution with the expression of the gene from a second normal tissue type of the first individual or of a second individual no A difference in expression indicates that the first individual has a disorder associated with cancer In a modality the biochip also includes a polynucleotide sequence of a gene that does not increase or decrease in cancer. In one, a method is provided for screening a bioactive agent capable of interfering with the binding of a protein that modulates the cancer modulating ovarian cancer or a fragment of the and an antibody The method comprises combining an ovarian cancer modulator or a fragment of the a bioactive agent and an antibody that binds to that ovarian cancer modulating protein or an ovarian cancer modulator protein. fragment of the method The method further includes determining the binding of that ovarian cancer modulating protein or fragment thereof and said wherein there is a change in the an agent is identified as an agent of the interference agent can be an agonist or an agent inhibits cancer Also provided in the present methods to elicit an immune response in a In a method provided in The present invention comprises administering to a subject a composition comprising a cancer modulating protein of or a fragment of the In another the protein is encoded by a nucleic acid selected from those of Tables 1 to 3. of eliciting an immune response in a In a composition provided herein comprises a cancer modulator protein preferably encoded by a nucleic acid of Tables 1 to a fragment of the and a pharmaceutically carrier In another this composition comprises a nucleic acid comprising a sequence encoding a cancer modulator protein of preference selected from the nucleic acids of Tables 1a and a pharmaceutically acceptable carrier. Methods are also provided for neutralizing the effect of a cancer protein or a fragment of which comprises contacting a specific agent for said protein being present in a sufficient amount to effect the In another the protein is encoded by a nucleic acid selected from those of Tables 1 a In another aspect of the method is provided for the treatment of an individual for cancer In a the method comprises administering to this individual an inhibitor of a cancer modulating protein In another the method comprises administering to a patient having cancer an antibody to an ovarian cancer modulating protein conjugated to a fraction This therapeutic moiety can be a cytotoxic agent or a DETAILED OF THE INVENTION In accordance with the objects described The present invention provides novel methods for the evaluation of diagnosis and prognosis of ovarian cancer including ovarian cancer as well as methods for screening compositions that modulate cancer. Methods are also provided for the treatment of ovarian cancer and conditions for example carcinoma of the ovaries. ovarian epithelial carcinoma example serous tumors mucinous tumors and germ cell endometrioid tumors polyembryoma carcinoma breast tumor? and stromal tumors of tubal carcinoma of the fallopian tubes and peritoneal carcinoma Tables 1 to 26 provide UniGen cluster identification numbers for the nucleotide sequence of genes that exhibit increased or reduced expression in cancer samples from Las Tablas 1 to 26 also provide an exemplary access number that provides a nucleotide sequence that is part of the cluster. Definitions The term cancer or cancer associated with cancer refers to nucleic acid and polymorphic variants of polypeptides and homologues. have a nucleotide sequence having a nucleotide sequence identity greater than about 60 by a nucleotide sequence identity of 65 times 70 times 75 times 80 times 85 times 90 times, preferably 91 times 92 times 93 times 94 times 95 percent 96 by 97 by 98 by or 99 percent or preferably over a region of at least about 000 or more with a nucleotide sequence or associated with a gene from Tables 1 to are linked to for example polyclonal antibodies reproduced against an immunogen comprising a amino acid sequence encoded by a nucleotide sequence or associated with a gene of Tables 1a and conservatively modified variants of those specifically hybridized under constraining hybridization conditions to an acid sequence or to the complement of that of Tables 1a and conservatively modified variants of the or have an amino acid sequence that has an amino acid sequence identity of about 60 by an amino acid sequence identity of 65 by 70 by 75 by 80 by 85 by 90 by preferably 91 by 92 by 93 by 94 by 95 by 96 by 97 by 98 by or 99 percent or preferably over a region of at least about 000 or more with an amino acid sequence encoded by a nucleotide sequence or associated with a gene from Tables 1 to A A polynucleotide or polypeptide sequence is usually one but not limited to, for example, one example or another A cancer of and a cancer of include both the naturally occurring form and the recombinant. A protein or nucleic acid of ovarian cancer refers to a polypeptide or cancer polynucleotide sequence or a variant of which contains all the elements normally contained in one or more wild-type ovarian cancer polynucleotide or polypeptide sequences that are presented La may be before or after different stages of post-splicing or splicing including alternating splicing as used herein is a sample of tissue or biological fluid containing nucleic acids or polypeptides for example from a polynucleotide or transcription of cancer from these samples but not limited to tissue isolated from for example animals or for example mice and biological samples may also include sections such as biopsy samples and frozen sections taken for purposes. Biological samples also include explants and transformed primary cell cultures derived from tissues of a biological sample. obtains from an organism more preferably a such as a for example chimpanzee or a being for example a guinea pig or a son of a particular interest the cattle and the animals a sample means obtaining a biological sample for use in the methods described in This is most often It will be done by removing a sample of cells from one but can also be carried out by using previously isolated cells isolated by another in another for another or by carrying out the methods of the invention. In particular, those tissues having a history of treatment or results The terms or percentage in the context of two or more nucleic acid sequences refer to two or more sequences or subsequences that are the same or that have a specified percentage of amino acid or nucleotide residues that are the same identity of approximately 60 by preferably 70 by 75 by 80 by 85 by 90 by 91 by 92 by 93 by 94 by 95 by 96 by 97 by 98 by 99 percent or a higher identity on a region when compared and aligned for maximum correspondence on a comparison window or region measured using a BLAST or BLAST sequence comparison algorithm with the parameters s by default described further or by manual alignment and visual inspection by the website of o Then it is said that these sequences are This definition also refers or can be applied to the complement of a sequence The definition also includes sequences that have deletions as well as those that have as well as variants that are presented for example and variants made As described above, preferred algorithms can take into account the gaps and De exists identity over a region that is at least about 25 amino acids or nucleotides in or more preferably over a region that is 50 to 100 amino acids or the comparison of the normally one sequence acts as a sequence with which the sequences are compared When using a comparison algorithm the test and reference sequences are introduced in one the coordinates of subsequences are designated if it is and they are designated the parameters of the program of the algorithm of De can use the parameters of the program loves by or can designate parameters Then the sequence comparison algorithm calculates the percentage of sequence identity for the test sequences relative to the sequence based on the parameters of the One as used in the reference to a segment includes one of the number of contiguous positions selected from the group usually consisting of 20 to usually about 50 to about 200 more usually from about 100 to about where a sequence can be compared to a reference sequence of the same number of adjacent positions After the two sequences are optimally aligned the methods of alignment of sequences for comparison are well known in the optimal alignment of the sequences for comparison can be by means of the algorithm of local homology of and Waterman Adv by means of the algorithm of alignment of homologies of Needleman and Biol through the method search of similarities of Pearson and Lipman EUA by computerized these algorithms and TFASTA in the Genetics Software Genetics Computer 575 Science or by manual alignment and visual inspection by Ausubel and collaborators 1995 and Current Protocols in Molecular The preferred examples of the algorithms that are Suitable for determining the percentage of sequence identity and sequence similarity include the BLAST and BLAST algorithms which are described in Altschul et al. Acids and Altschul et al. and with the parameters described in the for determining the percentage of sequence identity for Nucleic acids and proteins in the software The software to perform BLAST analyzes is publicly available through the National Center for Biotechnology Information This algorithm involves first identifying pairs of high-scoring sequences by identifying short words of a length W in the sequence That match or satisfy any threshold score T of positive value by aligning with a word of the same length in a base sequence of T is referred to as the neighbor word score threshold and these initial neighbor word hits act as sows to initiate searches in order to find pairs of high-punctuation sequences longer than words. The word impacts extend in both directions along each sequence so that the alignment score can be increased. Cumulative scores are calculated by sequences of parameters M of reward for a pair of residuals that are always and N of punishment for residues that remain wrong always For the sequences of a scoring matrix is used to calculate the score The extension of the word impacts in each direction stops the cumulative alignment score falls out by the amount X from its maximum value the cumulative score reaches zero od due to the accumulation of one or more waste alignments The BLASTN program determines the sensitivity and speed of the BLASTN program uses as omissions a word length of an expectation and a comparison of both For the sequences of the program BLASTP uses as omissions a word length of 3 and an expectation of and the score matrix BLOSUM62 and Henikoff EÜA uses expectation alignments and a comparison of both The BLAST algorithm also performs a statistical analysis of the similarity between two sequences by Karlin and Altschul Nat EÜA A measure of similarity provided by the BLAST algorithm is the smallest sum probability that provides an indication of the probability by which a match would occur between two nucleotide or amino acid sequences by a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a compar The nucleic acid test with the reference nucleic acid is less than about 0 2 more preferably less than about 0 01 and most preferably less than about 0 001 The record values can be negative numbers by 5 10 20 30 40 40 70 90 110 150 170 An indication that two nucleic acid sequences or polypeptides are substantially is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the antibodies reproduced against the polypeptide encoded by the second acid as further described. a polypeptide is usually substantially identical to a second by when the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially that the two molecules or their complements join each other under conditions as described more yet another indication that two is nucleic acid sequences are substantially that the same primers can be used to amplify the sequences A is a cell that is presented or a transformed cell that contains an expression vector and supports the replication or expression of the vector of the host cells can be cells cells in and host cells can be prokaryotic cells such as from or eukaryotic cells such as de or such cells and the like by the American Type Culture catalog or website. The terms refer to material that is substantially or essentially free of components that normally accompany it as it is in its state Purity and homogeneity are usually determined using chemistry techniques such as gel electrophoresis or high liquid chromatography A protein or nucleic acid that is the predominant species present in a preparation is substantially In an acid n The isolated loop is separated from some open reading frames that naturally flank the gene and encode proteins other than the protein encoded by the term. The term in some embodiments denotes that a nucleic acid or protein gives rise to essentially one band on an electrophoretic gel. the nucleic acid or the protein is at least about 85 percent more preferably at least 95 percent and most preferably at least 99 percent or in other embodiments means removing at least one contaminant from the leaving composition In this the purification does not require that the purified compound be for example 100 percent The terms and are used interchangeably herein to refer to a polymer of amino acid residues The terms are applied to polymers of amino acids wherein one or more residues of amino acids is an artificial chemical mimic of an amino acid that s is present naturally as well as to amino acid polymers that are present those that contain amino acid residues and polymers that do not occur The term refers to naturally occurring amino acids and as well as to amino acid and amino acid analogues that function in a manner similar to the amino acids that occur. The naturally occurring amino acids are those that are encoded by the code as well as amino acids that are modified for example and amino acid analogs refer to compounds that have the same basic chemical structure as that of the amino acid that is presented by one that is linked to a group a group and a group sulfoxide These analogs can have modified R groups or peptide base structures but retain the same basic chemical structure as the amino acid that is presented as amino acids refer to chemical compounds that have a structure that is different from the general chemical structure of a but that works in a similar way to an amino acid that is presented The amino acids may be referred to herein by their three-letter symbols commonly or by the symbols of a letter recommended by the Nomenclature. Of the same the nucleotides may be referred by their commonly accepted single-letter codes applied to both the sequences of amino acids as well as nucleic acids With respect to nucleic acid sequences, conservatively modified variants refer to nucleic acids that encode identical or essentially identical amino acid sequences or where the nucleic acid does not encode a sequence up to essentially identical sequences or for example naturally Because of the degeneracy of the code a large number of functionally identical nucleic acids encode most of the codons and GCU encode the amino acid alanine At each position where an alanine is specified by a codon can be altered to another of the corresponding codons s described without altering the polypeptide These variations of nucleic acids are that they are a kind of variations conservatively Each nucleic acid sequence in the present that encodes a also describes the silent variations of the acid In certain each codon of a nucleic acid that is ordinarily the only codon for and that ordinarily is the only codon for can be modified to produce a molecule functionally According to what a silent variation of a nucleic acid encoding a polypeptide is implied in a sequence described with respect to the product of but not necessarily with respect to the probe sequences With respect to the sequences of an expert will recognize that the individual additions to an acid or sequence of which either delete a single amino acid or a small percentage of amino acids in the sequence are a conservatively wherein the alteration results in the substitution of an amino acid or with a chemically amino acid. Conservative substitution tables that provide functionally similar amino acids are well known in this. These conservatively modified variants are in addition and not the homologous variants and alleles of the typically conservative substitutions ones by Alanine Glycine Aspartic Acid Glutamic Acid Asparagine Glutamine Arginine Lysine Isoleucine Leucine Methionine Valine Phenylalanine Tyrosine Tryptophan Serine Txeonine and Cysteine Methionine by Creig ton Proteins Structures such as polypeptide structures can be described in terms of different levels of A general discussion of this by Alberts et al Molecular Biology of the Cell Garland Pub and Cantor and Schimmel Biophysical Chemistry Part The Conformation of Biological Macrornólecules refers to the amino acid sequence of a peptide refers to ordered three-dimensional structures within these structures. They are commonly referred to as domains. Domains are portions of a polypeptide that often form a compact unit and are typically from 25 to about 500 amino acids. Typical domains are formed from sections of an organization such as stretches of and refers to the complete three-dimensional structure of a polypeptide refers to the three-dimensional structure usually by association non-covalent of tertiary units Anisotropic terms are also known as terms of one or the grammatical equivalents used in the meaning of at least two nucleotides covalently linked to each other. Oligonucleotides are usually about 50 or more nucleotides up to about 100 nucleotides in nucleic acids and polynucleotides they are polymers of any including longer lengths. A nucleic acid of the present invention will generally contain linkages in some nucleic acid analogues which may have at least one linkage per u-linked Eckstein Oligonucleotide. is and? Practical Oxford University and base structures and nucleic acid linkages Other analog nucleic acids include those with base structures, non-base structures and base structures that are not including those described in U.S. Patents Numbers and and in Chapters 6 and 7 of Sanghvi and Cook in Antisense ASC Symposium Series Nucleic acids containing one or more carbocyclic sugars are also included within an acid definition Modifications of the base structure can be made by a variety of for example to increase the stability and half-life of these molecules in the environment or as probes on a One can make mixtures of naturally occurring nucleic acids and in a way one can make mixtures of different analogs of acids and mixtures of naturally occurring nucleic acids and analogs A variety of references give to know these acid analogs by and collaborate s Tetrahedron and references in the Letsinger Sprinzl and collaborators Letsinger and collaborators Acids Sawai and collaborators Letsinger and collaborators and Pauwels and collaborators Chemica Scripta phosphorothioate and collaborators Nucleic Acids and US Patent Number phosphorodithioate and collaborators Eckstein and Analogues links Practical Oxford and base structures and peptide nucleic acid linkages Meier et al. Engl Nielsen Carlsson et al. Nature each of which is incorporated as other nucleic acid analogs include those with positive base structures and non-ionic bases of the United States. North America Numbers and Kiedro shi and collaborators Letsinger and collaborators Jung and collaborators Nucleoside Nucleotide Chapters 2 and in Sanghvi and Cook Carbohydrate Modifications in Antisense ASC Symposium Series Mesmaeker and collaborators Bioorganic Medicinal Lett Jeffs and collaborator Biomolecular Tetrahedron 37 and base structures that are not including those described in the Patents of the United States of America Numbers y and in Chapters 6 and in Sanghvi and Carbohydrate Modifications in Antisense Symposium Series Nucleic acids containing one or more carbocyclic sugars are also include within a definition of nucleic acids Jenkins et al. Soc Rev pages Various nucleic acid analogs are described in June 2, CE News All of these references are expressly incorporated herein by reference Peptide nucleic acids are especially preferred which include Nucleic acid analogs These base structures are non-ionic conditions in contrast to the highly charged phosphodiester base structure of the nucleic acids that are presented. This results in two the base structure of the peptide nucleic acid exhibiting better kinetics of nucleic acids. Idicos have major changes in the melting temperature for pairs of mismatched bases against which they are perfectly The and the RNA normally exhibit a fall of a in the Tm for an evil With the base structure of the peptide nucleic acid the fall is not closer to in a way due to its nature not the Hybridization of the bases bound to these base structures is relatively insensitive to the concentration of nucleic acids in peptides are not degraded by enzymes and so can be more Nucleic acids can be single-stranded or double-stranded or can contain portions of bdouble-stranded and single-stranded sequence As will be appreciated by the experts in the single-chain illustration it also defines the sequence of the chain so the sequences described herein also provide the complement of the nucleic acid. be bgenomic or RNA or one in which the nucleic acid can contain combinations of and and combinations of including normally referred to A RNA that is presented for example as a nucleotide and nucleoside and nucleoside analogs and nucleosides such as nucleosides modified by En includes the analogous structures that are not presented by the individual units of a nucleic acid. each containing one are referred to herein as a "Una" or "a" is a composition detectable by immunochemical or photochemical spectroscopic means or r means. Useful labels include dense reagent dyes in enzymes as commonly used in a haptens or proteins and r entities that they can be made for example by incorporating a radiolabel into the peptide used to detect antibodies specifically reactive with the. The labels can be incorporated into the ovarian cancer acids and antibodies in any way. Any method known in the art can be used to conjugate the antibody with the including the methods d Written by Hunter and collaborators Nature 144 David and collaborators Biochemistry Pain and collaborators and and An oo is a molecule that is linked either in a way through a linker or a link or not through van der links or With an El it can be a variety of by fractions of including compounds an enzyme or signals such as signals of a fractions an agent or a radioisotope that emits radiation for example A nucleic acid or oligonucleotide is one that is either one way through a linker or a link or in a manner not through van der links or with one such that the presence of the probe can be detected by detecting the presence of the linked brand In a way the method that uses high affinity interactions can achieve the same where one of a pair of the binding components binds to the by streptavidin as it is used in the one nucleic acid is a nucleic acid capable of binding to a target nucleic acid of the complementary sequence through one or more types of bonds normally through complementary pairing of usually through the formation of link As used in the one probe can include natural bases or modified bases In the bases of a probe can be linked by a different link of a link provided that does not interfere with the So for the probes can be nucleic acids where the constituent bases are linked by peptide bonds instead of by phosphodiester bonds. The probes can be linked to objective sequences lacking complete complementarity with the sequence depending on the restriction of the conditions of the probes. Preferably they are marked for example with or are marked such as with biotin to which a streptavidin complex can subsequently be linked The presence or absence of the test can detect the presence or absence of sequence or subsequence Diagnosis or prognosis can be based on the level or level of expression of RNA or protein The term when used with either a or an acid or indicates that the acid or vector has been modified by introducing a nucleic acid or protein or altering a nucleic acid or protein or that the cell is derived from a cell so by recombinant cells express genes that are not within the native form of the or express native genes which otherwise are abnormally or totally not The nucleic term means in the present nucleic acid originally formed in in by the manipulation of the acid for example using polymerases and in a form that is not normally found in the This is achieved an operational link of sequences So a nucleic acid in a form or an expression vector formed in vitro ligand molecules that are not normally considered to be It is understood that once a recombinant nucleic acid is made and reintroduced into a cell or organism it will be replicated in a manner not by using the cellular machinery in vivo of the cell instead of in-cell manipulations. these acids once produced in a way although subsequently they are replicated in a manner not yet considered as recombinants for the purposes of the invention. In a manner it is a protein made using techniques is through the expression of a recombinant nucleic acid as illustrated The term when used with reference to portions of an acid indicates that the nucleic acid comprises two or more subsequences that are not normally found in the same relation to each other in the nucleic acid normally occurs in a manner having two or more by from unrelated genes configured to make a new nucleic acid by a promoter to pa One and one coding region from another In a way a heterologous protein will often refer to two or more subsequences that are not in the same relationship with each other in nature a protein of Un is defined as an arrangement of nucleic acid control sequences that direct the transcription of an acid As used in a promoter includes the necessary nucleic acid sequences near the start site of such in the case of a polymerase-type promoter an element A promoter also includes enhancer or repressor elements which can be localized to as many as several thousand base pairs from the start site of the A promoter is a promoter that is active under most environmental conditions and a promoter is a promoter that is active under environmental regulation or The term refers to a functional link between a nucleic acid expression control sequence as a or a arrangement of factor binding sites and a second acid sequence for example wherein the expression control sequence directs the transcription of the nucleic acid corresponding to the second one is an acid construct generated in a manner or with a series of specified nucleic acid elements that allow the transcription of a particular nucleic acid in a cell The expression vector may be part of an acid fragment or the expression vector includes a nucleic acid to be transcribed operably linked to a The phrase refers to the or hybridization of a molecule with only a particular nucleotide sequence under constraining hybridization conditions when that sequence is present in a complex mixture of RNA or total cellular DNA or of the hybridization phrase refers to the conditions under which a probe will hybridize to its Subsequence normally in a complex mixture of acids but not other Restricting conditions depend on it and will be different in circumstances Longer sequences hybridize specifically at higher temperatures. An extensive guide to nucleic acid hybridization is found in Tijssen Hybridization with Nucleic Probes Techniques in Biochemistry and Molecular Biology in terms of restricting conditions. they select from approximately to lower than the thermal melting point for the specific sequence at a pH of ionic concentration. The temperature is the concentration and nucleic concentration at which 50 percent of the probes complementary to the objective hybridize to the objective sequence. in equilibrium to that the objective sequences are present in the 50 percent of the probes are occupied in The restricting conditions will be those where the concentration of salt is less than about M ion of normally a concentration of about a ion of other sodium at a pH of a and temperature is at least about 30 for short probes from 10 to 50 and from at least about 60 for long probes over 50 Restricting conditions can also be achieved with the addition of agents such as For selective hybridization or a positive signal It is typically at least twice that of preferably 10 times the hybridization of The exemplary restriction hybridization conditions can be as formamide 50 by 5x and SDS by 1 by incubation at 42 or 5x SDS 1 by incubation with with washing in and SDS per cent to 65 For the chain reaction of the typical one is a temperature of approximately for the amplification to low although the temperatures of tempering can vary between approximately and 48 depending on the length of For the amplification with chain reaction of the polymerase of high a temperature of about 62 is typical, although the high-resilience tempering temperatures can be approximately at about 65 depending on the length of the primer and the typical cycle conditions for both high and low restraint amplifications include a denaturation phase of a for 30 to 120 a tempering phase lasting from 30 to 120 and a extension phase at approximately 72 during 1 to 2 Protocols and guidelines for low and high restriction amplification reactions are in Innis et al. PCR A Guide to Methods and Academic Nucleic acids that do not hybridize to each other under restrictive conditions they are still substantially identical if the polypeptides they encode are substantially This by when a copy of a nucleic acid is created using the maximum codon degeneracy allowed by the code In such nucleic acids typically hybridize under moderately restrictive hybridization conditions The hybridization moderately for example include a hibr In a regulator of 40 by 1 NaCl 1 SDS at 1 percent and a wash in IX SSC a A positive hybridization is at least twice as much Alternative hybridization and washing conditions can be used to provide restrictive conditions Additional guidelines to determine Hybridization parameters are set forth in Ausubel et al. 1001 and Current Protocols in Molecular Biology Lippincott The phrase in the context of assays to test compounds that modulate the activity of an ovarian cancer protein includes the determination of a parameter that is indirectly or directly under the influence of the cancer nucleic acid or protein of for example an effect or such as the ability to diminish the cancer of the cell growth binding activity on agar dependence of contact inhibition? limitation of proliferation density transformation growth factor dependence or specific marker levels of invasiveness in Matrigel tumor growth and metastasis in my protein expression in suffering cells and other characteristics of cancer cells include in vi in and ex activities of the effect means testing a compound that increases or decreases a parameter that is indirectly or directly under the influence of A cancer protein sequence of for example the effects and These functional effects can be measured by any means known to those skilled in the art for example changes in the spectroscopic characteristics index of the chromatographic or hydrodynamic properties of solubility for the measurement of the inducible markers or transcriptional activation of the cancer protein measuring binding activity or assays for eg binding with antibodies or others and measuring proliferation The determination of the functional effect of a compound on ovarian cancer can also be carry out using ovarian cancer trials They are known by the experts in this such as assays for eg cell growth on agar dependence of contact inhibition and limitation of proliferation density transformation, growth factor dependence or specific marker levels of invasiveness in tumor growth and metastasis in expression of MRNA and protein in the suffering cells and other characteristics of cancer cells The functional effects can be evaluated by means known to those skilled in the art for example microscopy to determine the quantitative or qualitative measurements of the alterations in the characteristics changes in RNA or protein levels for cancer-associated sequences measuring the stability of or identification of downstream expression or the reporter gene and for example by colorimetric reactions marker binding and binding and sequence assays of polynucleot two and cancer polypeptides are used to refer to the identified molecules or compounds or modulators using in vitro and in vivo assays of the polynucleotide and cancer polypeptide sequences of the inhibitors are composed by binds partially or totally block the delay or They decrease the activity or expression of cancer proteins for example. Nucleic acids or inhibitors can inhibit the expression and subsequent function of the proteins. The compounds that improve or increase the activity of the cancer protein or modulators also include genetically modified versions of the cancer proteins of for example the versions with an activity as well as the naturally occurring ligands and chemical molecules and the assays for inhibitors and activators by the expression of the ovarian cancer protein in or in membranes the application of modulating compounds and then the determination of functional effects on how it is described Activators and inhibitors of ovarian cancer can also be identified by incubating ovarian cancer cells with the compound of and determining the increases or decreases in the expression of one or more proteins of cancer of for example 50 or more cancer proteins such as the ovarian cancer proteins encoded by the sequences stipulated in Tables 1 to The samples or assays comprising the ovarian cancer proteins that are treated with a modulator or They compare with the control samples without the or to examine the degree of A the control samples treated with are assigned a relative protein activity value of 100 per The inhibition of a polypeptide is achieved when the activity value in relation to the control is about 80 by preferably 50 by more preferably 25 percent or activation of a polypeptide of ovarian cancer is achieved when the activity value in relation to the control treated with is of 110 by more preferably 150 by and in a most preferable way from 200 to 500 percent by 2 to 5 times higher in relation to and most preferably from percent to more The phrase in growth refers to a change in the characteristics of cell growth and proliferation in vitro or in for example the viability formation of growth independence in semisolid agar or changes in the contact inhibition and in the limitation of the density of the growth factor loss or of the changes requirements in the morphology gain or loss of gain or loss of specific markers of the ability to form or suppress tumors when injected into host animals immortalization of the per pages in Freshney Culture of Animal Cells? Manual of Basic refers to precancerous and normal cells in one of or in a culture of refers to spontaneous or induced phenotypic changes that do not necessarily involve the recovery of the new material Although the transformation can occur by infection with a transforming virus and the Incorporation of a new DNA or DNA recovery can also occur spontaneously or immediately after exposure to a mutant in this way a gene Trans ormation is typically associated with changes such as immortalization of growth control changes not See Freshney Culture of Animal refers to a polypeptide that comprises a region of structure from an immunoglobulin gene or fragments of which it specifically binds and recognizes an immunoglobulin recognized genes include the genes of constant region and as well as the myriads of genes of variable region of light chains are classified either as the kappa or heavy chains are classified as or that in turn define the classes of e the antigen binding region of an antibody or its equivalent will be the most critical in specificity and affinity of by Paul Fundamental Immunology A structural unit of immunoglobulin example comprises a tetramer Each tetramer is composed of two identical pairs of chains each pair having a chain approximately 25 and a chain approximately 50 to 70 The term N of each chain defines a variable region of approximately 100 to 110 or more amino acids responsible for the The terms light and heavy refer to these light chains and antibodies as globulins or as a number of well-characterized fragments produced by digestion with different Pepsin by digests an antibody below the disulfide bonds in the joint region to produce a Fab dimer that in itself is a united light chain a by a bond of El 2 can be reduced under mild conditions to break the disulfide bond in the region thereby converting the dimer into a monomer The monomer is essentially Fab with part of the region of See Paul Fundamental Raven Although they are defined different fragments of antibodies in terms of the digestion of an antibody an expert will appreciate that these fragments can be synthesized from either or by using recombinant DNA methodology. By the term as used in the also includes antibody fragments either produced by modifying antibodies or those synthesized de novo using single-Fv recombinant DNA methodologies or those identified using display libraries by McCafferty et al. Nature 348 For the preparation of for example antibodies or polyclonal antibodies many known techniques can be used in this by Kohler and Milstein Nature Kozbor yc Today Colé collaborators and pages in Reisfeld and Sell Monoclonal Antibodies and Cancer Coligan Current Protocols in Harlow and Lane A Laboratory CSH and Goding Monoclonal Antibodies Principles and Practice The techniques for the production of single-chain antibodies of the United States of America Number can be adapted to produce antibodies to the polypeptides of this One can use transgenic or other mice for example others to express antibodies In a way you can use phage display technology to identify antibodies and heteromeric Fab fragments which are specifically linked to antigens by McCafferty et al. Nature et al. Biotechnology Un is an antibody molecule in which the region or a portion of it is or such that the antigen binding site is linked to a constant region of a function a different species or an entirely different molecule that confers new properties to the antibody for example a factor of the region or a portion of it or is exchanged with a variable region having a different antigen specificity or identification of sequences associated with ovarian cancer a are determined l The expression levels of genes in different patient samples for which information is desired in order to provide the profiles of an expression profile of a particular sample is essentially a wprinting of the state of the patient although two states may have any Particular gene similarly the evaluation of a number of genes allows the generation of a profile of gene expression that is characteristic of the state of the normal or ovarian tissue or other tissue can be distinguished from the metastatic or cancerous tissue of the o can be compared Ovarian cancer or metastatic cancer tissue from with samples of ovarian tissue and other tissues from surviving patients By comparing tissue expression profiles in different ovarian cancer states information is obtained regarding which genes are important both the increase as the reduction in each of these The molecular profiling can distinguish subtypes of a disease designation currently eg different forms of The identification of sequences that are differentially expressed in ovarian cancer tissue versus non-cancer tissue allows this information to be used in a Por number can be evaluated a regimen of treatment a drug acts to reduce the cancer of and therefore the growth or recurrence of in a patient In a way the existing treatment induces the expression of a In a way the diagnosis and the results of the treatment can be done or confirmed by comparing samples of patients with expression profiles The tissue can also be analyzed to determine the stage of ovarian cancer in the origin or of the tumor. These gene expression profiles allow genes to be screened for candidate drugs in order to imitate or alter an expression profile by itself. can do screening for drugs that suppress the E cancer expression profile This can be done by making biochips that comprise sets of ovarian cancer genes which can then be used in these. These methods can also be based on the evaluation of the expression of the ovarian cancer. Ovarian cancer for diagnostic purposes or to track agents In nucleic acid sequences of ovarian cancer can be administered for therapy purposes including the administration of nucleic acids or ovarian cancer proteins can be administered antibodies and other modulators of ovarian cancer As drugs, the present invention provides nucleic acid and protein sequences that are differentially expressed in cancer in relation to normal tissue tissues not referred to herein as "cancer" as described further. Ovarian cancer sequences include those that increase they are expressed at a higher level in the the same as those that are reduced that are expressed in a more level In a modality the sequences of ovarian cancer are from beings without as will be appreciated by experts in the ovarian cancer sequences of other organisms may be useful in animal models of the disease and in the evaluation of other ovarian cancer sequences are provided including including rodents guinea pigs of farm animals and pets Cancer sequences of for example the genes of others can be obtained using the techniques described followed both nucleic acid sequences and nucleic acid sequences of ovarian cancer are useful in a variety of including applications of which will detect the nucleic acids that are presented. Applications are also provided by biochips comprising nucleic acid probes or chain reaction microtitre plates with selected probes for cancer sequences. Ovarian cancer can be initially identified by ho Substantial mology of the nucleic acid sequence of amino acids with the ovarian cancer sequences described in this homology can be based on the nucleic acid or amino acid sequence and is generally determined as illustrated further using either homology or homology programs. Good conditions of To identify the sequences associated with cancer of the ovarian cancer screening normally includes comparing the genes identified in different eg normal tissues and / or tumor tissue samples from patients having metastatic disease against non-tissue tissue. Other suitable tissue comparisons include comparing ovarian cancer samples with other cancer metastatic cancer samples Samples of different stages of cancer of eg tissue resistant states and tissue suffers are applied to biochips that comprise acid probes First those microbes are dissected and try for the preparation of The bio Suitable chips are commercially for example in Gene expression profiles are generated as described in and analyzed in In the genes that show changes in the expression between the normal and compared states with the genes expressed in other tissues preferably ovarian but also and not limiting bowel intestine In a modality the genes identified during the ovarian cancer screening that are expressed in any significant amount in others are removed from the profile although in some modalities the expression in others can be tolerated. It is when they are tracked normally it is It is preferable that the objective be specific to minimize possible side effects due to the interaction with the target present in others. In one modality, the ovarian cancer sequences are those that increase in cancer, the expression of these genes is higher in the ovarian cancer tissue compared to tissue not as used in the co n frequency means a change from at least about the one preferably a change from at least about the preferred one to at least about the quintuple or more. Other modalities refer to sequences increased under non-malign conditions in relation to the UniGen cluster identification numbers and the access numbers in the refer to the sequence database and the sequences of the access numbers are expressly incorporated herein as GenBank is known in the by Benson et al. Acids http nih There are also sequences available in other databases for example European Molecular Biology Laboratory and DNA Datábase of Japan In some the sequences can be derived from the assembly of the sequences or can be predicted from the genomic DNA using prediction algorithms such as Ver and Solovyev Res In others the sequences have been derived from the cloning and sequencing of nucleic acids icos isolates In another modality the ovarian cancer sequences are those that are reduced in cancer is the expression of these genes is lower in the ovarian cancer tissue compared with the tissue not as used in the frequently means a change of at least approximately the one of preference a change of when less about the preferred at least about fivefold or higher Computing The ability to identify genes that are or in cancer can additionally provide high resolution and high data sets which can be used in the areas of structure development development of and other areas Expression profiles can be used in the diagnostic or prognostic evaluation of cancer patients Subcellular toxicological information can be generated to better direct the structure and activity correlation of the Anderson drug of June and document presented at the conference or on a biological sensing device co to predict the possible toxicological effect of the exposures and the possible tolerable exposure thresholds Patent of the United States of America Number Similar advantages of the relevant data sets are presented for other biomolecules and acid bioactive agents and the like. The invention provides a database that includes at least one data set of the data contained in the database by using analysis either individually or in a database format. The database may be in a form that can be maintain and transmit but preferably it is a database and can be maintained on any electronic device that allows storage and access to the base of such a computer but is preferably distributed in an area network such as the World Wide The approach of the present section on the databases that include data of peptide sequences is for greater It will be apparent to those skilled in the art that similar databases can be assembled for any test data acquired using an assay of the compositions and methods to identify quantify the absolute relative abundance of a variety of molecular species and from a biological sample that suffers from cancer by identifying sequences associated with ovarian cancer described in the provide an abundance of that can be correlated with the conditions the predisposition to the test of monitoring the causal links of disease the identification of correlations of immunity and state between Although the data generated from the assays of the invention are suitable for review and analysis in a modality a data processing using high-level computers is used. In the art a set of methods for indexing and retrieving information is known. The Patents of the E United States of America Numbers 659 and disclose a relationship database system for storing information from biomolecular sequences in a manner that allows sequences to be cataloged and searched according to one or more hierarchies of functions of the patent. The United States of America Number discloses a relationship database that has sequence records containing information in a format that allows a collection of partial length DNA sequences to be cataloged and searched in accordance with the association with one or more projects to obtain full-length sequences from the collection of length sequences The United States Patent Number discloses a gene database retrieval system for making a recovery from a similar genetic sequence to a set of sequence data in a gene database based on the degree of similarity between a key sequence and a sequence The United States Patent of North America Number discloses a method that uses peptide fragmentation patterns by mass spectroscopy to identify amino acid sequences in databases by comparing predicted mass spectra with mass spectra using a measure of proximity to the Patent of the United States of North America Number discloses a multidimensional database comprising a functionality for multidimensional data analysis described as online analytical processing involving the consolidation of projected and real data according to more than one path or dimension The United States Patent Number reports a hybrid database structure in which the fields of each database record are divided into two navigation data and with the navigation fields stored in a topological hierarchical map which can be seen as a structure of or as The fusion of two or more of these tree structures The fundamentals of bioinformatics are in Mount and collaborators Bioinformatics Sequence and CSH Durbin and collaborators Biological Sequence Probabilistic Models of Proteins and Nucleic Acids Cambridge Baxevanis and Oeullette Bioinformatics A Practical Guide to the Analysis of Genes and Proteins Rashidi and Buehler Bioinformatics Basic Applications in Biological Science and Medicine CRC Setubal and collaborators Introduction to Computational Molecular Biology Misener and Bioinformatics Methods and Protocols Humana Higgins and Taylor Bioinformatics and Databanks A Practical Approach Oxford Brown Bioinformatics A Guide to Biocomputing and Internet Eaton Han and Kamber Data Concepts and Introduction to Computational and Hall The present invention provides a computer database comprising a computer and software for in a form recoverable by test data records tabulated by data specifying the source of the sample containing the objective from which each record of specificity was obtained In a modality of at least one of the sources of the sample containing the objective is from a sample of control tissue that is know that it is free from disorders In at least one of the sources is a sample of pathological tissue such as a neoplastic lesion or other tissue sample that is to be analyzed to determine cancer In another the test records cross tabulate one or more of the following parameters for each objective species in a unique identification code that can by an objective molecular structure a separation coordinate characteristic electrophoretic position coordinates or the source of the and the relative absolute quantity of the objective species present in the invention it also provides storage and retrieval of a collection of objective data in a device from a Storage of data that can include disk disks DDR disks bubble memory devices and other storage devices including logs in and storage arrays of data in the target data records are stored as a bit pattern in an array of magnetic domains in a medium or as an array of load states or gate states of such as an array of cells in a DRAM device with each cell comprised of a transistor and a storage area of which it may be in the one in which the invention provides these devices and computer systems integrated with the comprising a bit pattern encoding a protein expression fingerprint print record comprising unique identifiers for at least 10 objective data records cross-tabulated with the source When the target is a peptide or an acid the invention preferably provides a method to identify sequences of peptides or nucleic acids which comprises perform a computerized comparison between a stored or retrieved nucleic acid or peptide sequence test record a computer storage device or base from and at least one other comparison may include an analysis of or an algorithm of or a computer program mode of the same the comparison can be of the relative amount of a peptide or nucleic acid sequence in a group of sequences determined from a sample of polypeptide or nucleic acid of a The invention also preferably provides a disc such as a unit of hard disk or hard disk compatible with IBM Windows or another SCO format which comprises a bit pattern that encodes data from an assay of the invention in a suitable file format to be retrieved and processed in a method of or relative quantization of The invention also provides one which comprises a plurality of devices for linked computing by means of a link such as an Ethernet cable or line fiber network or other means of signal transmission whereby at least one device in the network unit comprises a pattern of magnetic domains disk load domains an array of cells that compose a bit pattern that encodes the data acquired from a test of the invention The invention also provides a method for transmitting data of which includes generating an electronic signal in a communication device such as a switch terminal adapter or wherein the signal includes the native format or a bit pattern encoding data from a database comprising one of the test results obtained by the method of the invention. In one embodiment, the invention provides a computer system for comparing a research objective with a database that contains an array of structures such as a test result or obtained by the method of and classifying the objectives of the database based on the degree of identity and weight of gaps with the data Preferably a central processor is initialized to load and run the computer program for alignment comparison of the results The data is entered for a target investigated in the central processor by means of a device The execution of the computer program results in the central processor retrieving the test data from the file comprising a binary description of a result The objective data or the record and the computer program can be transferred to the memory which is usually a random access memory or the objectives are classified according to the degree of correspondence between a test feature selected link with an affinity fraction and the same characteristic of the objective and the results are produced by means of Or a device from a central processor can be a conventional Intel MIPS MIPS computer a program can be a package of commercial or public domain molecular biology software ÜWGCG Sequence Analysis a data file can be an optical disk or a server of a memory device memory memory a device can be a terminal comprising a video display and a a terminal adapter a port a card reader a tape reader or another device The invention also preferably provides the use of a system by which typically one or more comprises a stored bit pattern encoding a collection of peptide sequence specificity records obtained by the methods of which it may be stored in a target such as a target and a program for alignment and normally with classified sorting of the results of the comparison based on value of calculated similarities Characteristics of proteins associated with ovarian cancer The ovarian cancer proteins of the present invention can be categorized as proteins or intracellular proteins In an ovarian cancer protein is an intracellular protein Intracellular proteins can be found in the cytoplasm in the intracellular proteins are involved in all aspects of cellular function and replication by pathways of aberrant expression of these proteins frequently results in unregulated or poorly regulated cellular processes by Alberts and collaborators Molecular Biology of the Cell By many intracellular proteins have activity such as activity phosphatase activity kinase activity activity and activity cyclases kinase intracellular proteins also serve as platform proteins that are involved in the organization of complexes or in the direction of proteins to different subcellular locations and are with Recurrence involved in the maintenance of the structural integrity of the organelles A concept increasingly appreciated in the characterization of is the presence in the proteins of one or more structural arrangements for which defined functions have been attributed In addition to the highly conserved sequences found In the enzymatic domain we have identified highly conserved sequences in proteins that are involved in the interaction of domains that bind to tyrosine-phosphorylated targets in a manner dependent on the domains that are distinct from the SH2 domains are also linked with phosphorylated targets with SH3 domains bind to rich targets in domains tetrapeptide repeats and domains to name but a few have shown that they mediate interactions of some of these may also be involved in binding with phospholipids or other second It will be ap reiado by an ordinary expert in this these arrangements can be identified based on the sequence of by a protein sequence analysis can provide an overview of the molecule's enzymatic potential of the molecules with which it can associate the A useful database is that it is a large collection of multiple sequence alignments and hidden Markov models that cover many common protein domains. The versions are available through the Internet at the University of Washington at the Sanger Center at and the Institute at by and collaborators Acids Sonnhammer and collaborators Proteins Bateman and collaborators and Sonnhammer and collaborators Nuc Acids Res In another modality ovarian cancer sequences are proteins Transmembrane proteins are molecules that extend in a phospholipid bilayer of one They can have a domain a domain or both The domains intracellular proteins can have a number of include of those already described for proteins By the intracellular domain may have activity can serve as a binding site for additional proteins With the intracellular domain of transmembrane proteins serves for both By certain receptor tyrosine kinases have both protein kinase activity and domains In the autophosphorylation of tyrosines on the receptor molecule creates binding sites for proteins containing SH2 domain Transmembrane proteins can contain from one to many domains By tyrosine kinases certain protein receptors and kinases contain a single domain Without other different proteins that include channels and contain numerous domains Many cell surface receptors such as G protein-coupled receptors are classified as domain proteins because they contain 7 extension regions of The characteristics of transmembrane domains include approximately 17 consecutive hydrophobic amino acids that can be followed by amino acids After the analysis of the amino acid sequence of a protein, the location and number of transmembrane domains within the protein can be predicted eg the http nibb site Transmembrane protein receptors but not limited to the receptor of the factor receptor growth type receptor growth hormone receptor transporters of the growth factor receptor the lipoprotein factor of the receptor low receptors of for example the receptor of the receptor The extracellular domains of the transmembrane proteins are no conserved arrays are found repeatedly between different domains structures have been ascribed functions conserved to different arrays Many extracellular domains are involved in binding with others In a the extracellular domains are found in the factors that bind to the receptor domain include ligands that can be or molecules such as or adenosine and factors such as and are circulating growth factors that bind to their cognate receptors to initiate a variety of cellular responses. Other factors include neurotrophic factors and extracellular domains are also linked to molecules associated with or can be processed or diffuse into the current In this they can mediate the interactions of the ligands associated with cells can be attached to the for example by means of an anchor or can themselves be proteins Extracellular domains are also associated with the extracellular matrix and contribute to maintenance The ovarian cancer proteins that are particularly preferred herein because they are easily accessible targets for the one described in En as illustrated further transmembrane proteins may also be useful in the modalities of seizure. can use antibodies to label these proteins In a way antibodies can also label proteins in which samples are normally provided to provide access to proteins. Some membrane proteins can be processed to release a protein or to expose a residual fragment. The soluble proteins released can be Useful as markers of and processed residual protein fragments can be useful as markers of the disease. It will also be appreciated by experts that a transmembrane protein can be made soluble by removing the sequences by through methods that can make proteins transmembrane that have been made are secreted through media by the addition of a signal sequence In another ovarian cancer proteins are secretion proteins that can be constitutive of either these proteins can have a signal peptide or a sequence of signal that leads to the molecule towards the path Secreted proteins are involved in numerous events in case they are frequently used to transmit signals to other different types of secreted proteins can function in an autocrine way on the cell that secreted it in a paracrine manner on cells in close proximity to the cell that secreted the or in an endocrine fashion over the cells to one by secretion into the current or exocrine through a duct or to an adjacent epithelial surface such as the glands the glands the ducts the glands the glands the producing glands cerumen of the secreted molecules often find use in the modulation or alteration of numerous aspects of the ovarian cancer proteins that are secreted proteins are particularly preferred as good markers of for example for tests of or those that are enzymes can be targeted therapeutic antic Other molecules or molecules may be useful as targets for example through mechanisms such as protein vaccines or ovarian cancer nucleic acid use was described in what is initially identified an ovarian cancer sequence by substantial homology of the amino acid nucleic acid sequence or the link with ovarian cancer sequences illustrated in This homology can be based on the overall nucleic acid sequence and is determined in general as illustrated further using either programs or conditions of sequences found linked to an mRNA in it. The nucleic acid sequences of cancer of ovary from the in Tables 1 to can be fragments of more genes is are segments of acids in this regions include non-regions and mixtures of coding regions and not in accordance with what will be appreciated by the experts in this using the sequences provided in the can be obtained sequences in any of the cancer genes using techniques well co in this field for the cloning of either longer sequences or length sequences see Ausubel and supra Much can be done by the and many sequences can be clustered to include multiple sequences corresponding to a single one eg systems such as UniGen ncbi Once the cancer nucleic acid is identified it can and if it is its constituent parts it can be recombined to form the coding regions of the ovarian cancer nucleic acid or the sequence Once isolated from its source by content inside a plasmid or another or separated from it as a nucleic acid segment the recombinant ovarian cancer nucleic acid can be used as a probe to identify and isolate other cancer nucleic acids from for example coding regions. It can also be used as a nucleic acid to make Modified ovarian cancer nucleic acids and proteins o Cancer nucleic acids of ovaries of the present invention are useful in various ways. In a first nucleic acid probes are made for cancer nucleic acids and they are attached to biochips for use in screening methods and as illustrated more or for by for applications of One way ovarian cancer nucleic acids that include ovarian cancer protein coding regions in expression vectors for the expression of cancer proteins can be put back in one way for screening purposes or to be administered to a The nucleic acid probes for nucleic acid ovarian cancer probes are made nucleic acid sequences illustrated in the Figures as the complements of the nucleic acid probes attached to the biochip are designed to be substantially complementary to the nucleic acid the objective sequence is the objective sequence of the or for other sequences of by in trials of e in such a way that the hybridization of the target sequence and the probes of the present is presented. As illustrated further this complementarity need not be there may be any number of mismatches of base pairs that interfere with the hybridization between the target sequence and the Single-stranded nucleic acids of the present Sin If the number of mutations is so large that hybridization can not occur under even the least restrictive hybridization conditions the sequence is not an objective sequence So it means in the present that the probes are sufficiently Complementary for the sequences to hybridize under reaction conditions in particular conditions of high cone is described in the A nucleic acid probe is generally a single but can be partially single-stranded and partially double-stranded The probe chain is dictated for the and properties of the sequence In nucleic acid probes are appropriate approximately 8 to about 100 bases, preferably about 10 to about 80 and in particular about 30 to about 50 is preferred. Genes are generally not used. In some, much more than hundreds of nucleic acids can be used. In one embodiment, more than one probe is used by probes or probes to be used. different sections of the Es four or more are used preferring to build a redundancy for a target The probes may be overlapped may have some sequence in or separate In some polymerase chain reaction primers may be used to amplify the signal for more sensitivity As will be appreciated by those skilled in the art, nucleic acids can be attached or immobilized to a solid support in a wide variety of and their grammatical equivalents means that the association or link between the nucleic acid probe and the support is sufficient to be stable under the conditions of and as described below The link can be e are typically covalent or not and their grammatical equivalents in the one means one or more of the hydrophilic and hydrophobic interactions. The non-covalent bond includes the covalent attachment of one such as streptavidin to and the non-covalent bonding of the biotinylated probe to the and its grammatical equivalents in the means that both the solid support and are bound by at least one including bonds links and bonds The covalent bonds can be formed directly between the probe and the support or can be formed by a or by inclusion of a specific reactive group either on the solid support or on or on both The immobilization may also involve a combination of covalent and non-interactions In the probes they bind to the biochip in a wide variety of how it will be appreciated by the experts in the is described in the nucleic acids can be first with subsequent binding to or can be directly synthesized The biochip comprises a solid substrate or other grammatical equivalents in the mean a material that can be modified to contain separate individual sites suitable for the binding or association of the acid probes and is susceptible to at least one method of As will be appreciated by experts in the number of possible substrates is very e but not limited to glass and modified glass or plastic and copolymers of styrene and other polysaccharides nylon or silica or silicon-based materials including silicon and glass In substrates allow detection and not have a fluorescence by the International Publication Reusable Number Low Fluorescent Plástic Bioc In the substrate is although it will be appreciated by those skilled in the art that other configurations can also be used For the probes can be placed on the internal surface of a for the analysis of the flow sample to in order to minimize the volume of the In one way the substrate can be such as a foam including closed cell foams made of plastics In one embodiment the surface of the biochip and the probe can be derived with chemical functional groups for the subsequent binding of the two By the biochip it is derived with a chemical functional group that is not limited to groups groups and groups groups being particularly preferred groups Using these groups the probes can be linked using functional groups on the nucleic acids containing amino groups can be attached to the surfaces comprising groups by example using linkers as they are known in the linkers or as are well known the 1994 Catalog of Pierce Chemical technical section on pages In some linkers such as alkyl groups substituted groups can be used and in this the oligonucleotides are and then bind to the surface of the support As will be appreciated by the experts in the you can join either the term or the term to the support or the binding can be by means of a nucleoside In another the immobilization to the solid support can be very and not non-biotinylated oligonucleotides can be made which bind to the surfaces co-coated with resulting in a way the oligonucleotides can be Synthesizing on how Por photoactivation techniques are known using photopolymerization techniques and techniques In one embodiment nucleic acids can be synthesized in using photolithographic techniques such as those described in the International Publications Numbers and WO and in the Patents of The United States of America Numbers and and in the references cited in all of which are expressly incorporated as these binding methods form the basis of the Affymetrix technology With amplification-based assays are performed to measure the level of expression of the sequences associated with cancer of These tests norm ally are carried out in conjunction with transcription In these a nucleic acid sequence associated with ovarian cancer acts as a template in an amplification reaction Chain Reaction of the o In an amplification the amount of the amplification product will be proportional to the amount of the template in the sample Comparison with appropriate controls provides a measure of the amount of RNA associated with cancer. Quantitative amplification methods are well known to those skilled in the art. Detailed protocols for the polymerase chain reaction are available by Innis and collaborators PCR A Guide to Methods and Applications Academic In some a TaqMan-based assay is used to measure the TaqMan-based assays using a fluorogenic oligonucleotide probe containing a fluorescent dye and a quenching agent The probe is hybridized to a product of the chain reaction of the but can not she same extend due to a blocking agent at the end When amplifying the product of the polymerase chain reaction in the cycles the nuclease activity of the for example results in dissociation of the probe This dissociation separates the fluorescent dye and the quenching agent thus resulting in an increase in fluorescence as a function of amplification by the literature provided by Other methods of adequate but not limited ligase chain reaction see Wu and Wallace Landegren et al. Science and Barringer et al. Gene transcription amplification and collaborators Proc EUA sequence replication and collaborators EUA chain reaction of polymerase chain reaction with adapter Expression of ovarian cancer proteins from nucleic acids In one embodiment nucleic acids are used cancer for example that they encode cancer proteins from for r a variety of expression vectors to express cancer proteins from which they can then be used in assays as described further. Expression vectors and recombinant DNA technology are well known and are used to express by and Fernandez and Gene Expression Systems Academxc Expression vectors can be vectors or vectors that are integrated into a vector. These expression vectors include transcriptional and translational regulatory nucleic acid operably linked to the nucleic acid encoding the cancer protein. to DNA sequences used for the expression of an operably linked coding sequence in a host organism. The control sequences that are suitable for include an optionally a sequence and a binding site. It is known that eukaryotic cells use signals from and enhancers. The nucleic acid is when placed in a rela functional with another acid sequence For DNA for a presequence or is operationally linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the or a ribosome binding site is operatively linked to a sequence coding if it is positioned as to facilitate the and two sequences can be operably linked when they are physically part of it. En means that the DNA sequences that are linked are and in the case of a contiguous leader and within the phase of the without the enhancers They do not have to be The binding is usually done by ligation in restriction sites If these do not exist, adapters or linkers of synthetic oligonucleotides are used according to the practice The regulatory nucleic acid of transcription and translation in general will be appropriate for the host cell used to express the cancer protein of are known in the technique numerous types of expression vectors and regulatory sequences for a variety of cells In the transcriptional and translational regulatory sequences can but are not limited sequences linkage sequences start and stop sequences of start and stop sequences of and enhancer sequences or activators In one embodiment the regulatory sequences include a promoter and start and stop sequences of promoter sequences normally encode constitutive or inducible promoters promoters can be naturally occurring promoters or promoters promoters that combine elements of more than one are also known in The expression vector can have two systems in this way allowing it to be maintained in two, for example in mammalian or insect cells for and in a prokaryotic host for the cloning and the for the expres vectors The expression vector contains at least one sequence homologous to the genome of the cell and preferably two homologous sequences flanking the construction of the integrator vector can be directed to a specific location in the cell by selecting the appropriate homologous sequence for The constructs for the vectors are available by Fernández and En. In one embodiment, the expression vector contains a selectable marker gene to allow the selection of host cells. The selection genes are well known in and will vary with the host cell. of ovarian cancer of the present invention are produced by culturing a host cell transformed with an expression vector containing nucleic acid encoding a cancer protein under the appropriate conditions to induce or cause expression of the cancer protein of the appropriate conditions for the expression of the protein of ovarian cancer will vary with the choice of expression vector and cell and will be easily asserted by a person skilled in the art through routine experimentation u By the use of constitutive promoters in the expression vector will require growth optimization and the proliferation of the cell while the use of an inducible promoter requires the appropriate growth conditions for the En in some the time of the harvest is by the baculovirus systems used in the expression of insect cells are viruses and so the selection of the harvest time can be crucial for the performance of the appropriate host cells include arquibacteria and insect cells and including Son cells of a particular interest Saccharomyces cerevisiae and other Bacillus cells cells cells HÜVEC cells endothelial umbilical vein cells THP1 cell line and other different cells and cell lines In One modality ovarian cancer proteins are expressed in cells of the expression systems of mammal are also known in the art and include retroviral and adenoviral systems. An expression vector system is a retroviral vector system as generally described in the International Publications Numbers and both of which are expressly incorporated herein as "promoters". Promoters from viral genes are of particular use because viral genes are often highly and have a wide range of. The examples include the early promoter of the LTR promoter of mammary tumor of the late promoter greater than the herpes virus promoter and the Fernandez promoter and the transcription and polyadenylation termination sequences recognized by mammalian cells are the regulatory regions located at the stop codon of and thus together with the elements flank the sequence The examples of the transcription terminator and the polyadenylation signals include Derivatives from Methods for introducing exogenous nucleic acid into hosts as well as others are well known in this and will vary with the host cell. Techniques include transfection mediated by transfection phosphate precipitation mediated by protoplast fusion infection encapsulation of polynucleotides in and direct microinjection of the DNA in the nuclei In an embodiment the ovarian cancer proteins are expressed in systems The bacterial expression systems are well known in the promoters can also be used from and are known in this En are also useful synthetic promoters and promoters by the tac promoter is a hybrid of the trp promoter sequences and a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind to the bacterial RNA polymerase and initiate the a sequence in a site is desirable or ribosome binding The expression vector may also include a signal sequence that provides secretion of ovarian cancer protein in the protein is secreted into the culture medium or into the space located between the inner and outer membrane The bacterial expression vector may also include a selectable marker gene to allow the selection of bacterial strains that have been selected. Suitable selection genes include genes that render the bacterium resistant to drugs such as tetracycline. Selectable markers also include genes. biosynthetics such as those of the biosynthetic pathways of and These components are assembled into vectors of expression vectors for bacteria are well known in the and include vectors for Bacillus Streptococcus and Streptococcus between Ver Fernandez and bacterial expression vectors are transformed into host cells bacterial using t Well-known techniques in such treatment as chloride and In ovarian cancer proteins are produced in cells The expression vectors for the transformation of cells and in particular expression vectors based on are well known in the One modality produces an ovarian cancer protein in cells The yeast expression systems are well known in this and include the expression vectors for Saccharomyces Candida albicans and Hansenula Kluyveromyces and Pichia guillerimondii and Schizosaccharomyces and Yarrowia ovarian cancer protein It can also be made as a protein using techniques well known in this by for the creation of antibodies if the desired epitope is the ovarian cancer protein can be fused with a carrier protein to form a cancer protein. ovary can be made as a fusion protein to increase the or by others By when the ovarian cancer protein is a cancer peptide of the nucleic acid that encodes the peptide can be linked to another nucleic acid for expression purposes. In one embodiment the ovarian cancer protein is purified or isolated after the ovarian cancer proteins can be isolated or purified in a variety of ways known to the skilled artisan. in this depending on what other compounds are present in the conventional purification methods include electrophoretic techniques and including high performance liquid chromatography by phase and phase exchange and chromatofocusing By the ovarian cancer protein can be purified using a standard column of antibody against the cancer protein of Ultrafiltration techniques are also useful and in conjunction with the concentration of For a general guide in the purification techniques see Scopes Protein Purification The degree of purification necessary will vary depending on the use of the cancer protein. In some it will not be necessary any Once expressed and purified if the ovarian cancer proteins and nucleic acids are useful in a number of ways, they can be used as reagents of as ovarian cancer agent variants. ovarian ovarian cancer proteins are derived or compared to the sequence of type Es as illustrated more fully plus the derivative ovarian cancer peptide will frequently contain at least one or more preferred insertion substitutions of La or amino acid deletion may occur at most at any residue within the cancer peptide. Also included within the modality of the ovarian cancer proteins of the present are the sequence variants of these variants normally fall into one or more of three variants of of or of these variants. They are ordinarily prepared by site-specific mutagenesis of nucleotides in A DN encoding the cancer protein using cassette mutagenesis or chain reaction of the or other techniques well known therein to produce DNA encoding the and then expressing the DNA in the recombinant cell culture as described Sin can be prepared variant ovarian cancer protein fragments having up to about 100 to 150 residues by synthesis in using the techniques Variant amino acid sequences are characterized by the previously determined nature of the one feature that sets them apart from the allelic or interspecies variation that occurs naturally from the amino acid sequence of the cancer protein. Variants normally exhibit the same qualitative biological activity as the analog that occurs although you can also select variants that have characteristics as described more fully even though the site or region for introduction r a variation of amino acid sequence is determined the mutation by itself does not need to be previously By in order to optimize the performance of a mutation at a site it can be randomly conducted at the codon or in the region and the variants can be traced ovarian cancer expressed for the optimal combination of activity The techniques for making substitution mutations at previously determined sites of DNA having a sequence by mutagenesis of the primer and mutagenesis of the chain reaction are well known. The screening of the mutants is done Using assays of the activities of the cancer proteins The amino acid substitutions are usually of residues the inserts will normally be of the order of approximately 1 to 20 although insertions can be tolerated considerably more The deletions are from approximately 1 to approximately 20 although in some cases the deletions can be much larger. The any combination of those can be used to reach a derivative In these changes are made about How many amino acids to minimize the alteration of the Sin can tolerate larger changes in certain When small alterations are desired in the characteristics of the cancer protein the substitutions are usually made according to the ratios of amino acid substitutions provided in the section of The variants normally exhibit the same biological activity and will elicit the same immune response as the analogue that occurs although the variants are also selected to modify the characteristics of the ovarian cancer proteins either way. In a way the variant can be designed in such a way that the biological activity of the Por cancer protein be altered or removed from the sites. Substantial changes in function or immunological identity are made by selecting substitutions that are less conservative than those described above. substitutions that affect in a more meaningful way the base structure of the polypeptide in the area of eg the structure of or of the charge or the hydrophobicity of the molecule in the site or the volume of the chain The substitutions that are expected in general to produce the largest changes in the properties of the polypeptide are those in which a residue for example serine or is substituted by a residue for example or a cistern or proline is replaced by any other a residue having a side chain for example or is replaced by a residue for example glutamic acid or a residue having a side chain for example is replaced by one that has no chain for example or a proline residue is incorporated or which changes the degree of freedom of rotation of the link Within the scope of this include the covalent modifications of cancer polypeptides A type of covalent modification includes reacting amino acid residues of an ovarian cancer polypeptide with an organic derivatizing agent that is capable of reacting with the selected side chains or residues or of a cancer polypeptide of the derivation with bifunctional agents is to for cross-linking the ovarian cancer polypeptides in a water-insoluble support matrix or surface for use in the method for purifying ovarian cancer polypeptide antibodies or for assays as described more fully below The cross-linking agents commonly used for esters of for example esters with homobifunctional imido esters including disuccinimidyl esters such as 3 3 of bifunctional maleimides such as and agents such as Other modifications include the deamidation of glutamine and asparagine residues to the glutamic and aspartic proline acid residues and phosphorylation of the hydroxyl groups of threonine residues or methylation the amino groups of the histidine side chains Creighton Proteins Structure and Molecular Properties pages acetylation of the amine and a carboxyl group Another type of covalent modification of the ovarian cancer polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the glycosylation pattern means for the purposes of suppressing one or more carbohydrate moieties found in an ovarian cancer polypeptide of the sequence adding one or more glycosylation sites that are not present in the ovarian cancer polypeptide of the sequence Glycosylation patterns can be altered by many By the use of different cell types to express the sequences associated with cancer can result in different glycosylation patterns The addition of glycosylation sites to the ovarian cancer polypeptides can also be carried out by altering The alteration can be made by adding the amino acid sequence of the or substitution of one or more serine or threonine residues to the ovarian cancer polypeptide of the native sequence the glycosylation sites The ovarian cancer amino acid sequence can be altered through changes at the particular level by mimicking the DNA encoding the ovarian cancer. ovarian cancer polypeptide in bases previously in such a way that codons are generated that are translated into the amino acids. Another means to increase the number of carbohydrate moieties on the cancer polypeptide is by chemical or enzymatic coupling of glycosides by International Publication Number O and pages in Aplin and CRC CRC The removal of the carbohydrate moieties present on the ovarian cancer polypeptide can be carried out in a chemical manner or by mutational substitution of codons coding for the amino acid residues serving targets for Glycosylation Deglycosylation techniques are applicable by Sojar and Bahl Biophys and Edge et al. Enzymatic dissociation of carbohydrate moieties on polypeptides can be achieved by the use of a variety of and by Thotakura et al. Enzymol Another type of covalent modification of ovarian cancer comprises binding to the polypeptide of ovarian cancer to one of a variety of non-polypeptide polymers or polyoxyalkylenes by US Pat. Nos. or ovarian cancer polypeptides of the present invention can also be modified in a manner to form molecules for example comprising an ovarian cancer polypeptide fused with another polypeptide or with a sequence In one this chimeric molecule comprises a fusion of an ovarian cancer polypeptide with a signal polypeptide that provides an epitope with which the antibody can be selectively bound. of epitope is usually placed in the term am The presence of these epitope-tagged forms of a cancer polypeptide can be detected using an antibody against the polypeptide of the epitope signal provision makes it possible for the ovarian cancer polypeptide to be purified. Easily by affinity purification using an antibody or other type of affinity matrix that binds to the signal of In an embodiment the chimeric molecule can comprise a fusion of an ovarian cancer polypeptide with an immunoglobulin or a particular region of an immunoglobulin. a bivalent form of the molecule this fusion could be with the Fe region of a molecule. Different signal polypeptides and their antibodies are well known in the art. Examples include the signals of the HIS6 ID and chelation signals of the signal polypeptide. Flu HA and its antibody 12CA5 and collaborators Cell signal and antibodies B7 and 9E10 for the same and collaborators and the glycoprotein D signal of Herpes Simplex virus and its antibody and collaborators Protein Engineering Other signal polypeptides by the Flag peptide and collaborators BioTechnology the peptide of the KT3 epitope and collaborators Science the peptide of the epitope of tubulin and coworkers and the peptide signal from protein 10 of the T7 gene and collaborators Proc Also included are other ovarian cancer proteins from the cancer family and other ovarian cancer proteins that are cloned and expressed as described further By degenerate polymerase chain reaction primer or probe sequences can be used to find other related ovarian cancer proteins from humans or others As will be appreciated by those skilled in the reaction primer probe sequences particularly useful polymerase chain include the unique areas of the acid sequence As is generally known in this, the preferred polymerase chain reaction primers are approximately 15 to about 35 nucleotides of from about 20 to about and may contain inosine as well. Conditions for polymerase chain reaction are well known in the PCR technique Antibodies to ovarian cancer proteins In a modality when it is going to use the ovarian cancer protein to generate for example for ovarian cancer protein must share at least one epitope or determinant with the protein of length or in the present normally means a portion of a protein that will generate will bind to a antibody or T-cell receptor in the context of the major histocompatibility complex. By most antibodies made for a more ovarian cancer protein will be able to bind to the protein of particular length to the epitopes. In one embodiment the epitope is the antibodies generated for a single epitope show little or no react The methods for preparing polyclonal antibodies are known to the person skilled in the art and Harlo and Polyclonal antibodies can be reproduced in one for example by one or more injections of an agent and if the adjuvant immunizing agent is added it will be injected into the mammal by multiple subcutaneous injections or The immunizing agent may include a protein encoded by a nucleic acid of the or a fragment of the fusion protein or a fusion protein. It may be useful to conjugate the immunizing agent with a protein known to be immunogenic in the mammal being examined. Immunogenic proteins but not limited to albumin limpet hemocyanin and seed trypsin inhibitor Examples of adjuvants that may be employed include Freund's complete adjuvant and trehalose adjuvant The immunization protocol may be selected by an expert in this field with a proper One way antibodies They can be antibodies. Monoclonal antibodies can be prepared using methods such as those described by Kohler and Milstein. In a method normally one or another host animal is immunized with an immunizing agent to cause lymphocytes that produce or are capable of producing antibodies that are specifically bind with the agent. In one way the lymphocytes can be immunized in. The immunizing agent will normally include a polypeptide encoded by a nucleic acid from Tables 1 to a fragment of an En fusion protein or peripheral blood lymphocytes if desired. cells of origin or spleen cells or cells of lymph nodes are used if mammalian sources are not desired. Then the lymphocytes are fused with an immortalized cell line using a fusion agent such as polyethylene glycol to form a hybridoma cell pages in Monoclonal Goding Antibodies Principies and Academic The lines immortalized cells are usually mammalian cells in particular cells of origin of or of being used rat myeloma cell lines or hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the immortalized cells no In case the progenitor cells lack the enzyme or the culture medium for the hybridomas it will normally include and thymidine whose substances prevent the growth of the deficient cells. In one the antibodies are bispecific antibodies. bispecific antibodies are preferably human or have binding specificities for at least two antigens or have binding specificities for two epitopes on the same In one of the binding specificities it is for a protein encoded by a nucleic acid of Tables 1 to 26 or a fragment of the and the other is for Any other and preferably for a cell surface protein or receptor or subunit of preferably one that is specific of In one way the tetramer-type technology can create multivalent reagents In one embodiment the antibodies to the ovarian cancer protein are capable of reducing or eliminating a biological function of a cancer protein such as It is further described It is the addition of antibodies against the ovarian cancer protein whether polyclonal or preferably monoclonal to the ovarian cancer tissue to the cells containing cancer can reduce or eliminate the cancer of En is preferred at least a reduction of 25%. percent in size or in particular preferred at least about 50 percent and especially preferred a reduction of about 95 to 100 percent In one modality antibodies to ovarian cancer proteins are humanized antibodies Xenerex Protein Design Humanized forms non-human antibodies are chimeric immunoglobulin molecules chains of or fragments thereof as or other antigen binding subsequences of those containing a minimal sequence derived from an immunoglobulin no Humanized antibodies include human immunoglobulins wherein the residues of a receptor complementarity determining region are replaced by residues from a complementarity determining region of a non-human species such as or having the ability and capacity In some the Fv structure residues of human immunoglobulin are replaced by non-human residues Humanized antibodies may also comprise residues that do not they are in the antibody of the receptor neither in the imported complementarity determining region or in the sequences of In a humanized antibody it will comprise substantially all or at least and typically domains where all or substantially all the regions determining complementarity correspond to that one. s of a non-immunoglobulin and all or substantially all regions of structure are those of an immunoglobulin consensus sequence. The humanized antibody optimally will also comprise at least a portion of an immunoglobulin constant region normally that of an immunoglobulin. Humanization can be carried out essentially following the Winter method and by using the complementarity determining regions or the rodent complementary regions determining sequences to substitute the corresponding sequences of an antibody by Jones et al. Nature et al. Nature Presta O and Verhoeyen et al. Science In accordance with what these humanized antibodies are chimeric antibodies from the United States of America Number where less than an intact human variable domain has been replaced by the corresponding sequence from a non-human species. can produce human antibodies using different techniques known in the including phage display libraries by and Winter and Marks and collaborators or human antibodies by Colé et al in Reisfeld and Monoclonal Antibodies and Cancer Therapy and Boerner and collaborators Immunol In a way antibodies can be made humans by introducing human immunoglobulin sites in transgenic animals for example mice in which the immunoglobulin genes have been partially or completely inactivated. After the production of antibodies is observed it closely resembles what is seen in humans in humans. all including reconfiguration of and repertoire of by the Patents of the United States of America Numbers and collaborators Lonberg and collaborators Morrison Nature Neuberger Nature Biotechnology commenting on Fishwild and collaborators Nature Biotechnology and Lonberg and Huszar Immunol Immunotherapy means the treatment or cancer of for example with an antibody reproduced against The cancer proteins of As used in the immunotherapy can be passive or Immunotherapy as defined in the is the passive transfer of the antibody to a receptor The active immunization is the induction of the antibody responses T cells in a receptor The induction An immune response is the result of providing the recipient with an antigen for which they are reproduced. The antigen can be provided by injecting a polypeptide against which it is desired to reproduce antibodies in a or by contacting the receptor with a nucleic acid capable of expressing the antigen. and under conditions for the expression of the leading to a response In one embodiment the ovarian cancer proteins against which they are reproduced are secreted proteins as described Without being bound by the antibodies used for the treatment they bind and prevent the secreted protein is linked to its inactivating in this way the ovarian cancer protein In another modality the ovarian cancer protein for which they reproduce is a protein Without being bound by the antibodies used for this treatment they bind to the extracellular domain of the cancer protein and prevent it from binding to others such as circulating ligands or molecules associated with the cells The antibody can cause the reduction of the ovarian cancer protein As will be appreciated by an ordinary expert in this the antibody can be a non-inhibitor or incompetiti or protein that binds to the extracellular domain of the cancer protein The antibody is also an antagonist of the cancer protein of the antibody prevents the activation of the ovarian cancer protein In a when the antibody prevents the binding of other molecules with the cancer protein the antibody prevents the growth The antibody can also be used to direct or sensitize the cell to the agents but not limited to chemotherapeutic agents including actinomycin and In some the antibody belongs to a subtype that activates serum complement when complexed with the protein thereby mediating the antigen-dependent cytotoxicity or ovarian cancer is treated by administration to an antibody directed against the ovarian cancer protein The antibody labeling can activate a localize a payload of or otherwise provide a means to locally ablate the cells In another embodiment the antibody is conjugated with a fraction The effector fraction can be any number of including fractions such as radioactive labels or the marks or can be a fraction In a therapeutic fraction is a small molecule that modulates the activity of the cancer protein In another the therapeutic fraction modulates the activity of the associated molecules or in close proximity the protein of c Therapeutic fraction can inhibit activity such as protease or collagenase activity or protein kinase associated with cancer. In a modality the therapeutic fraction can also be an agent. In this the direction of the cytotoxic agent towards the tissue or Cancer cells result in a reduction in the number of cells thereby reducing symptoms associated with cancer. Cytotoxic agents are numerous but not limited to cytotoxic drugs or toxins or active fragments of these toxins. The appropriate toxins and their Corresponding fragments include chain of diphtheria chain of exotoxin chain of ricin chain of abrin and cytotoxic agents also include radiochemicals made by conjugation of radioisotopes with antibodies reproduced against cancer proteins or by linking a xadionuclide to a chelating agent which is has covalently linked to La direc tion of the therapeutic fraction towards ovarian cancer proteins not only serves to increase the local concentration of the therapeutic fraction in the area afflicted by cancer but also serves to reduce the side effects that may be associated with the therapeutic fraction not In another embodiment the ovarian cancer protein against which the is an intracellulax protein In this the antibody can be conjugated with a protein that facilitates the entry into the In the one the antibody enters the cell by endocytosis In another the nucleic acid is administered to the individual or to the cell that codifies to the More where the protein of Ovarian cancer can be directed into an eg an antibody to the same contains a signal for that location for example a nuclear localization signal The ovarian cancer antibodies of the invention specifically bind to the cancer link proteins means in the present that antibodies bind to the protein with a Kd from at least approximately more usually from at least about 1 preferably from at least about μ? or and in a very preferable way μ? o The selectivity of ovarian cancer sequence detection is also important for diagnostic and therapeutic applications. In one, the expression levels of genes for different cell stages in the cancer phenotype are determined. the genes in the normal tissue that does not suffer from cancer and in the ovarian cancer tissue in some for different ovarian cancer severities that are related to the as described more or in disease not in order to provide the profiles of a The expression profile of a cell state or particular developmental point is essentially one of the state of the. Although two states can have any particular gene similarly the evaluation of a number of genes in a simultaneous manner allows the generation of an expression profile of the gene that reflects the state of the By comparing the expression profiles of the cells in different get In the information regarding which genes are important both the increase and the reduction in each of these can be carried out the diagnosis or can be confirmed to determine if a tissue sample has the gene expression profile of the normal tissue or This will provide the molecular diagnosis of related conditions or the tical equivalents used in the referred to qualitative or quantitative differences in cellular temporal expression patterns within and between cells and for a differentially expressed gene can qualitatively have its expression including a activation or inactivation by normal tissue against cancer tissue. Genes can be activated or deactivated in one state in relation to another, thus enabling the comparison of two or more. A qualitatively regulated gene will exhibit an expression pattern within a state or cell type that is detectable median conventional techniques Some genes will be expressed in a state or type of but not in a way the difference in the expression can be by which the module is either resulting in a greater amount of or resulting in a lower The extent to which the expression differs needs to be only sufficient to quantify by characterization techniques as described further such as by using Affymetrix expression arrays by Nature Other techniques but not limited polymerase chain reaction with reverse transcriptase analysis and protection As is described in the preferred embodiment, the change in expression increase is from at least about 50 to more preferably from at least about 100 to more preferably from at least about 150 to very preferably when less than about 200 by preferring in particular from 300 to at least one by the evaluation can be done at the level of the transcript or the amount of gene expression can be used nucleic acid probes for the equivalent of DNA or RNA of transcription and the quantification of the expression levels or the final gene product itself can be by antibodies to the ovarian cancer protein in conventional or others including spectroscopy assays of gel electrophoresis assays. The proteins corresponding to the cancer genes of for example those identified as important in an ovarian cancer phenotype or can be evaluated in a cancer diagnostic test. In a modality the genetic expression is performed in a simultaneous manner in a number of. Multiple expression or on a base In this the ov cancer nucleic acid probes Aryos bind to biochips as described in the for the detection and quantification of ovarian cancer sequences in a cell. The assays are further described below in the Polymerase chain reaction techniques can be used to provide an enhanced In one embodiment, the nucleic acids encoding the cancer protein can be detected. Although DNA or RNA coding for the cancer protein can be detected, methods detecting a protein encoding a cancer protein are of particular interest. detecting mRNAs can be a probe that will be emitted and hybridize e but not limited to oligonucleotides o The probes should also contain a tag as defined in the In a the mRNA is detected after immobilizing the nucleic acid to be examined on a support such as membranes and the probe is hybridized with the Following the wash to remove the probe is not detected In another mRNA detection is carried out in In this the permeabilized cells or the tissue samples are contacted with a detectably labeled nucleic acid probe for a sufficient time to allow the probe to hybridize with the mRNA followed by the wash to remove The probe is not specifically detected. A digoxigenin-labeled riboprobe is detected that is complementary to the mRNA that encodes a cancer protein by binding digoxigenin with a secondary antibody and is revealed with nitro blue tetrazolium and phosphate. They use different proteins from the three classes of proteins described herein or intracellular in the assays. In the diagnostic assays proteins of cancer of acid proteins and cells containing cancer sequences are used. This can be performed on an individual gene or on the level of the polypeptide In a modality the pre-profiles are used in conjunction with high screening techniques to allow the monitoring of the expression profile genes of the polypeptides As described and defined in the cancer proteins including intracellular proteins or find use as prognostic or diagnostic markers The detection of these proteins in the ovarian cancer tissue allows the diagnosis or prognosis or of the disease and for the selection of the strategy. In one, antibodies are used to detect cancer proteins, a preferred method separates the proteins from a It shows by electrophoresis on a gel a denaturing protein gel and but it can be another type of including isoelectric focusing gels and following the separation of the cancer protein is detected by means of immunoblotting with antibodies reproduced against the cancer protein. The methods of are well known by the ordinari experts os in this In another method the antibodies for the ovarian cancer protein find use In the imaging techniques in by in Assai Methods in Antibodies in Cell Academic The cells are contacted with from one to many antibodies to the cancer proteins. After washing to remove the antibody binding the presence of the antibody or of the In the one antibody is detected by incubating with a secondary antibody containing a tag In another the primary antibody for ovarian cancer proteins contains a label for example an enzyme marker that can act on a one of multiple primary antibodies contains a distinct label and This method finds particular use in the simultaneous screening of a plurality of cancer proteins from As will be appreciated by one ordinarily skilled in the invention provides many other imaging techniques In one embodiment The mark is detected in a fluorometer that has the ability to detect and distinguish the missions of different lengths of En can be used a cell sorter activated by fluorescence in the In another modality antibodies find use in the diagnosis of ovarian cancer from samples of and others For these samples are useful as samples to be probed or tested To determine the presence of cancer proteins The antibodies can be used to detect an ovarian cancer protein by previously using techniques including immunostaining technology and the presence of antibodies can indicate an immune response against an ovarian cancer protein. modality is made the hybridization itself of the ovarian cancer nucleic acid probes labeled with the arrangements of By are made sample arrangements of including ovarian cancer tissue tissue Then hybridization is performed if your by When the impression is compared of footprints between an individual and an expert can make an ou In addition, it is understood that the genes that indicate the diagnosis may differ from those that indicate and the molecular profiling of the condition of the cells may lead to distinctions between the response conditions or may be predictive of the results. modality proteins of cancer of acids are used proteins and cells that contain cancer sequences of in the tests of As gene expression profiles can be generated that are correlated with ovarian cancer and information or other in terms of long prognosis this can be do either at the level of the or at the level of the preferred use of a plurality of As ovarian cancer probes can be attached to biochips for the detection and quantification of ovarian cancer sequences in a tissue or the assays proceed as is described above for the The chain reaction method of the can provide a quantification m Sensitive and Testing for Therapeutic Compounds In one embodiment the acid and antibody members described in the screening assays are used. In the screening assays the proteins of cancer of acids proteins and cells containing cancer sequences are used. or the evaluation of the effect of the candidate drugs on an expression or expression profile of polypeptides is made In a modality the profiles are preferably used in conjunction with the screening techniques to allow the monitoring of the genes of the expression after treatment with an agent by Zlokarnik et al., Science and Heid Res. In one embodiment protein cancer proteins and cells containing native ovarian cancer proteins are used or in the assays of the invention. to track compositions that modulate the ovarian cancer phenotype or a function n physiological identified a protein of cancer As this can be done at the level of a gene or evaluating the effect of candidate drugs on an expression profile In a modality profiles are preferably used in conjunction with high-level screening techniques to allow the monitoring of genes of the expression profile after treatment with a agent by supra Having identified the genes differentially expressed in the can be carried out a variety of In one modality the assays can be run at the level of an individual gene or gene. tracing test compounds to determine their ability to modulate expression or to bind to the cancer protein of Por includes both an increase and a reduction in expression. The preferred amount of modulation will depend on the original change of gene expression in normal tissue against the tissue that suffers from cancer with changes of at least 10 percent, preferably 50 percent more preferably from 100 to 300 by and in some embodiments from 300 to percent. In case a gene exhibits a quadruple increase in the cancer tissue compared to the tissue, a reduction of approximately one in a reduction manner is desired. 10 times in cancer tissue compared to tissue often provides an objective value of a 10-fold increase in expression that will be induced by the compound. The amount of gene expression can be monitored using nucleic acid probes and the quantification of expression levels or in a way the genetic product itself can be through the use of antibodies to the cancer protein and immunoassays. Proteomic and separation techniques can also allow quantification of the monitoring the genetic or protein expression of a number of by a profile can be done in a These profiles will normally involve a plurality of these entities described herein. In these the ovarian cancer nucleic acid probes bind to biochips as described in the for the detection and quantification of ovarian cancer sequences in a cell. One way can be used chain reaction of the Por can be used a by plates of with primers dosed in the wells Then you can carry out a chain reaction of the and is analyzed for each You can effect the expression to identify compounds that modify the expression of one or more cancer-associated sequences of for example a polynucleotide sequence stipulated in Tables 1 to En in one embodiment a test modulator is added to the cells before the Plus traces are also provided to identify the agents that modulate cancer by modulating cancer proteins that bind to a cancer protein that interferes they were with the binding of an ovarian cancer protein and an antibody or other binding component The term of ooo its grammatical equivalents as used in describes any such organic molecule that is to be tested to determine its ability to alter a directly or indirectly the ovarian cancer phenotype or the expression of a cancer sequence of for example a nucleic acid sequence or modulators In the embodiments the modulators alter the profiles of the nucleic acids or the profile of the proteins or proteins provided in the In one the modulator suppresses a cancer phenotype of eg up to a normal tissue imprint or not In another a modulator induces an En cancer phenotype a plurality of assay mixtures are tested in parallel with different concentrations of the agent to obtain a response differential to the different one of these concentrations serves as a control for example in a zero concentration od below the level of Candidate drugs encompass numerous classes although normally Preferred molecules are small organic compounds having a molecular weight greater than 100 and less than approximately. Preferred small molecules are less than or less than or less than or less than 500. Candidate agents comprise the functional groups necessary for the structural interaction with the particular linkages of and typically include at least one group or preferably at least two of the chemical groups. The candidate agents often comprise cyclic carbon structures or aromatic or polyaromatic structures substituted with one or more of the functional groups. candidate agents are also found among the biomolecules including analog acids or combinations of peptides. In particular, the peptides in a modulator will neutralize the effect of a cancer protein means that the activity of a protein is inhibited or blocked and the consequent effect about the In certain will be traced The combination libraries of potential modulators to determine the ability to bind to an ovarian cancer polypeptide or to modulate the formation of new chemical entities with useful properties by identifying a chemical compound with some property or activity for example an activity the creation of variants of the compound and the evaluation of the property and activity of those compounds With high-throughput screening methods are employed for this In one embodiment the high-throughput screening methods involve providing a library containing a large number of therapeutic compounds These chemicals are then screened in one or more assays to identify members of the library chemical species or subclasses that exhibit a characteristic activity. The compounds thus identified may serve as or may themselves be used as potential therapeutics. Combination physics is a collection of various chemical compounds generated either by chemical synthesis or by synthesis by combining a number of such as by a chemical combination library such as a polypeptide library is formed by combining a set of chemical building blocks named in any way possible for a given length of the compound the number of amino acids in a compound can be synthesized millions of chemical compounds through this mixture of combination of the building blocks by Gallop and collaborators The preparation and the screening of chemical combination libraries are well known to those skilled in the art. These chemical libraries of combination but are not limited to peptide libraries by US Patent Number Furka Pro and Houghton and collaborators peptoides of the TCP Number WO coded peptides from l TCP TCP random number WO number of benzodiazepines from the United States of North America Number of diversomers such as and dipeptides and collaborators Nat EUA vinyl polypeptides and non-peptidic peptidomimetic partners with a scaffolding of and collaborators analogous organic synthesis of small compound libraries and oligocarbamates and collaborators Science peptidyl phosphonates and collaborators Org 59 See in Gordon et al. Nucleic acid libraries by peptide nucleic acid libraries by US Patent Number of antibody libraries by Vaughn et al. Nature and Publication of the TCP Number of carbohydrate libraries by Liang et al. Science and US Pat. Number and libraries of small organic molecules by benzodiazepines page January isoprenoid Baura US Pat. Number thiazolidinones and metathiazanones Patent of the United States of North America Number of pyrrolidines Patents of the United States of America Patent Numbers and Compounds of the United States of America Patent Number of the United States of America Number and Devices for the preparation of combination libraries are commercially available for 357 390 Advanced Chem Louisville 433? Applied Foster 9050 A number of well-known robotic systems for phase chemistry have also been developed. These systems include automated work stations such as the automated synthesis apparatus developed by Takeda Chemical Industries and many robotic systems using Palo robotic arms that mimic Manual synthetic operations carried out by any of the foregoing apparatuses is suitable for use with the present invention. The nature and implementation of modifications to these devices in such a way that they can operate as described herein will be apparent to those skilled in the art. In many combination libraries are themselves available by St 3D Martek Trials to identify modulators are susceptible to high screening. Preferred assays detect the improvement or inhibition of transcription of the cancer gene by inhibiting or enhancing the expression of y the inhibition no improvement of the activity of the high production assays to evaluate the or other properties of nucleic acid products or proteins are well known by the experts in this way the binding assays and the reporter gene assays are similarly well US Pat. Number discloses high production screening methods for U.S. Patent Number discloses high production screening methods for nucleic acid linkage in the U.S. Patent Number. The United States of America Numbers and discloses high production methods for link tracking of High production tracking systems are commercially available by Air Technical Beckman Precision These systems typically automate procedures including pipetting samples and dosage of incubations and final readings of the microplac These systems provide a high production and a fast as well as a high degree of flexibility. The manufacturers of these systems provide the detailed protocols for different systems of high. By Zymark provides technical bulletins describing tracking systems for To detect the modulation of the transcription of binding of and In a the modulators are often proteins that are presented or protein fragments that are presented Por by can be used cell extracts containing or digested random or directed proteinaceous cell extracts This can be Protein libraries for screening in the methods of the invention In particular, the protein libraries are preferred and preferred, and human proteins are especially preferred. The particularly useful test compound will be directed towards the class of proteins to which the protein belongs. for example Examples of substrates for enzymes or ligands and receptors In one embodiment the modulators are peptides from about 5 to about 30, preferably from about 5 to about 20 and in particular from about 7 to about. The peptides may be protein digestions that occur naturally as they are. illustrated in the peptides or random peptides or their grammatical equivalents in the means that each nucleic acid and peptide consists essentially of nucleotides and amino acids Because in general these more randomly described acidic peptides are synthesized can incorporate any nucleotide or amino acid in any synthetic process can be designed to generate proteins or nucleic acids in order to allow the formation of all or most of the possible combinations over the length of the thus forming a library of candidate bioactive proteinaceous agents In a the library is completely without preferences or sequence constants in any In one embodiment the The library is Some positions within the sequence are maintained or are selected from a limited number of For in one embodiment the nucleotides or the amino acid residues are randomized within a class for example of hydrophobic amino acids residues hydrophilic spherically forced residues are small or towards the creation of acid binding domains the creation of for prolines for domains or histidines for o sites for ovarian cancer modulators can also be acidic as defined as described in the above in general for the agents Nucleic acid modulators can be nucleic acids If nucleic acids or random nucleic acids are present Por digestions of prokaryotic or eukaryotic genomes can be used as described above for proteins In one embodiment the candidate compounds are chemical fractions a wide variety of which are available in the After The agent has been added and the cells have been allowed to incubate for some period of time. The sample containing an objective sequence is added to the biochip. If the objective sequence is prepared using techniques, the sample can be treated for The lysis is carried out using covalently linked labels to the nucleotides. In the nucleic acids are marked with or or with cy3 or In a modality the objective sequence is with a signal or to provide a means of detection the esp link The sequence can also be such as alkaline phosphatase or peroxidase when provided with a substrate produces a product that can be In a way the label can be a labeled compound or molecule such as an inhibitor that is bound but not catalyzed or altered The label may also be a fraction or such as an epitope or biotin signal that specifically binds to streptavidin. For the example of the streptavidin it is labeled as described thereby providing a detectable signal for the target sequence Labeled and unbound streptavidin is normally removed before the As will be appreciated by the experts in these assays may be hybridization assays or may comprise of which include the use of multiples as generally illustrated in Patents of the United States of America Numbers and each of which is incorporated herein as In this in the target nucleic acid is prepared as illustrated and then added to the biochip comprising a plurality of acid probes under conditions that allow for the formation of a complex A variety of hybridization conditions can be used herein including conditions of restriction and as described The assays are generally run under conditions of restriction that allow the formation of the hybridization complex of the label probe only in the presence of the restriction. The restriction can be controlled by altering a step parameter that is a variable but not limited concentration concentration of salt concentration concentration of solvent These parameters can also be used to control the bond not as generally illustrated in the US Patent Number Per it may be desirable to perform certain steps under conditions of higher restriction to reduce the link no The reactions i illustrated herein may be carried out in a variety of the components of the reaction can be added in a manner or in different with the preferred embodiments described further In the reaction can include a variety of other reagents These include protein regulators for example that can be used to facilitate hybridization and detection to reduce interactions Non-specific reagents may also be used that otherwise improve the efficiency of such as inhibitors of inhibitors of agents depending on the methods of sample preparation and the purity of the assay. The test data are analyzed to determine the levels of and changes in expression levels between genes forming an expression profile Traces are made to identify the modulators of the cancer phenotype In one the screening is done to identify the modulators that can induce or suppress an expression profile generating in this way preferably the phenotype In another by for apl In the case of having identified the differentially expressed genes important in a state, the scans can be carried out to identify the modulators that alter the expression of the individual genes. In another, the screening is done to identify the modulators that alter a biological function of the expression product. of a gene having identified the importance of a gene in a state, the scans are performed to identify the agents that link the biological activity of the product. In it can be traced genes that are induced in response to an agent After identifying a modulator Based on their ability to suppress a cancer expression pattern from leading to an expression pattern or to modulate a single expression profile of the ovarian cancer gene to mimic the expression of the gene from a tissue an tracing as described to identify genes that are specifically The comparison of expression profiles between normal tissue and ovarian cancer tissue treated with the gene reveals genes that are not expressed in normal tissue or cancer tissue but are expressed in the tissue. treated with the These specific sequences of the agent can be identified and used by the methods described herein for cancer genes or proteins In these sequences and the proteins they find use in the labeling or identification of the cells treated with the En can reproduce antibodies against the proteins induced by it and can be used to direct novel therapeutics towards the treated ovarian cancer tissue sample. In one a test compound is administered to a population of cancer cells of which they have an expression profile of ovarian cancer or mean in which the candidate agent is added to the cells in such a way that the agent acts on either by recovery and action or by action on the surface In some the nucleic acid encoding a proteinaceous candidate agent can be put into a construct such as an adenoviral construct and can be added to it in such a way that expression of the agent be carried out as described in International Publication Number Genetic therapy systems can also be used Once the test compound has been administered to the cells they can be allowed and allowed to incubate under conditions of physiological preference for some period of time the cells will be and a new expression profile is generated as described in the Por por ovarian cancer tissue can be traced or not to determine agents that by inducing or suppressing the cancer phenotype A change in at least one preference in the profile indicates that the agent has an effect on the ivity of cancer By defining this signature for the phenotype of cancer can be devised traces of new drugs that alter the With this you do not need to know the goal of and you do not need to represent on the platform of expression tracking nor do you need to change the level of transcription for the protein In a modality such as describes in what you can do traces on genes and gene products It is having identified a particular differentially expressed gene as important in a state you can do the tracking of modulators either of the expression of the gene or of the gene product The gene products of the genes Differentially expressed are sometimes referred to herein as cancer of or as a cancer modulator. The ovarian cancer modulating protein may be one or alternatively may be the full length protein for the fragment encoded by the nucleic acids. of the ovarian cancer modulating protein is a sequencing modality The amino acid sequence of ovarian cancer that is used to determine the identity or similarity of is encoded by a nucleic acid of the other In the sequences are allelic variants that occur naturally of a protein encoded by a nucleic acid of the Tables In another sequences are variants of sequences as described in the ovarian cancer modulator protein is a fragment of approximately 14 to 24 amino acids in one more way the fragment is a fragment of the fragment includes a region that is not in a modality the fragment has a Cys to help the other In the C term of the fragment is kept as a free acid and the term N is a free amine to help the ej with the 0 ovarian cancer proteins are conjugated with an agent for with albumin of serum Cancer or cancer-like cancer polypeptide activity measurements can be carried out using a variety of the effects of the test compounds on the function of the ovarian cancer polypeptides can be measured by examining the described parameters. An appropriate physiological change can be used that affects the to evaluate the influence of a test compound on the polypeptides of this. functional consequences are determined using cells or animals can also be measured a variety of such in the case of ovarian cancer associated with tumor growth metastasis release of transcript changes for both genetic markers known as uncharacterized spots changes in cellular metabolism such as cell growth or changes in and changes in the intracellular second messengers such as cGMP In the assays the ovarian cancer polypeptide is typically used for example preferably. Tests can be performed to identify compounds with modulating activity in By first It gets in co An ovarian cancer polypeptide with a modulator is incubated and incubated for a period of time, for example, at 48. In one, the levels of ovarian cancer polypeptide are determined by measuring the level of protein or protein level. immunoassays such as spot and with an antibody that is selectively linked to the ovarian cancer polypeptide or a fragment of the For the measurement of the preferred is for example using chain reaction assays or chain reaction of for example hybridization protection dot level The level of protein or mRNA is detected using directly or indirectly detecting agents for example nucleic acids fluorescently or radioactively radioactive antibodies and as described in the In a manner a reporter gene system can be devised using the protein promoter of ovarian cancer operatively linked to a gene such as fluorescein protein te ó The construction of the reporter is usually transfected into an After of the treatment with a modulator the amount of or activity of the gene is measured according to conventional techniques known to those skilled in the art. In a manner as described, it is possible to make traces on genes and gene products. A particular differentially expressed gene has been identified as important in a state the tracing of modulators of the expression of the gene or of the genetic product can be done Genetic products of differentially expressed genes are sometimes referred to herein as cancer of the ovarian cancer protein can be a or alternatively it can be the full-length protein for a fragment shown in the In one the tracing of gene expression modulators is performed the expression of only one or a few genes is evaluated In another, traces are designed to first find compounds that bind to proteins These compounds are then evaluated to determine their capacity d to modulate the activity differentially More once the candidate compounds are identified, variants can be further tracked to better evaluate the ratios of In one modality En assays are carried out the purified gene product is used or genetic products of one or more are made Differentially Expressed Nucleic Acids By antibodies are generated for the genetic products of and conventional immunoassays are run to determine the amount of protein. In a way, cells comprising the ovarian cancer proteins in the Por can be used in a modality the methods comprise combining an ovarian cancer protein and a compound and determine the binding of the compound to the cancer protein The preferred modalities use the ovarian cancer protein although other proteins can also be used for example for the development of animal models of ovarian cancer. diseases In some as describes in which variant or derivative ovarian cancer proteins can be used. In a preferred embodiment of the ovarian cancer protein methods or the candidate agent is bound in a non-diffusible manner to an insoluble support preferably having The insulating supports can be made of any composition to which they can be bonded which can be easily separated from the material and which is otherwise compatible with the overall method of the surface. solid and in any way Examples of suitable insoluble supports include and plates These are usually made of plastic or microtitre plates and arrays are especially because they can be carried out a large number of tests in a way using small quantities of reagents and samples The particular way of linking the composition is not always compatible e with the reagents and the global methods of maintaining the activity of the and that is not diffusible. Preferred methods of binding include the use of antibodies not sterically block either the binding site of or the sequence of when the protein to the direct bond with supports or cross-linking the synthesis of the protein or agent on the Next of the protein binding or of the excess material is removed not by Then the sample receptor areas can be blocked through incubation with albumin of bovine serum or other innocuous or other protein In an embodiment the ovarian cancer protein binds to and a test compound is added to In a manner the candidate agent binds to and adds the cancer protein of the novel binding agents They include antibodies, non-natural binding agents identified in the scans of analogous libraries of Son of particular interest, the screening assays for the agents that have a low toxicity to the cells can be used A wide variety of assays for this including binding assays in electrophoretic mobility shift assays immunoassays for the binding of functional assays and The determination of the binding of the compound modulator test to the ovarian cancer protein can be done in a In an embodiment, the compound is and the linkage is determined by binding all or a portion of the ovarian cancer protein to a support by adding a labeled candidate agent a label by washing the excess and determining whether the label is present on the support Several blocking steps can be used and depending on whether or not only one of the proteins can be marked by the proteinaceous candidate compounds. In a way, more than one component can be marked with different ones and a fluorophore. Useful reagents from for example the shutdown or transfer reagents In a pru compound link eba is determined by binding assay. The competitor is a binding moiety that is known to bind to the target molecule a cancer protein such as a component. Under certain there may be a competitive bond between the compound and the moiety displacing the fraction of link to In one the compound of First is added either the one or the one is added for a sufficient time to allow the one if it is. Incubations can be carried out at a temperature that facilitates the activity typically between and. Periods of for example to facilitate a rapid tracing of high Typically it will suffice between and 1 The excess reagent is usually removed or the second is then added and the presence or absence of the component is followed to indicate the followed by the compound The displacement of the competitor is an indication that the test compound is binding to the protein cancer can be marked and therefore it is able to bind and modulate the activity of the cancer protein. In this it can be marked any by itself marking the presence of the mark in the washing solution indicates the displacement by the a way if the compound of the presence of the mark is marked on the support indicates the In a modality the compound of incubation is first added and followed by the The absence of link by the competitor may indicate that the test compound is bound to the ovarian cancer protein with a further affinity So if the compound is marked in the presence of the mark on the together with a lack of linkage it may indicate that the test compound is capable of binding to the cancer protein of the ovarian cancer. In one embodiment, methods comprise differential screening to identify agents that are capable of modulating the activity of cancer proteins. e ovarian cancer and a competitor in a first A second sample comprises a compound of a cancer protein and a The competitor link is determined for both and a change or difference in the link between the two samples indicates the presence of an agent able to bind to the ovarian cancer protein and to potentially modulate its Is if the competitor's link is different in the second sample in relation to the first the agent is able to bind to the ovarian cancer protein In a way it is used Differential screening to identify candidate drugs that bind to the ovarian cancer protein but can not bind to ovarian cancer proteins The structure of the ovarian cancer protein can be modeled and used in a rational drug design to synthesize agents that interact with that Candidate drugs that affect the activity of an ovarian cancer protein are also identified by tracking drugs to determine their capacity already It can be used to improve or reduce the activity of the. Positive controls and negative controls can be used in the Control and test samples are carried out at least to obtain results statistically. The incubation of all the samples is for a sufficient time for the link of the After the samples are washed to be released from the material non-specifically and the amount of agent is usually determined. When one is used the samples can be counted in a scintillation counter to determine the amount of compound. A variety of other reagents in these assays include reagents such as proteins that can be used to facilitate the optimal binding of to reduce non-specific interactions or reagents that otherwise improve the efficiency of such inhibitors can be used. inhibitors of agents The mixture of components can be added in an ord in which provides the link In one embodiment the invention provides methods for screening a compound capable of modulating the activity of a cancer protein. The methods comprise adding a compound of as defined to a cell comprising cancer proteins. Preferred include almost any. The cells contain a recombinant nucleic acid encoding a cancer protein. In a modality a library of candidate agents is tested on a plurality of In a the assays are evaluated in the presence or in or in the previous exposure or signals for example potential factors of pharmacological agents including carcinogenic or other contact cells of In other determinations are made in different stages of the cycle process This is identified compounds that modulate cancer agents of Compounds with pharmacological activity are capable of improve or interfere with the activity of the protein of cancer Once similar structures are evaluated to identify the critical structural feature of the compound In one a method is provided to inhibit cancer cell division The method comprises the administration of a cancer inhibitor In another method is provided for inhibit cancer The method comprises administering a cancer inhibitor In a modality methods are provided for treatment of cells or individuals with cancer The method comprises administering an ovarian cancer inhibitor In an ovarian cancer inhibitor is an antibody as described In another ovarian cancer inhibitor is a molecule or AR A number of proliferation assays are known to those skilled in the art and as described in Soft agar growth or suspension colony formation Normal cells they require a solid substrate to bind and when the cells are lost they and they grow separately from the transformed cells can grow in a suspension culture or suspended in a medium such as agar or cells when transfected with suppressor genes regenerate the phenotype and require a solid substrate to bind and can be used. growth in soft agar or colony formation to identify modulators of cancer sequences when expressed in cells inhibit cell proliferation and transformation A therapeutic compound would reduce or eliminate the ability of host cells to grow in the culture in agitated suspension or suspended in a medium such as solid o The techniques for soft agar growth or colony formation assays are described in Freshney Culture of Animal A Manual of Basic Technique incorporated herein as well See also the methods section from Garkavtsev et al. incorporated herein as Inhibition by contact and limitation of growth density Normal cells normally They grow in a flat pattern and organized in a Petri dish until they touch other cells When the cells touch each other they are inhibited by it and stop when the cells are not inhibited by the cells and continue to grow to high densities. in foci By the transformed cells they grow up to a higher saturation density than the cells This can be detected morphologically by the formation of a disoriented cell or rounded cells in foci within the regular pattern of the surrounding normal cells In a way it can be used the index of labeling with density to measure the density limitation of Freshney by Cells when transfected with suppressor genes regenerate a phenotype and become inhibited by and grow to a density more In this the index of marked with thymidine in density is a preferred method to measure the density limitation of the transformed host cells Adas are transfected with a sequence associated with cancer and cultured for 24 hours at the density of under no media conditions. The percentage of labeled cells with is determined autoradiographically by Freshney. Dependence on the growth factor or serum. Transformants typically have a lower dependence on serum than their counterparts by Cancer Eagle and collaborators Ex Med and this is due in part to the release of different growth factors by the cells Dependence on growth factor or serum of transformed host cells can be compared to that of the control levels of tumor-specific markers Cells release a greater amount of certain factors in the specific than their normal counterparts by the plasminogen activator is released from the human glioma at a higher level high that from the normal cells of the brain by tumor and potenti pages to the tumor interference in Mihich Biological Responses in In a way the tumor angiogenesis factor is released at a higher level in the tumor cells than its counterparts by Folkman Cancer Different techniques that measure the release of these factors are described in Freshney Also see Unkless and collaborators Strickland and Beers et al. Br Cancer sites tumor and potential interference with tumor in Mihich Biological Responses in and Freshney Anticancer Invasiveness in atrigel The degree of invasiveness in Matrigel or in some other matrix constituent can be used as an assay to identify compounds that modulate the sequences associated with cancer of the tumor cells exhibit a good correlation between the malignancy and the invasiveness of the cells in Matrigel or in some other constituent of extracellular matrix In this normally cells such as cells are used The expression of a suppressor gene of tumor in these host cells ped would reduce the invasiveness of the host cells. In a way, the level of invasion of the host cells can be measured by using filters coated with Matrigel or with some other matrix constituent. The penetration into or through the distal side of the host is evaluated as and it is evaluated histologically by the number of cells and the distance or by previously marking the cells with and counting the radioactivity on the distal side of the filter or the bottom of the Freshney tumor growth in vivo The effects of the sequences associated with cancer of the ovary on cell growth in transgenic mice o Transgenic mice can be made with elimination where the cancer gene is altered from or where a cancer gene is inserted. Transgenic mice with genetic deletion can be made by inserting a gene marker or other heterologous gene at the site of the endogenous ovarian cancer gene in the noma of mouse by means of recombination These mice can also be made substituting the endogenous ovarian cancer gene with a mutated version of the cancer gene or by mutating the ovarian cancer gene for example by exposure to it A DNA construct is introduced into the nuclei of the totipotent cells The cells containing the newly acquired genetic lesion designed to inject into a mouse embryo which is in a female Some of these embryos develop into chimeric mice that have germ cells partially derived from the cell line By reproducing the mice it is possible to obtain a new line of mice containing the genetic lesion by Capecchi et al. Science Chimeric directed mice can be derived according to Hogan et al. Manipulating the Mouse A Laboratory Handbook CSH and Robertson Teratocarcinomas and Embryonic Stem A Practical In a way different host animals can be used or Por can be used as host the genetically atomic mouse by Giovanella and collaborators Nat Cancer a mouse a mouse or a mouse irradiated by Bradley and collaborators Cancer Selby et al. Cancer Approximately 106 transplantable tumor cells injected into hosts will produce invasive tumors in high proportions while normal cells of similar origin do not. the tumor developing hosts are injected subcutaneously with cells expressing a cancer-associated sequence. After a time of preference of 4 to 8 the tumor growth is measured by volume or by its two more dimensions and compared with the tumor. tumors that have a statistically significant reduction by the T test have a growth. Polynucleotide modulators of ovarian cancer Eolinucleotides and A In certain the activity of a cancer-associated protein is reduced or inhibited by the use of a polynucleotide by an acid nucleic complementary and that of preferential A mRNA nucleic acid sequence can be specifically hybridized, for example a cancer protein mRNA or a sub-sequence of the polynucleotide to the mRNA reduces the translation stability of the nucleic acid. synthetic species formed from subunits that occur or their homologs Polynucleotides may also have sugar fractions or bonds Among examples are the phosphorothioate and other species that are to be used in the analogues are understood by this as long as they work effectively for hybridize with cancer protein mRNA by Pharmaceuticals These polynucleotides can be easily zoned using media or can be synthesized in The equipment for this synthesis is sold by several including Applied Biosystems The preparation of other oligonucleotides such as thioates and derivatives is also well known by The experts in the The molecules as used in the include oligonucleotides or in The oligonucleotides in por can be used to block the transcription by the link to the chain The oligonucleotides and in sense comprise a sequence of nucleic acid of a single chain is or able of binding to the objective sequences of mRNA or DNA for cancer molecules of A preferred molecule is for an ovarian cancer sequence of Tables 1 to a for a ligand or activator of the oligonucleotides or in accordance with the present comprise a fragment generally at least about 14, preferably about 14 to 30 A sense oligonucleotide can be developed or based on a cDNA sequence encoding a protein by Stein and Cohen Cancer and van der Krol et al. BioTechniques RNA interference is a mechanism to suppress genetic expression in a specific way of the by and collaborate ores Sciencexpress March Sharp Genes and Curr Op Cell Biol In cells has been shown that small interfering double-stranded RNAs for example of 21 are effective to induce a response by Elbashir et al. Nature The mechanism can be used to decrease the expression levels of genes for example the treatment or validation of relevance addition to the polynucleotides can be used to direct and inhibit the transcription of nucleotide sequences associated with cancer of Una is an RNA molecule that catalytically dissociates other molecules from. Different classes of including ribozymes of the ribozyme group of head of RNAse ribozymes have been described. and Ax-head ribozymes by Castanotto and collaborators Pharmacol for a general review of the properties of different The general characteristics of fork ribozymes are set forth in et al. Acids European Patent Publication Number Patent of the United States of America Number The methods of preparation are well known two by experts in the International Publication Number WO Ojwang and collaborators Proc EUA and collaborators Gene Leavitt and collaborators EUA Leavitt and collaborators Gene and Yamada and collaborators Virology Modulators of ovarian cancer polynucleotides can be introduced into a cell containing the sequence of nucleotides by the formation of a conjugate with a linker molecule as described in International Publication WO Number Suitable ligand binding molecules but not bound by surface receptors other factors or other ligands that bind to surface receptors The conjugation of the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its molecule or receptor or to block the entry of the oligonucleotide in the sense or its conjugated version in the introduce a cancer polynucleotide modulator of ovary in a cell containing the nucleic acid sequence by the formation of a complex as described in International Publication Number WO It is understood that it is also possible to use molecules or models with elimination and increase in screening assays described in addition to the methods of treatment. In one, methods are provided for modulating ovarian cancer in cells. In one the methods comprise administering to an ovarian antibody that reduces or eliminates the biological activity of an ovarian cancer protein. The method comprises administering to a cell or a recombinant nucleic acid that encodes a cancer protein of this. It can be carried out in any number of In a modality by when the ovarian cancer sequence in the cancer of this state is reduced. be reversed by increasing the amount of the ovarian cancer gene product in the This can be or by overexpression of the ovarian cancer gene or administration of a gene encoding the cancer sequence using genetic therapy techniques. In one embodiment, gene therapy techniques include the incorporation of the exogenous gene using enhanced homologous recombination by described in the International Publication Number incorporated herein by reference in its In a manner by when the ovarian cancer sequence is increased in the cancer the ovarian cancer gene activity is reduced for example by the administration of a nucleic acid or of RNAi of cancer In an ovarian cancer proteins of the present invention can be used to generate polyclonal and monoclonal antibodies to cancer proteins of ovarian cancer proteins can be used to chromatography columns by Then can be use these columns to purify antibodies from ovarian cancer useful for de o purposes In one modality antibodies are generated for unique epitopes for a cancer protein the antibodies show little or no cross-reactivity with other ovarian cancer antibodies can be attached to affinity chromatography columns and can be used to purify cancer proteins from antibodies can also be use as polypeptides as described because they will bind specifically with the cancer protein of Methods to identify variant sequences associated with ovarian cancer Without compelling us by the expression of different ovarian cancer sequences is correlated with cancer With this, disorders based on the ovarian cancer mutant or variant genes can be determined. In one the invention provides methods for identifying cells containing ovarian cancer genes for example by determining all or part of the sequence of at least one cancer gene of the ovarian cancer. endogenous ovary in a This can be Carry out by using any number of sequencing techniques In one embodiment the invention provides methods for identifying the ovarian cancer genotype of a by determining all or part of the sequence of at least one ovarian cancer gene of the The method may include comparing the sequence of the ovarian cancer gene with an ovarian cancer gene by a gene of the La type, in general in at least one tissue and may include the evaluation of a number of different tissues or samples thereof. The sequence of all or part of the cancer gene can then be compared to the sequence of an ovarian cancer gene to determine if they exist. This can be done using any number of homology programs such as In one embodiment the presence of a difference in the sequence between the patient's ovarian cancer gene and the ovarian cancer gene correlates with a disease state or a propensity to The ovarian cancer genes are used as probes to determine the number of ovarian cancer gene copies in the ovarian cancer. In another modality ovarian cancer genes are used as probes to determine the ovarian cancer genes. chromosomal location of cancer genes Information such as location finds use to provide a diagnosis or in particular when abnormalities are identified such as and in place of the cancer gene of composition and vaccine administration In one it is administered to a In the present case, a therapeutically effective dose of an ovarian cancer protein or modulator of therapeutically means a dose that produces effects for which the exact dose will depend on the purpose of and may be asserted by a person skilled in the art using Ansel et al. Pharmaceutical Dosage and Drug Delivery Pharmaceutical Dosage Forms ISBN Lloyd T he Science and Technology of Pharmaceutical Pharmaceutical and Pickar Dosage Calculations It may be necessary to make adjustments for cancer degradation of the systemic supply against and the rate of synthesis of new as well as for the health weight of the interaction time and severity of the and may be asserted with routine experimentation by the experts in this. US Patent Application Number also discloses the use of compositions and methods of diagnosis and treatment in cancer and is expressly incorporated herein by A for the purposes of the present includes both humans and others in particular mammal By the methods are applicable for both human therapy and for applications In the modality the patient is a preferably one and in the modality more the patient is a being The administration of the proteins of ovarian cancer and the modulators thereof of the present invention can be do in a variety of as described but not limited or intraocularly In some for example in the treatment of wounds and proteins and ovarian cancer modulators can be applied directly as a solution or The compositions of the present invention comprise an ovarian cancer protein in a form suitable for administration to a Pharmaceutical compositions are in a soluble form as they are present as pharmaceutically salts meaning that they include both acid addition salts and addition salts. Pharmaceutically acceptable addition salts refer to salts that retain the biological effectiveness of free bases and that are not biologically undesirable or otherwise formed with acids such as acid, acid, acid, and acid, and acids such as acid, acid, acid, acid, and the like derived from such bases is as salts of and Particularly preferred are salts of and Salts derived from pharmaceutically acceptable non-toxic organic bases include the salts of amines and amines including substituted amines which occur cyclic amines and ion exchange resins such as tripropylamine and The pharmaceutical compositions may also include one or more of the proteins such as albumin from filler regulators such as corn starch cellulose and other sweetening agents and other agents and polyethylene glycol. The compositions may be administered in a variety of dosage forms depending on the method For the dosage unit forms suitable for oral administration but are not limited and it is recognized that the ovarian cancer protein modulators constructs organic molecules when administered should be protected from the This is usually carried out either by the formation of complex of mol The composition for making it resistant to acid hydrolysis and / or by packaging the molecule in a carrier appropriately such as a liposome or a barrier of The means for protecting the digestion agents are well known in the art. an ovarian cancer protein modulator dissolved in a pharmaceutically vehicle preferably a vehicle A variety of vehicles can be used eg regulated serum and these solutions are sterile and generally free of matter These compositions can be sterilized by conventional sterilization techniques Well-known compositions The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate conditions such as adjusting agents and adjuvants of the adjusting agents of and for example lactate chloride chloride chloride acetate. The active ingredient in these formulations may vary and will be selected primarily based on the volumes of the weight and in accordance with the particular mode of administration selected and the needs of the Pharmaceutical Science f and Hardman and Limbird Goodman and The Pharmacological Basis of Therapeutics. Typical pharmaceutical composition for intravenous administration would be about 10 milligrams per patient. Dosages of up to about 100 milligrams per patient may be used in particular when administering the drug to an isolated site and not in the current such as in a body cavity or In a lumen of a In the administration it is possible to use substantially more dosages The actual methods for the preparation of the compositions parenterally are easily The compositions containing modulators of ovarian cancer proteins can be administered for therapeutic or prophylactic treatments. In applications, the compositions are administered to a patient suffering from a disease in an amount sufficient to cure or at least partially arrest the disease. An adequate amount to do this is defined as a therapeutically effective amounts for this use will depend on the severity of the disease and the general state of health of the patient. individual or multiple of those depending on the dosage and frequency required and tolerated by the In any composition should provide a sufficient amount of the agents of this invention to effectively treat an amount of modulator that is able to prevent or slow down the Cancer development in a mammal is referred to as a prophylactic The particular dose required for a prophylactic treatment will depend on the medical condition and the history of the particular cancer that is being as well as other factors such as the the the way of the prophylactic treatments can be by in a mammal or that previously had had to prevent a recurrence of or in a mammal suspected of having a significant probability of developing by in the expression profiles. Strategies can be employed either in a form of vaccine or a vaccine. It will be appreciated that the present ovarian cancer protein modulating compounds can be administered alone or in combination with ovarian cancer modulating compounds or with another agent for example other agents or treatments against the ovarian cancer. In many one or more cells will be introduced into the cells. acids for example polynucleotides comprising the nucleic acid sequences stipulated in Tables 1 to such as polynucleotides or in vitro or in. The present invention provides and cells useful for the expression of polypeptides and nucleic acids associated with cancer using expression systems in in vitro or in vivo in the cells or in the process particulates The methods used to introduce nucleic acid sequences into cells can be used to introduce nucleic acids into host cells for the expression of a specific protein or acid. These include the use of transferase with phosphate of spheroplasts of vectors and any of the other well-known methods for introducing DNA genomic DNA or other genetic material into a cell by Berger and Guide to Molecular Cloning Techniques of Methods in Enzymology Academic Ausubel and 1999 and Current Protocols and Collaborators Molecular A Laboratory Manual Volumes CSH In one modality proteins and Ovarian cancer modulators are administered as agents and can be formulated as described In a manner ovarian cancer genes the sequence of length sequences or regulatory sequences of the cancer coding regions can be administered in an application of therapy These cancer genes from ovarian may include applications either as gene therapy to be incorporated into or as compositions as will be appreciated by those skilled in the art. Ovarian cancer polypeptides and polynucleotides may also be administered as vaccine compositions to stimulate and respond to these vaccine compositions. can peptide compositions encapsulated in poly by Eldridge et al. by Immunol Alonso et al. Vaccine Jones et al. Vaccine peptidic compositions contained in complexes by Takahashi and collaborators Nature Hu and collaborators Ex Immunol peptidic systems of multiple antigens by Tam Nat Tam Methods peptides formulated as peptides multivalent peptides for use in delivery systems normally peptides viral delivery vectors and aufmann page Concepts in Vaccine de Chakrabarti et al. Nature Hu et al. Nature ieny and co Top laborers and collaborators Chanda and collaborators Virology particles of viral or synthetic origin by Kofler et al. Methods Eldridge et al. Hematol Falo et al. Nature adjuvants and collaborators An Gupta et al. Vaccine liposomes and collaborators Rock Immunol Today or naked or absorbed in particles and collaborators Science Robinson et al. Vaccine Shiver and page Kaufmann Concepts in Vaccine Development by Cease and Berzofsky and Eldridge and co-workers. Also can be used delivery technologies directed to the also known as mediated direction such as those of Avant Immunotherapeutics. Vaccine compositions often include Many adjuvants contain a substance designed to protect the antigen of catabolism such as aluminum hydroxide or oil and a stimulant of the responses such as lipid proteins derived from Bortadella pertussis or from Mycobacterium tuberculosis Certain adjuvants are commercially available as by Incomplete Adjuvant and Complete Adjuvant Freund's Adjuvant Merck 65 and aluminum salts such as aluminum hydroxide gel or iron salts phosphate or an insoluble suspension of tyrosine sugars polysaccharides or anionically microspheres and quil such as and other growth factors that can also be used as adjuvants The vaccines may be administered as nucleic acid compositions wherein the RNA or one encoding one or more of the or a fragment thereof is administered to one per Wolff et al. Science Patents of the United States of North America Numbers and International Publication Number WO Examples of DNA-based delivery technologies include DNA delivery facilitated by lipid complexes and particle-mediated delivery or pressure mediated by the US Pat. No. For therapeutic immunization purposes or the peptides of the invention may be expressed by viral vectors or examples Expression vectors include viral hosts such as vaccine or varicella This approach involves the use of the virus for example as a vector for expressing nucleotide sequences encoding polypeptides or fragments of cancer polypeptides after being introduced into a virus. of recombinant vaccine expresses the peptide and thus elicits a response. Vaccine vectors and methods useful in immunization protocols are set forth in U.S. Pat. No. Other vector is BCG Calcium BCG vectors are described in Stover and collaborators Nature A wide variety of other vectors useful for therapeutic administration or for example adenovirus and virus vectors retroviral vectors Salmonella vectors anthrax toxin vectors and by Shata et al. Today Shedlock and collaborators Hipp et al. In Vivo The methods for the use of genes as vaccines The DNAs are well and include placing an ovarian cancer gene or a portion of an ovarian cancer gene under the control of an adjustable promoter or of a tissue-specific promoter to be expressed in a cancer patient. ovary used for DNA vaccines can encode ovarian cancer proteins in length but more preferably encodes portions of cancer proteins including peptides derived from cancer protein In a patient is immunized with a DNA vaccine that comprises a plurality of nucleotide sequences derived from a Por cancer gene genes associated with ovarian cancer or a sequence encoding subfragments of a cancer protein are introduced into vectors and tested for their immunogenicity in the context of MHC Class and the ability to generate T cell responses This procedure provides the production of cell responses Cytotoxic T cells against the presenting cells including the intracellular epitopes In one embodiment, the DNA vaccines include a gene encoding an adjuvant molecule with the vaccine. These adjuvant molecules include cytokines that increase the immunogenic response to the ovarian cancer polypeptide encoded by the vaccine. Additional adjuvants are available. of ovarian cancer find use in the generation of cancer animal models When the identified ovarian cancer gene is repressed or diminished in the tissue of the therapy technology by when the RNA is directed towards the cancer gene it will also decrease or The ovarian cancer animal models find use in the tracing of modulators of a sequence associated with ovarian cancer or cancer modulators In a way the technology of transgenic animals that includes elimination technology for example as a result of homologous recombination with a genetic direction vector give as a result the absence or increased expression of the cancer protein of When it may be necessary to specific expression of tissue or the removal of ovarian cancer protein It is also possible that the ovarian cancer protein is in cancer transgenic animals can be generated that overexpress the cancer protein. Depending on the level of expression, promoters of different strengths can be used to express the number of copies of the transgene and can be compared to make a determination of the expression level of the animals generated by these methods find use as animal models of cancer and are additionally useful in the screening of modulators to treat cancer of kits for use in diagnostic applications. For use in the applications of and suggested therapies the invention also provides kits in Diagnostic applications These kits can include any or all of the reagents of nucleic acid regulators or cancer-specific antibodies of hybridization probes polynucleotides of siRNA or ovarian cancer polypeptides or polynucleotides negative small molecule inhibitors of cancer-associated sequences A therapeutic product can Include sterile serum or other pharmaceutically based emulsion and suspension. In kits, instructional materials may be included that contain instructions for practicing the methods of this. Although instructional materials typically comprise written materials or are not limited to the any means capable of storing such instructions and of communicating them to a user. These means but not limited means of electronic storage media and optical discs. These means may include addresses of Internet sites that provide these materials. present invention also provides kits for screening modulators of cancer-associated sequences These kits can be prepared from materials and reagents easily. These kits can comprise one or more of the following a polypeptide or polynucleotide associated with cancer tubes and instructions for test the activity associated with cancer of the kit contains the ovarian cancer protein biologically A wide variety of kits and components can be prepared in accordance with the present depending on the intended user of the kit and the particular needs of the diagnosis would normally involve the evaluation of a plurality of genes o Genes will be selected based on correlations with important parameters in the disease that can be identified in the historical or EXAMPLE data. Example 1 Analysis of the Genetic Chip The molecular profiles of the different genes were determined and analyzed. ntes normal and cancerous tissues using chips RNA was isolated and the analysis of the genetic chip as already described and collaborators Nature Zhao et al. Genes 454633 3T014 c 407291 AAC01464 1 sapera 455203 403547 401530 9 411057 c 415953 ESTs ESTs 422949 402112 458145 ESTs 452332 ??? 14359 ESTs 5 ESTs 446205 ESTs 54 423200 53Ts A1633744 5 754 420111 NC1 CGAP 5 432140 414304 409479 ESTs 404727 446011 E3Ts AVffi0398S 417173 H ESTs 132267 0 5 155024 403525 to ESTs 11C523 5 134523 H 5 5 102131 438913 Hs ESTs 5 5 415973 ESTs 11 Horro 442750 ESTs 11 11 5 5 5 5 5 1 5E 5733 6 1 1469320 1 S 414540 1464063 414605 1465301 1 SE387771 3E 1492524 1 T35345 3E53 354 50299 415654 41571S 415747 Z44135 416168 1574545 1 K46460 416425 159368 1 416141 159480 AA132474 416665 1607797 1 416313 163001? AW934714 3E161007 3E162438 AA190449 417344 I 417549 AA203651 417611 AW9S4798 AW993S90 AA204755 417682 1692759 69561 AVY749855 AA22S995 418709 AA227394 AA641866 419753 187763 AA249574 AA563553 419936 Al AA 5019 422 949 223 184 1 AA319435 4A319377 AA894424 423735 1 423756 231725 1 AA834683 AA331633 BE17047S AW964175 424101 AA335394 AA335535 424324 241151 1 AA343628 424872 AA347923 425574 AA359654 425612 BE0Q4257 426,055 N32049 261414 426544 AAS03675 426650 270283 AA3823I4 429163 300543 AA592975 AA447312 430264 315008 eE303010 430757 322347 AA485570 431071 327550 AA491379 431322 AA5I6C49 A 432159 AA635266 432340 345248 AA632632 432363 345469 AAS34489 432 966 356 839 A 974 148 AA572946 364276 AW87727 433449 A 772282AA592974 43386Í 375629 AA812960 AA625499 2348 38C 06 434 374 384 889 AA6252S9 434804 434950 AA631439 AA721522 T33070 AW97489 A654375 436084 436843 437096 433008 AA744406 AA745347 AA824Saa 437146 43371 938044 AA730977 BE565575 A 437152 437229 434947 A123972 5 439 031 439 152 469 AW976005 20 47334 W76326 440051 3E559980 BE397203 3E2577253E513654 E257742 8E561356 441194 51193 3E274Í81 BE275382 441369 515638 442257 AW503831 443161 561305 AJ038316 I53 561 882 N57863 443 198 039 813 168 642 443 534 572 957 A1076123 443,613 AÍ073356 57913J I342 l 531 644 554 825 AI374527 714150 824 A AJ530313 AI702055 R86260 35144S31 AÍSC6422 452 947 933 810 96 453 845 S83027 454182 454389 AW752S71 1 AW7S27l0 121S584 454556 1223878 AW307775 07737 A AVY809133 454597 AAA 1227504 A AW812227 454650 AW8S471S? 454707 1230250 AW6337S3 A AVY8337S5 AW833377 454874 1238494 AW8364073E175Ó008E175579 454913 1242238 AW8414629? 454934 AW846074 AiV846130 454,963 AW847547 S56? 847717 455013 1248899 3? 073,250 AW850529 455092 3? 154505 3? 1544899E1544S6 3E154472 455121 47 455152 1255227 455203 1259973 19 AW865 455,275 AW977806 455,435 1,290,546 AW939530 455,441 AW946C20 AW946021 AVW6015 AVW6039 AW946045 6E 1,348,141 3? 064,056 3? 0639? 4 1349206 455713 1352512 455753 ?? 080477 3E08CS463E08O54S 455851 3 ?? 46379 ?? 146914 455353 137S671 1 8E147225 BE147205 455379 ?? 153275 ??? 53189 BE 3E 1530223? 1530308E1S2974 455993 1398665 8? 179085 3? 179254 ?? 293262 45Í101 151654 901089 593 456212 1655565 177025 ?? 225423 A 4S6714 AW897274 ?? 326794 457405 333127 ?? 504860 ?? 504911 371514 457727 39356Í AW974687 ?? 643656 AAS5214S 457868 458154 491766 458804 78 A1904723 459170 920646 AJ905518 5 AW17E037 459185 ?? 908287 iOSSSZi írora oí 403786 30S3636 403831 7249249 s 403944 7711864 P 7535322 4O4340 i 7342122 3705107 9796751 2 404727 3C61050 404767 7882827 404828 6580415 404349 5350447 404893 7331420 104952 404972 404992 Minus I 405071 7230083 405227 inus 405277 405285 6139075 Minia 405,292 Plus 405336 5094535 405362 2337862 Wnua 405,382 6,552,767 405,454 Plus 4053 405465 7767904 8439781 Plus 405,547 1,054,740 Plus 405575 4003382 405621 Plus 405636 5123990 405675 4557087 4156182 Plus 7,018,349 5,738,434 Milus 405793 405800 2791346 Plus 4,938,307 Minus 7551809 6758731 405896 6758795 Plus 405904 7705118 Minus 405917 7712162 Minus 405582 8247790 Minus 405582 8247790 406052 6608267 406703 Plus 6608267 406163 406503 7158901 Plus 406250 406504 406504 406541 406589 406589 Plus TABLE ABOUT ELL P PASSION 404767 ESTs 414276 IH 17 Homo sapiens cONA 444055 sapiere l44l 447981 proton 5 410677 400S82 exon 452933 AW391423 H mo sapiens FU22425 done HRC08635 407233 X16354 adhesion 26 430127 AA219496 sutKiniL alpha 7 10 448218 A1188489 413511 AJ527178 proton 26i 459511 AI142379 Soaras lesas BE379794 A18234I0 15 451219 AA054209 ESTs 448939 proton fU10637 400800 eyes 3 446342 8E298665 Homo sapiens A c AW070211 Homo sapiens ra 20 433348 448497 ta 415279 F04237 proton 419323 A1092379 EST 430265 1 25 014214 4 2 425535 AB007937 gene 412923 A1179922 proton delta 1 447980 ESTs AI98975I ESTs 400246 predicted exon 404971 exon 422954 similar ta Similar to 2 432201 AI538613 ESTs 455993 AL134577 ESTs 456525 A protein A3 Í44060 Homo sapiens clone 448199 ESTs 443422 R1C288 ESTs 401117 predicted predicted 431214 AA29492I viral B te 431649 predicted exon exon 165 430478 NU 063880 enrómeseme pro 165 401244 predicled exon 415167 AA160784 ESTs 438291 Homo sapiens FU22380 done 405183 predicted exon 436460 AJ271643 ESTs 425332 ESTs 418332 ESTs AA3S8760 Fetal II Homo sapiens end AW449137 ESTs 165 437192 AW975786 ubiquitiveonjugaiing enr to 165 400891 predicted 165 AW445166 ESTs 425798 AA364002 giand II Horro sapiens cONA at 165 459253 57476 420746 ESTs 414717 BE27103S 5 400727 exon 422691 c reduced core prolein l 405639 predicted exon GCJ7 Homo sapiens 456146 AL034349 recipient 8E388044 Homo sapiens cONA 414267 AL078459 dimelhyiargmine din 1 predicted exon 403613 predicted exon 414203 454315 AW373564 nuclear pore cemplex inleracBng protein 452114 N22687 ESTs 404638 predicted exon 404600 predicted exon AF070574 Homo sapiens done 163 406629 AW277078 factor 1 alona 1 450S57 sapera mR 449966 H60542 ESTs 163 402585 exon 163 436008 AI078428 HsiS785 predicted exon 163 P protein C 163 405088 predicted exon 437345 6? 259522 subco 163 432280 8E440142 recogniSon 163 BE379320 Cu protein 163 428801 163 431394 2 163 452998 Homo sapi ens FU21288 dona 163 Al 147392 ESTs 163 AA972412 and proton 2 163 443534 AK376123 H 163 459510 AA0767O6 cONA 450517 A1523755 451938 AJ354355 Oi T 163 454478 AYV805749 Horo sao AA412048 protein cea proton exon 416841 N33878 A1 16L2 458710 AV660856 gbAV660856 Homo sapiens ctona GLCG K2 450657 AK001579 H425277 404230 exon predtóed A1582743 like S 1 X75363 15 431972 AI805145 ESTs sxon 404,703 delta 449,335 STAT3 avian virus Homo sapiens 433,782 sapiens HG0670 405473 exon 42CB31 AA2Í0824 ESTs 402939 exon 405,196 Predicted 452947 AW130413 sapiens ConA 414170 24 437133 KIAA0776 prolein 458356 AJ024855 ESTs 153 407 857 AJ928445 h prolein FU20163 405587 accession 408562 AW247699 ESTs 448338 AI492857 cdn 402,694 430,224 458,792 402,944 predicíed exon ofc íranslafion iniiialion 5A 408,651 Horro sapiens ConA 423238 AA323569 ESTs 421,517 K1AA0809 prolein AB023217 prolein 440,815 Ulive 400534 exon 451034 AL050341 A1375726 proton 450105 BE281124 Similar EASL 8ET3 407464 AJ276396 sapiens inse rí cONA 451337 T92157 ESTs 435313 ESTs predicted CGAP Pr3 Homo sapiens AW470302 ESTs 401269 predicted 427509 M62505 S receiver 1 416846 ESTs ESTs 445930 Homo sapiens do 24747 sequence 421254 proton 447073 AW20Í821 ESTs 445438 AB014578 prolein 432126 AA865239 ESTs 424091 AF235097 9263 1F 440832 AICS7548 ESTs 449228 7 b 434253 ESTs 459270 434 Ovens 454425 AW300927 AA099907 ESTs 400837 458865 Homo FU14299 done PIACE1010 BE122762 1541 414376 simaa prolein AW749855 Homo 454128 2 156 441074 AWS00001 Homo J22035 done HEP03838 451742 T77609 1 403687 431838 ESTs 402855 exon 449635 A1989942 ESTs AW983709 ESTs 444301 prolein 414973 428374 prolein 415745 AJ301107 ESTs 432532 AW058459 ESTs 15J AA193439 Homo sapiens 418101 AL047476 gap 15J 453110 AW384928 H 2516Q Homo sapiens 458,606 AJZ39397 H 436389 AA741028 Hs ESTs 15J 428 068 1 AA732647 AF085936 H64017 AF066285 AA846963 440190 AW752597 AW752604 AW752700 440669 A1206964 AA902772 441552 AA937975 F1121S BEC4JS63S 442,257 A 443,193 AI664642 443534 1 6S5239 65388 1 358760 446593 1 AW250546 BE257108 BE251006 BE2559573E250926 8E5I3012 AV659318 447224 71279 BE617125 447252 AI369730 447383 BE617964 447775 73665 1 BE179318 BE620O44 4477 S7 73719 1 6 448213 75525 1 BE622201 448338 AI492857 AW070478 AIE85157 448838 AA263136 00335 W00327 44S231 1 AA442406 450594 N42915 F07753 AA010329 451400 A1793147 452544 AW351888 452947 AW13041 453758 U83527 Ai120938 454163 AW175997 AW176000 A 175S99 AW175994 AW176004 AW175939 454178 AW177274 A 177223 AW177233 454181 AW177377 AW177357 AW177335 AW177358 AW177395 AW177394 AW177396 AW177333 AW177384 AW177382 454209 AW179083 AW179081 AW179002 AWB01714 454249 A 249008 BE295653 BE2S6765 454377 1 AA076811 AW814764 454478 A 805372 AW794466 AW798102 A 736 921 AW794538 AW794380 454485 AW795322 AW795306 AW795310 AW795314 AW795321 454505 A AW801365 AW801435 AW801372 AW809109 AW809122 AW809133 AW809131 AW809126 A 3C9128 A AW809132 AW810224 454610 454633 454666 1380AW811385 AW812723AW812930 AW812994 AW847807 AW847935 454961 454803 AAA 45 5132 AW857955 AW857943 AW85794SAW8S7963 AW857956 AW5573S2 A 8S7935 AW857940 AW857944 A 857 947 AW857934 AW937792 BE072250 BE072251 8E072264 455,640 BE0639038E063838 BE063863 BEO540568E0S39748BK3904 BE063906 455694 BEO673O0 BE067293 BE067279 455910 Z43712 Bei56729 BE156533 BEI566738E1565398E156674 BE156430 BE156432 BE156541 455993 BE179085 BE1790848E1790868E179264 8E313241 BE383148 456329 T41418T41320T41379 456,394 W28506 AA469146 AA4693S6 AA469218 AA463395 458025 L23206 AJ239397 AV6557Í4 458640 AI284935 AW409822 BE408182 458792 459170 AJ905515 AW176037 459270 TABLE Eos posiScra Rsf 400449 9887692 400613 400634 10 400642 8117693 400661 8118474 400684 8118763 400685 8118768 400727 400749 7331445 8567878 Pia 400337 9188531 400842 1927148 400891 9958279 400917 7283166 400931 7651921 Minus 400,964 7,139,719 Minus 400,965 Minus 7,960,452 Minus 6078794 401010 8117391 401072 3687273 401088 8492704 Rus 401116 99665S9 Plus Minus 9438331 401204 9743388 Minus 401220 9929324 Minus 401244 4627300 Minus 4012 68 97971S4 Plus 401,269 8,954,206 Plus 401283 S800093 Minus 401,373 7,248,205 Minus 401,405 Minus 401465 401492 7341778 401521 7705251 401566 8469090 Minus 401575 7229804 Minus 401589 Plus 8575954 Mnus 401,657 9,100,664 Minus 401747 9789672 Minus 7,239,630 401,780 7,249,190 Minus 401781 7249190 Minus 401785 7249190 401789 7249213 Minus 401,809 7,342,191 Mima 401847 7139731 Plus 401887 7229981 Plus 401,913 Minus 401,962 3,176,728 Minus 401,991 Plus 4,153,858 Minus 402,023 7,528,158 Minus 402,066 6,649,269 Plus 402,071 8,117,361 Plus 402075 8117407 Plus 402,131 7,704,961 Mnus 402144 7242326 402203 8576119 2894631 402292 2447220 Plus 402,297 6,598,824 Plus 402,407 Minus 402421 9796341 Mnus 402,427 9,796,372 Plus 402430 9796372 9801137 402538 Look Minus Mnus 402520 402,543 9,884,747 Minus Minus 4 2S7O 402585 402639 9953129 402634 402699 Minus Minus 7,331,557 402,738 Mnus 872 402855 9662953 402869 6434643 402939 9187334 402944 9368423 402348 9368458 Mnus ptus 403,010 3,132,346 Minus Plus Rus 403036 6654 66712 403051 4827080 403065 89541 Minus 97 Minus 403077 8954241 403093 8954241 Plus 403151 7407965 Mnus 403153 Minus 403177 Minus 403223 7630969 Plus 403277 Plus 403273 Plus 403286 8060320 Plus in Unique Eos Gene n 410498 120611 1 AA355749 418441 421258 AA2S6731 423T95 W96225 443296 56539 TABLE what an Eos Sequence The 7 are Ounham the telera published it sequence of human et al Indícales posiuons oí predicled Pkey Bel 400464 9929670 400834 8705192 Plus i 402114 8318536 402172 402406 Plus 402425 9796347 403077 8954241 Plus 403089 8954241 403691 Minus 405024 7107727 405285 Minus 405368 2104517 Plus TABLE 5A lists 685 genes in compared normal These as and were greater trian or normal TABLE 685 OVARIAN CANCER VERSUS NORMAL Exemplary 1 416333 H05175 ESTs 402142 415820 ESTs 441140 ESTs 449376 10 AJ7388I5 ESTs 411542 CT0220 sapien 10 403375 AJ022240 ESTs 10 406241 420306 AA25S318 ESTs 413161 448221 BE622615 gbí01440775T1 Homo sapiens cONA 415920 Z45684 brain 10 459135 Homo sapiers cONA 425357 AA355842 Horro sapiens cONA 454724 fetal ZAP Ex 429395 10 427607 AA406119 ESTs 443598 ESTs 437348 ae73c09j brain Homo sapien 10 418105 ESTs 10 426763 Human tan on 10 403473 427501 AI3692S0 ESTs 10 10 M99S87 firing 1 ESTs 10 453472 5S4 10 433183 W89093 ESTs 10 425626 A153753S ESTs 428931 AAS94979 10 426593 AWS58560 MAGE MAGE 10 431899 AA521381 ESTs 10 422406 Opa May 10 448178 AM79482 ESTs 10 404227 excn 440,575 ESTs 10 AL047834 ESTs 10 434 221 PR02543 10 459459 AA460445 10 Eos Gene CAT Aecession 407596 370 H43764 407647 AW821859 409365 103649 1 408315 409211 AA078835 AA079319 AA079026 AA068989 AA550522 409699 BE1546S086154785 AVY468343 BE154816 40S84S 409854 AW501833 AW502145 A 40S892 AW5035S0 410065 AW812744 AW531974 AW812725 410495 1 H81987 410,596 AA374186AW963684 410667 AW336099 BE162104 AW794263 410758 1219899 1 1226008 1 AW80S575 BE090626 BE09O617 A AW936530 AW936550 AW936481 410990 1 AW812929 AW812779AW813088 411,256 411,279 1 AW935737 AWS35263 AW835240 411280 1237585 1 50617 411337 AVV837349 AW837355 AW882717 411542 1249095 1 AW850767 411543 1249127 1 BE064863 BE153820 BE0S47378E153674 BE064730 BE065O62 BE15366S BE0646S1 411899 AA370S73 BE16 500 BE160498 N72424 AA096462 411922 1 AW876260 AW876269A 876340AVro75145 AW876243 412319 1288602 1 AW936908 9,144,087 7,253,992 7,417,725 Plus 406255 7 Rus 9,256,114 406,454 406,481 7,711,534 TABLE 5A to 53 genes ovarian to These as í and TABLE ABOUT OVARIAN CANCER VERSUS NORMAL OVARY TAfiLE E io CAT Gene numbers 1003489 1 RS5913 RE6901 VY21298 40S633 1148033 1 410495 1 AW7513S6 H31337 412319 12S3602J 412460 129929 1 BE142364 413401 1 AA236S69 202288 1 AA806639 422046 1 4262S4 AA3741S5 BE267477 434733 46867 1 445332 AI251545 N59134 AVVB75371 454102 1 AW7523S3 BE147120 4553S3 1 AW936234 AWS36227 TABLE b Eos The 7 in L 9212516 402105 3131588 403283 9454593 406505 7A 770 genes 35403 protested would pray 2nd normal selh boil befare rafe vras 770 E tumor Ex Trie 10S6SO 119743 W70242 132528 ??? C 210 129571 WSms 102151 172S0 receiver 3A 17J 64319 HSJ0743 101243 1Z2EQ2 ESTs 135242 The 101804 123005 ESTs 11 ESTs AA449431 121 SS3 AA42SS87 HsJ3502 ESTs 115331 A 35577 G 64 119780 ESTs similar 105 104301 D45332 ESTs 131646 s 24750 M421714 122S12 M449311 1 M399623 100341 proton 3 116348 ESTs 120321 Hs 56870 Homo insertion 130690 3 122661 AA454936 Hs245541 ESTs similar to 110799 Human Ring ge AA2B4372 ESTs AA46022S ESTs AA047344 similar ta 102323 U90914 D 129390 L05425 Homo sapiens 134859 proton 115555 AA446121 Homo sapiens done 7q31 105516 AA257971 Hs21214 ESTs M242751 AA461300 ESTs AA424O06 ta 110595 H93463 ESTs 2 Hi250355 S of easfl 119708 120695 AA291458 ESTs 12S651 ESTs 103152 X66S33 beta 3 108599 AA121514 115094 AA255921 ESTs AA40S2S3 ESTs AA489671 AA947601 ESTs 130527 C17384 21 134470 proton 2 100449 110970 Oven mRNA do 115901 lo 103799 F10770 Homo done 669 te 116195 ESTs 132122 ESTs 109055 ESTs X74331 2A 131200 AA609427 similar to ALU 46 ?? 405657 Human DNA done on 45 ESTs 45 127386 W33SS2 ESTs 45 122386 ?? 479063 45 135286 AA4012S9 130155 7 slraj 45 106103? 21104 ESTs 102654 Human bc647 mRNA 107876 AA02S315 X 44 1D3454 AA2322S5 125960 ESTl 125892 ta EW 100269 D38550 134161 U97188 rnFWrtinrjing 3 100502 105542 b stock protein 43 F10610 rf DA 110759? 21671 129970 AA478S75 ESTs 43 134666 ?? 482319 I 117693 simSar b EST c 43 111003 120977 ?? 398155 ESTs 42 K1AA0438 product 121381 ?? 405747 sim ta ?? 621762 ESTs 42 118975 ESTs 42 ESTs 42 106540 ?? 454607 coded C 119367 ESTs 42 133633 D21262 nodedar p p130 42 105520 reoe3i? 40074 ESTs to 108746 ESTs AI341818 1 239301 ESTs AA509053 104957 sM rb 124073 product L28S97 1 104276 126160 Hs to proton 100405 D86425 2 101335 L49054 sapiens NP 108761 AA127S14 ESTs NB9829 ESTs AA251083 to 10 116003 M4 sinillary poten 020313 ESTs ESTs 10 to ESTs ta 1AA0437 131185 25753 B1 134380 038073 wax 105740 ESTs 10 130919 AA291710 3 10 134423 WS6151 piuteii 10 104636 AA054228 ESTs 134407 X72964 10 10S373 ESTs 10 112283 53S45 Hi20952 sapiens done 24411 10 AA1S6960 ESTs 10 114239 239742 ESTs ESTs 116408 sapiens D c 10 ESTs Z9 ESTs 113811 W44928 ESTs 107248 D59894 ESTs U09284 and 1 134064 D87685 proton 127370 A1024352 4 29 113277 protein l 132783 897 box 10SO10 12 19 ESTs 19 AA4S9249 skriter 103427 XS7303 mRNA be proton 133950 19 111353 ESTs 19 AA235303 ESTs 19 134498 53180 s 19 117910 and 1 118303 ESTs similar b 19 121713 AA419198 ESTs 19 129030 H19307 ESTs 129404 AA172056 ESTs 19 129457 X55330 19 130352 D87450 WAA0251 proton 19 133415 X59699 wall suitcase 8 19 120649 ESTs 19 131257 AA256042 ESTs 19 134480 1 19 116734 19 105028 AA126719 ESTs 19 114S86 ESTs 19 105651 AA282481 ESTs 19 101714 19 123398 AA521265 ESTs 106 AA411462 to reí 1 19 109450 AA2321B3 ALU J 19 Human done 19 108677 ESTs 19 116028 19 105404 AA243303 19 132355 AA593694 Homo sapiens PAC done roro 19 W52430 19 124637 Human done on 19 130588 AA287735 Human hour 19 105640 AA281623 to 19 131818 239297 19 128742 HsJ51531 its alph 19 115089 ESTs ALU J 19 on 10A Acere ltt 10 raffia Essues Aren 432938 T27013 acule proton Wim s AA250737 voucher 452838 415511 422S56 BE545072 410929 ESTs 400289 X07620 r Homo sapera 427585 031 ta 1 428392 1 448243 AW369771 ESTs C14187 ESTs 444783 ESTs 407638 EST 423739 ESTs 436982 AB018305 or 4S1110 A19S5040 42S427 protan 453279 AW393940 ESTs AYVS54552 zinc 4S3884 444473 1 427975 ESTs 424620 7 442314 sapiens done 417995 ESTs 418946 ESTs 419963 AA743276 ESTs 420362 HsJ7206 proton 1 AA371612 432837 AA310693 HS2795I2 447020 T27306 458027 L49054 b your divisions 450434 438279 AA605166 to SU 420328 Y19062 436586 A1308862 ESTs 435793 ESTt 422306 Homo sapiens SJ 425154 001851 1 453293 ESTs 429944 sapiens dono 24881 434891 ESTs 415263 ESTs 409506 ESTs 412848 EST124504 EST124485 ESTs 4756267 ESTs 439506 ESTs 434265 AA841511 ESTs Homo sapiens FU23089 donated WP503857 proton 415539 protein receptor 442717 ta 432358 ESTs 409731 c 419699 ESTs 420313 AB023230 proton 422S0S 425733 F13267 Homo sapiens done 23578 ESTt A1560129 EST Ho 432415 T16971 406,117 0 438,018 447,505 448,621 AI097144 ta 453001 ESTs 410 561 FU22044 418811 A D01407 FU10545 43S754 AJ061288 437212 AI765021 447312 A1434345 HsJ6908 1 409,732 434,690 ESTL 444,172 Estt 424,539 UI2911 l 418677 S83308 YVbox 5 406 076 AU90179 sapieiis AD 420179 N74530 Estt 450,375 AA00S647 to and 12 419 247 S65791 HsJ97S4 X 1 420850 BE139590 42S420 ESTs 428664 AKD01666 similar SA 419131 AA406253 ESTl 422278 ESTl 451684 AF215751 CDA14 400296 AA305627 408425 AW058674 sapiens cONA ra c 417168 AL133117 cONA c 429486 442917 AA314907 ESTs 443268 AJ8O0271 proton 46 452795 FU21620 32 12 3 3 TABLE Reí Sequera The 7 Their are I the Human c the at the CHA Nucleoidal Indigenous Rei 400531 Minus Plus 401197 9719705 Plus i Minus Plus 8576138 Plus 401711 402077 8117111 102222 Plus 402408 Minus 102820 6156853 Minus 8918111 Plus 9138267 7656757 103729 7513752 Minus 403861 7709019 Minus 101108 8247D71 Minus 101232 8218015 Minus 7213881 Plus 401567 7219169 Minus 8705107 wildebeest Minus 101996 6007690 Plus 40 5095 8072599 406069 Plus 106117 9112932 A fots 222 are encojo as doman oí are 431183 H 431846 4O4210 U02478 417181 L10123 423945 4 006799 448350 448165 005591 44S349 H51E251 432S54 Eos Ptey 400534 6981826 401197 9719705 Flui genes oí by pidan domara norm Pkoy while AA250737 4O02S9 426427 424905 418007 M13503 L13S3 L4S4 4 L9S54 L4295 4 L92911 L4295 4 L9293 L4293 4 L9S3 4 L9S3 4 L9S3 4 L4 3 4 4 4 4 4 8 8 8 8 34 344 4 4 4 8 8 8 8 34 344 4 4 4 8 8 8 3 3 3 3 3 4 421270 ESTs 414 695 431 341 307 211 his 424 085 Cla 2 424687 S AAA 11 prcducl 400509 recept 430057 AW450303 re 421,841 AA9G8137 proton 453078 Ht31584 C 411190 AA306342 407740 BE378432 420490 ESTs 42615S receptor 423945 AA410943 Hs 411773 447298 BE617527 proton 427,617 RAN 1 453546 SEPP E Rei 9,212,516 Ts genes as fcr raijo man and xas median for OTARÍAN VERSUS 0RI4AL Acc n UG ID 433706 1 bo or 447111 AJ 017574 1 W2 431130 HsJ719 proton 818 4313S3 413859 446291 BE337753 717 426050 3 home 411469 nain 429504 XS9133 HSJ0423S 2 416971 1 3 2 c 3 FU20171 AK001782 428753 AA433988 sapiens 57J 441859 ta Homo D 414602 A S300S8 satee AW97Í155 reV 7 irteri 53 412635 6 51 430534 AI860651 ESTs 439318 AW837048 417259 SOO 2 407785 AA687538 1 50 42S83S 417308 product 436878 AI12475Ó HSJ337 2 43 433130 AÍ333742 avian c 2 405484 0 404678 9797204 Plus 404743 8834169 Mnus 404780 9887810 404790 7230958 404931 7342203 wildebeest 6899705 Bus 7107727 Plus 40SC89 8072523 Plus 405034 8072579 Plus 7107890 Mnus 405145 9438278 Plus 405192 405224 6731245 Mnus 405295 3818412 2811095 Plus 405358 7243869 Mnus 405426 7243900 405452 7656638 Mnus 405484 5922025 405552 1552506 405570 Pus 405,626 Mnus 4155331 405702 5931935 405802 924004 405804 7274891 406329 406429 9256476 406502 7711350 Mnus from 59680 proceséis on OVARIAN standard to lissues or what the OVARIAN sing vras sel lo 901 0V3riai renové of vas from Ihs lhe beiore while TA8LE 695 CANCE R VERSUS NORMAL AOULT T1SSUES ID normal raijo ID 452838 U55011 438817 432938 regutatory proton 421478 418179 1 sapiens cONA done receptor 64 428153 AW513143 FU2Z25 43SS82 ?? 0183? 5 eirjrace8ular matrix 427585 3 152 EST C14187 ESTt 430491 AL109791 mRNA plugs AJ732617 448243 AVY369771 428187 4G8381 AVY451597 ESTs 410007 M13509 422956 ESTs 413335 423739 ESTs 410929 H47233 424086 424905 ESTs 424905 EST 427906 ESA 407168 R4517S Soares Homo 407638 AJ404672 EST AA403084 438993 AA82899S YA to HS360204 Ks283S53 Homo sapiens mRNA tul cONA done 421155 BE395109 ESTl 431989 AW972870 ESTl 422805 AA436989 H2A mind A 4 0 5 0 5 50 55 60 65 70 75 80 414142 ESTs 412170 ?? receiver 410011 436476 AA326108 Hs ESTs 414132 ESTs 437789 to 450192 AA263143 prolein AI962493 ESTs 440238 AW451970 wall box gene 2 403657 0 Horro sapiens mRNA 75 4S769 4509 ESTs 413627 ESTs 446293 22 ESTs 441627 ?? 947552 ESTs tonse C iota 409242 prolein AW409872 simia SU8FA 440250 AAS76179 451659 to ALU Er roid 436032 ?? 150797 prolein 407771 AL138272 ESTs 435039 AW043921 ESTs 444342 to 407829 sapiens done T2 P300445I 409731 ?? 125985 12 404253 0 424120 Hi290270 ESTs 429126 2356 ESTs 413573 49039 ESTs 4214S4 ESTs 430388 ?? 356923 nuclear cap prolein to 420352 protein 1 444743 ?? 045848 x 415138 tactor 2 410568 factor 429418 ESTs 409178 446606 ESTs 425905 ?? 032959 KIAA1133 protein 428532? 69125 431322 AW970622 MAGK Homo sapiens 437950 AI6595SS ESTs and 424085 C 2 44SS74 ESTs 438122 AJ620270 440048 AAS97461 b protein 418478 fcnase 2A 407162 znc finger protein 410604 U inccerebeSar ataxia 424639 AJ917494 ESTs 432415 ESTs 421470 27496 A3 445459 ESTs 418203? 54942 2 432809 ?? 555509 ESTs 409234 ESTs 438394 ?? 379323 452037 ?? 002364 453745 sapiens HSPC316 cds 414136 ?? 812434 ESTs 423248 ?? 380177 454018 ESTs 452281 TS3500 EST 424620 ?? 101043 7 55 452594 faniy 26 65 434149? 43829 p30 15 425776 59499 2 418677 S83308 region Y 409517 ? 90780 432666 similar b prolein product 448706 AW291095 11 receiver ZCYTOR7 Homo take out 413582 AW295647 Homo sapiens FU21971 54 419917 Homo sapiens D F2p434E232 done 424153 2 434265 ?? 846811 Homo 435082 441081 584019 sfciitar lo 2b 54 443539 ESTt A ESTs A 417251 similar as Y R074w 447207 proton 4 9 ESTs 425292 435420 435532 88 443268 446140 AA356170 452 891 431 130 408 938 432 842 AW674093 436754 AJ061288 442573 H93366 409,049 A1423132 422475 AL359938 447 112 410 530 429 414 AI783656 422505 R15138 428555 452909 449535 452232 409732 415115 AA2 228 423161 AL049227 441,035 AW13655I 423575 415211 428405 Y00762 432865 433330 453047 AW023798 HS 86025 456273 Af154846 443933 A1091631 BE387162 440351 426300 U15S79 453775 HS35120 446102 420547 AF155I40 429436 429944 R139 49 433042 434988 452571 W31518 434361 AF129755 46 406,400 0 410,227 AB0092S4 2 419945 ESTs 428301 AWS28665 430,153 AW96812S MAGE AGJ Homo sapiens c AAS03653 simlar SU8FA BE17S829 Homo sapiens aj12632 447505 AL049266 Homo sapiens 448,027 ESTs AI970394 ESTs 459,574 sapiens FU 14232 done NT2RP4000035 AL137163 dJ473B 409,387 ESTs AE006625 3 435244 ESTs 404996 0 407905 AW103655 AWB51186 Homo e 424341 Homo c S 441675 329 ESTs 452172 H00797 Homo sapiens mRNA 230 46 420276 AA290935 similar 45 402820 0 41SSS9 AA24S998 ESTs ESTs 4J 438018 A 001160 prolein FU10298 441826 iestase 4J 453931 AL12127B ESTs 45 5 10 15 20 25 30 40 45 50 55 60 65 70 75 80 as 413623 AA825721 ESTs TM 447350 AI375572 ESTs 428227 PRO 452461 BE382701 416203 ESTs TM 452249 ESTs 1X4 416566 c 416661 AA634543 3 TM 1 TM AA054726 TM 400298 TM 421451 HSI0831 TM 443715 A15S3187 413472 1 high AW248506 Ht279727 SS AJ436323 far TM TM S69 3 A12S3307 ESTt 412723 ESTt TM 400250 0 438167 R2S363 ESTt 434539 AW748078 ESTt TM 450375 a and TM 400289 2 446142 A1754633 ESTs 421285 418506 G receptacle 39 TM 433447 U29195 SS 414245 ?? 148072 WAS 1 TM 3 416601 SS 415227 AW821113 ESTT TM 409269 ?? 576953 Homo raptas done 0 TM 426471? 22440 SS 4 AJ245671 6 414972 product TM 435509 ESTs TM 445413 ?? 151342 446999 TM 414569 cancer 1 TM 405687? 31126 9 40890S ?? 296227 15 451807 WS2 854 TM 420159? 1572490 ESTs TM 432677 lecsn besaran TM 433885 ESTt TM 447342 ?? 199268 ALU TM 437212 ?? 765021 UDPGT 424717 H037S4 TV 450505 Z TM 436396 Horro tapiara H 425695 447268 6S63 Horre tapiwt FU22418 400195 0 TM ai 424905 TM 438202 AW169287 ESTt TM 439759 mRNA insert TM ao 453102 10 424001 W67883 KIAA1051 TM 442655 AW027457 0323 ESTt TM 445657 AW612141 ESTt 2 412170 D16532 HL73729 receiver 436476 ?? 32? 103 Hsi3S31 TM ESTt TM 437783 rb TM 450192 AA2S3143 TM Horro done m TM ?? 182082 ESTt TM 446293 ESTs 409242 prolein 450262 AW409872 lo TM 451659 lo TM 444342 TM 429126 ST 421464 ?? 291553 ESTT TM 420362 1 TM 413792 AB037805 tón TM Homo sapiens N L24 TM AW382S87 1 EGP 448089 Al 457945 ESTs SS 422278 ESTs 15 442133 ESTs TM 410908 121686 ESTs ESTs TM 408730 AV660717 proton 3 435483 h FU20958 TM 409745 AA077391 C 7 TM 3 445870 TM 3 451743 AW074266 ESTs TM 3 407846 G TM 432350 SS AA121514 ESTs TM 413625 AW451103 ESTs 417801 AA417383 1 422972 ESTs TM N 450377 ABO33091 TM 443475 ESTs TM 419452 brosirw 7 T 409744 Homo TM A TM 404440 0 417412 1 411828 AW161449 MMTV srte 417177 52 rne A n 3 421013 345 mu cance TM 3 427072 K3S046 433703 AA2108S3 loriase 434294 AJ271379 ESTs TM ESTs TM 446109 ESTs TM 400881 0 33 A 162998 KWA1376 proton TM 418336 AI655499 ESTs TM 33 437951 T345X sapiens FU13069 N TM 44689S FU21084 TM 430687 BE274217 nuclear ral 410060 SS 419546 AA244199 Homo sapi TM 429609 ai TM AA128061 ESTs TM 13 AK000517 rr TM 401435 0 TM 420072 AW961196 ESTs TM AA291 Oven sapiens done TM 13 425851 core SS 13 443295 ESTs TM 12 453116 A1276680 456546 AIS90321 TM 430016 TM 12 418281 12 433800 A1034361 TM 12 aspartat TM 428882 AA43691S sMar lo 12 409533 AW969543 prterí kjnase TM AA551538 TM 421379 Y15221 B 430259 proán TM 414945 BE076358 i SS SS AB020684 TM T10707 neoonal PAS would give 2 12 ESTs TM 1AAO990 protein SS 12 AW439900 ESTs TM 12 414147 BE091634 TM 12 414661 T97401 ESTs TM 12 437S37 similar to TM 12 439702 ESTs 11 420552 A proton TM 11 441028 11 425264 AA3S 3953 to TM 11 422109 S73265 441859 AW194364 F1G1 MOUSE U 11 415 451 to 11 A 444754 ESTs 419 978 11 446 219 ESTs 11 D F2P556B0848 praíein 11 407615 CT0247 11 TABLE 15Efc CAT CATNurnbar Ac 1005404 1 AW753082 AW53087 409,073 AA063018AM44822 409,745 115237J AA077391 207491 BE152353AW188822 410003 AA079552 414315 AA143127 416120 1571266 1 K45739H51513 H19779 419311 183793 1 A235240 A631399 AW974262 41954S 185766J AA244199 ?? 244272 422128 211994J AA490718 AA331991 427072 274884 1 H38046 428679 467651 1 AA828995 AA834879 4471S7 711623 1 R36075A1366546 TAflLE number corresponding to Eos Tne 7 are L sequencs or the DA codes Indícales oí Rel Slrand 2842777 401197 Plus 401435 8217934 inus 7528051 Plus 404939 6862697 404995 6007890 Plus 405547 1054740 406137 Minus 9256126 Minus 406400 9256298 sel 92 OVARIAN CANCER NORMAL E Exemplary UG prolein doman normal raijo UG TOs 430691 ESTs 432938 T27013 acule proton START 418007 13509 1 SS 451181 AI796330 ESTs 452838 in 407638 04672 EST 4501 59 AI702416 HS 00771 CAN2 HUMAN 92 426890 AA3S3167 ESTs 421155 oxidase 437099 to L 453866 Hs 50557 ESTs 435496 AW840171 to 41B738 AW388633 431956 AKD02032 Oven sapiens FU11170 done P RA 443579 A 207260 6 NM 003401 445891 AW391342 ESTs 62 site 452705 ESTs NM 000102 XVII 408562 AI436323 Homo sapiens prole 420159 A1572490 451105 January 52 409,049 23,132 ESTs 448,574 W31178 ESTs TM 423811 AW2S959Í 427469 AA403084 ESTs 447 033 AI357412 PH 424433 H04607 ESTs 448,811 TM 444330 AI537655 ESTs 409041 AB033025 prolein 418,735 416,661 3 430,073 proton 1 407 881 AW072003 hiparan sulfate SS 422 260 421 110 AJ250717 SS A12477S3 430704 ST0186 414,569 cancer 1 TM 438078 434032 ESTs 44S657 79575 ESTs 4397S9 Homo sapiens mRNA MI 15 455666 BE065813 AI581519 15 449048 Z45051 Hs 22920 sirrilarto S68401 Muced g 15 438018 AK001160 proton FU10238 TM 14 458123 AW892675 0004 14 407385 AA610150 lo 14 424894 H83520 A1917494 ESTs 13 414083 Hs ESTs 12 426471 12 428927 AA441837 ESTs 11 0 11 ESTs 425342 AI557490 baneo box 11 428976 AL037824 ras gene ras 436396 sapiens FU11441 done H AC005352 HsJ7C62 404253 0 452461 factor 19 429597 a and 413289 128061 ESTs HS ESTs 19 407623 saper N 424796 ESTs 28 408427 AW194270 ESTs 17 450375 ?? 009647 a and 428819 422356 8? 545072 ESTs VI 428949 AA4421S3 lo 426300 U15979 16 420380 ESTs AF196478 AIO 16 417849 16 453700 ?? 009426 B to 16 ?? 641836 Homo sapiens cDNA FU23186 16 448756 ESTs 425087 ESTs 15 444153 AK 1610 FU10748 Kerch 15 443211 43655 ESTs 15 415263 ESTs 15 432867 ESTs GSHPx 15 ESTs 15 455385 15 41S092 305581 mu 15 ESTs 15 Genbank accession CAT 430704 451105 AW880937 455386 AiV935875 BE069116 BE160251 1349545 1 Ptey Rei 404253 9367202 406123 TABLE CANCER VERSUS Oornalns while Ptey Ex UGID tail 452838 333 435094 AJ560129 EST 428153 sitiar SR 428187 A1637303 233 449034 AK24049 Horro sari 453102 Hs31664 10 T 157 446693 AW750373 Homo FU 13036 dore N 15 AA135159 Horro dore Z5 400882 0 15 15 424081 15 451936 ESTs 15 403381 0 15 419488 AA316241 3 SS 15 418882 C 25 Eos numoer CAT Gene CAT 40S0S4 1099611 1 A 337237 AW861642 186252 431322 331543 AAS 437338 44573 2 AWS676T7 H59397AlrW1573 P AW96767I AA251875 U71456T82391 T75102 R34725 A1219788 F13433 AA32T794 AW23S363 AA563345 AW008282 AA488964 AA283144 AI89C387 A1950344 A1689062 AA282915 AI763273 AI653832 AI762688 AW103813 A1539642 AA642789 AA337499 AA251669 AA251B74? 1,819,225 AW205862 AW276905 AI633006 AAS08741 AW072629 AA233273 AA369759 W80701 A1564269 H83488 78802 A10O2839 AA300207 438966 457436 AS34841 AA828650 43B993 442438 542469 1 AA9959S8 T77332F07756 448404 761515 1 BE089973 AW805032 449034 794817J 452771 930983 1 798085J A1630223 A1630470 ta sn Eos 7 c5grl numbers in are the refere 0NA human and Natura Indícales 0NA exons exons Ptóy Fiel 400882 2842777 402606 9909429 mus 403391 9438267 TABLE GENES SECRETEO OVARIAN CANCER tale TABLE 17 ANO USEFUL FOR OSIS CANCER UG ID UmGene percenl of dete led Single UG spondin 77 6 36 7 66 2 mesolhelin 57 21 5 27 tone morphogenelic prolein 7 prolein 54 6 3 1 1 23 secretad lo 46 e core 91 r prolein 25 21 23 6 2 93 7 mesolhelin 2 bone prolein 7 EGF 6 7 91 kallikrem 7 tone prolein I 75 7 2 2 bone prolein 7 TGF beta 2 91 6 bone prolein 7 MMP 1 95 accession numbers for laddng for a gene number from Gene were using derives from ESTs Thesa sequences on Sera OaWand Genbank accession fcr cluster are Eos pro Accession Genbank accession number Unigene number Unigene lito Pidan doman Prolein R1 421296 NU 453028 AB006532 RecQ 4 422310 with US 770561 prolein FU22969 446374 with k 441021 AWS7B716 H1 2 2Z3 409,518 prolein SS 424420 SE6I4743 proslaglandin E 422S45 in 3 d 422 098 to 429 556 AW139399 436485 X59135 kappa 423652 AF052122 Homo sapiens 23,929 431,773 BE409442 plectotrin 422,179 420,839 piolen MGCI0870 441356 BE384361 JC5024 424 659 AW891298 0 439924 AI985897 SS 458814 451643 M64437 439109 AW163034 3 432 945 FU ESTs EFT AF Horro sapiens fe 415441 ESTs 450461 proton SS 4 A1471630 K1AA0144 product 400923 6 CGAP c 419757 M773820 ESTs 451721 006S46 Hs ESTs 422633 X56832 n 438452 SS 4 21445 AA9130S9 Homo done 434,743 A1363410 proton S18 039S4 4H3T 442394 ESTs 434333 AA186733 427221 L15409 rum BE43S952 gamma 2 444670 Hs332938 prolein SS 449495 A1652833 GC6 Hom SS 444507 ESTs 449125 Homo sapiens 447,151 Homo sapiens m W27670 proton RJ22531 430,432 A803775a Ht241419 proton 428309 AJ190714 ESTs BE257293 lime surround to 155214 4 ESTs 442232 ta A47582 439539 EST 400286 TM 7J3 BE559681 KlAA0124proiem WD40 AA196552 MGC31S9 427721 4S0716 T57758 ESTs 407435 AF211976 sapiens pa 413956 ta 427899 serum 406495 430387 A 372884 cap 406601 U47928 to AW963293 446043 ESTs 421148 16 420970 AA305079 c V 419295 BE397712 BE 448330 AL036449 ESTs 419639 AB037785 proton 456487 I heard A19108S8 Hi212957 ESTs SS 427433 441076 Homo done 4S2S54 lo 411448 M17S955 ta 442313 ESTs 425055 AW961969 412935 BE267045 contact me c 403748 447282 AI969963 ESTt 73 422305 AI92S242 to AF1984 SS 416472 AA180758 similar to AL 73 427Z73 AD 73 412265 AA101325 73 447859 A 73 432747 73 405727 AI219282 etongal 404199 l2 445434 BE3 31690 prtein 11 428550 ESTs 12 454718 AW815144 S 11 407B86 21 open Ira 418304 Ho serpn 11 424263 L1 11 407581 R484Q2 430746 ESTs 5S 11 11 407323 11 407619 2 11 434035 similar T28770 11 5 20 25 30 35 40 45 50 55 60 70 75 80 421543 A proton AA961613 ESTs 432751 AF152099 17C SS 433943 AW300961 Homo dore 431,328 ESTs 451,481 295,866 Orotan DKFZP434N 430344 M476827 HLH 419516 413564 H10942 Soa 401402 Target 456145 proton 431,536 AL133066 ESTs T stock proton 435800 AI248285 ESTs 449,235 A1912702 ESTs 418,256 AW845318 ind 417442 AA199940 ESTs 405931 455286 6E144384 H SS 446931 CGAP ESTs 401984 404066 Target ESTs 458198 AJ ESTs 432278 AL137506 FU23563 432328 421871 2 415514 F11301 ESTs 426208 AI370379 ESTs 429367 405939 Target 457331 AV64740S 8 438705 AJ049624 ta 210926 42B624 A1125222 SS 419389 HS 19095 ESTs 447535 9A AVY136771 epidemial 413041 5 B SS 452849 AF044924 proton 434357 AW732284 455274 BE151622 H 453904 AW003821 ESTs 424624 AB032347 nuclear protei touch receiver 419125 AA642452 CL 450207 T87615 ESTs 405211 413937 ESTs H6577S cea regulates 412091 fetal 446536 SS 451117 ESTs 403547 TM 412673 ESTs 426440 caira 2 sugar 55 449225 ESTs 5J 403938 Target 441197 BE24463S HLH 455604 B 457468 ESTs 447677 1 H 415473 ESTs ta 442780 AKI17S21 ESTs as 451558 439422 AW452791 ESTs 423479 453558 lo 210926 SS 441187 A 195237 SS 420394 AA744597 ESTs 404710 447827 and 448387 AI874402 ESTt 419541 AW749617 Hi780776 449686 J72813 AL 426315 AA854219 Homo 451312 AI769631 EST SS L5 432538 IS 446790 A 452105 ESTs 448682 T09471 proton FU14827 ü 50 50 50 T10798 M78746 AW250Q02 AA503756 BE14128S 10 AJ221491 AA194239 193426 15 AWB09847 AWE35832 A 835516 AW835849 20 A1672156 AA094230 A1633815 AA526153 W86151 25 AI696372 AIS79394 AJ653605 W26914 30 A12O1035 35 AA12787S AI685293 AW77 N6S010 AW070312 BE146963 BE14S907 40 BE439610 45 50 AA214097 55 A120429 A1205744 60 AW364848 A1222031 AA907216 65 70 A AW378754 BE267205 BE312782 BE392818 AW327483 75 AA766891 AA814103 80 AW8165S4 434315 363402 1 AI126321 A I96549 434743 AI363410 AW505595 131836 AA527132 T32315 AA421961 N31947 AAS21151 AA044784 393400 1 AA812046 A 974 514 402 143 1 AI263835 435262 A1022246AA6771O7 415,339 AI35630OAI762981 M678073 436,094 AWÜ08826 AA704731 436389 706 AW297940 AA293502 436393 A1274032 AJ227898 AI160412 A1064451 437018 AA889078 AAS07263 AA742199 437050 AA766420AA743319AW976442 437215 AL044479 AA765387 AA832241 437834 AA769294 AW749299 AW749302 AW749295 A 74S304 AW749293 AW749298 AW749Z88 AVY74S2S1 AW749296 AW75331 438723 25802 AW938720 439034 H52291 H52528 439150 H64722 1 440546 AI491994 AW139809 AA889258 A1700895 AW173212 AA931334 AW514263 AI567908 AI2S9S28 AI299043 N51706 AA936483 441794 AW197794 AW1S5867 AA968466 442145 R52399 T65201 F11984F13186 AA977679 H12167 442 318 1 A1792199 991 378 442 472 4427B0 AI017521 A1017613AW511133 H78133H90849 I023482 443952 AI128885 444406 AI147237AI BE163341 AI207756BE17I477 445625 BE246743 AW024744 AW242177 AA975476 AW385185 R07536 R73462 R50073 A1769689 AA317806 AI678000 AI986207 R73463 AI954604 T25141 AA853793 44S631 AK001822 AW860325 AA335296 AW130957 AW193951 A1347975 AW662527 AI343924 AI380749 AA938153 AJ655000 AW418837 A1380485 BE5Q1355 AW593995 A1336927 R60592 H19058R11124T1 445837 652068 1 446780 692897 1 H04953 693 032 1 AW452105 AI341280 AI91744S 447045 AW392394 AA010316 BE146145 BE146152 BE146040 BE145972 BE1460S9 AA868470 BE146306 T85009 BE146299 BE146319 BE146307 912 A1703134 AE55933 BE551223 AA847664 447128 AI271898 BE048502AI452S09AI244810 AI5S393 C00201 AA961610 AW059537 R77127 447 904 741 913 1 AW206303 AW207644 AI765705 758690 1 AW0167O5 AI492482 448993 A1471630 BE540637 BE265481 BE5138828E546739 AA053597 BE140503 BE218514 AW956702 AI636283 BE20779 AA293504AJ659741 AA346416 BE047245 AA730380AA394063AA454 804806 1 AI636706BE550292 449,495 808,345 1 AI652B33 AI695904 AWS8S916 450251 1 AJ689298 837848 1 BE161564 BE077251 450807 847591 1 AI739262 28418 451045 451752 AB032997 BE467119 AW237035 AJ141678 AA934774 AV 978722 H09497 AI934521 A716567 Z40632 Z4 H09496 4853 BE465983 H62S33 AA325444 899664 452113 453413 966269 1 1 A1859393BE177742 AJ003294 AJ003315 453829 453904 454438 AW003821 AW025661 AA21427S AA224053 AA114150 AA669657 AAZ24027 T58431 ?? 21190ß 199,744 AA164864 AA214334 AA161378 AA223625 AA191190 454,453 454,577 AW752781 BE143749 AW752727 AW752559AW752578 AYÍ809272 AYVB09I69 AW809179 AW809192 AW809166 AWS09197 AW809237 AW809199 AW809259 AW809273 AW809188 454682 1228976 1 AW813292AWB16156 AVS816I59 AW813302 AWS13344 454718 AW815144 AW815150 AW861007 454756 1233S4S 1 AW819273 AW819283AW819287 AW819274 AWS19282 454923 1 AVVS97236AW845406 455035 AW851734 AW851676AW851693 AW851648 AW852215 455274 BE151622 AW885643 455286 127357SJ AW887403 BE144385 455504 BE011183 BE011170BE011333 BE011169 1349914 1 BE066274 BE066356 BE066359 455778 1364506 1 BE088746 BE088755 BE088952 455385 1380385 1 BE153524 BE153S76 BE1535S3 456487 13270 1 W05727 T30969 T30970 AA AI392796 AA829283 1 AA74 389 M745330 457978? 776638 5 1 1 W664628 ng lo Eos 7 L ref Ere he of human the aL 400460 8389428 Plus 400500 9796136 Miras 400528 Rus 40074a 8119063 wildebeest 400762 3131623 Mnus 40C333 8705148 Mnus 400863 9798616 400323 7637836 Mnus 401121 8570295 Plus 9433648 Mnus 9743387 7712287 401215 Plus 401264 Plus 9799936 Plus 401349 Plus 401402 7710964 Plus 401488 7341775 PUS 401507 Plus 401539 8072433 6202862608 401553 8059284 8399044161 401594 7230963 Plus 401674 7689903 401677 9965537 401722 7655694 Plus 401724 7656694 Plus 6730624 Plus 401035 6140731 401S35 3,806,091 plus 401,938 6,102,666 Rus 401,984 8,576,043 Mnus 402197 8576113 402285 2689079 Mnus 9,454,515 Mnus 402445 9,797,862 plus 9,838,114 Mnus Plut 402916 7406502 Mnus 403003 5441423 403128 7331426 Plus 403672 7283286 403748 Mnus 403,885 7,710,403 Mnus 403,938 771179S Plus 404,001 8,655,948 Mnus 404,066 3,367,505 Mnus 404,149 7,534,008 Plus 404,199 6,010,176 Mnus 404,311 404,333 9,602,821 Mnus 404,365 9,964,977 Plus 404,430 7,407,979 Plus 404,438 6,984,205 Plus 404,571 7,249,163 Mnus 404596 9958262 Mnus 404,676 9,797,204 Mnus 404,710 9,601,097 Mnu s 404752 7109522 Mnus 404807 4165210 404956 73S7343 405085 8072509 Mnus 405,113 8,096,927 Plus 405,143 9,433,278 Pta 405,153 9,966,252 Plus 444,364 AA506101 85813 443759 415322 BE019494 406573 411030 55 410653 BE333768 433,012 NM 004045 437741 BE561610 55 4273S1 AW732480 411,574 54 457,313 AF047002 54 42S34S AI242431 434845 427162 AB011133 3864 447402 433676 Hi250173 54 424 373 54 423 402 409 983 D50922 YV31096 431629 AU077025 430413 53 440333 424327 53 412275 53 416131 AA174126 HSJ32163 53 440603 A12S7585 53 435 327 421 139 AW953933 453449 S2 414 411 52 440 905 AW161556 421699 439473 A1215529 52 AK001171 52 407191 427515 179526 52 405325 434119 AF193844 HsJ758 413052 445109 AF039916 51 409323 H28855 438707 108239 51 442599 AF078037 51 420 372 51 51 418 910 Z2S821 51 414 849 51 425 743 BE396495 51 418231 AA326895 50 419238 AW5S553S 437617 AI026701 50 412867 AU076861 419,579 50 425,824 433,414 50 43S042 50 410775 AB014460 50 453350 AS17771 400300 BE2S9228 421179 U72664 49 429762 A1346255 426331 BE296216 AA333367 414820 AA371931 426347 AA454912 423830 429545 417080 441455 AJ271671 HsJ32040 416976 43S057 i1 11 11 11 11 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 CATnume accession rumbéis CAT 408,215 BK14290AA307674 N35629AA33853BAI193603AA7B1096A1680061 AI44646I AI343638 AI343640 M78746 AW262795 A 250002 AA503756 AW272056 AA626639 409938 AW974648 411674 AW856784 AWB56776 AW856767 413052 13472141 BE062699 BE BE062719 BE293541 413837 AW157459 AI929284 A1340993 AW299522 AW664650 AW2S9513 413,891 A1950958 778,973 A1963931AW515101 AW150029 414023 BE243628 BE246081 BE247016 BE242329 BE241417 BE241457 BE241989BE24I464 416,535 H74099T67099 417,998 AW967420AA210915AA236991AA210916 AA421401 T49326 W63573 AA758023 AA976306 AA877107 AA458586 AJ891097 AI811174R698S6T49327AA233722AA631138AA910314 AA948287AA62 419069 AA233801 4192S0 A 420,160 A1492640AI287657AA25598S A1468S58 421572 Z92546 AA330S86 AW341487 AI015633 AT733599 A1244716 fx AA573152 A1910796 AW338984 M729145 AI093722 FD9835 35995 T57002225379 AJ906851 88270447 AW409921 BE3 92439 BE3143008E267719 BE26S715 BE513876 BE237D66 AA210923 8E622905 A 250313 AA355115 AA316879 BE269633 AA290724 AK001212 AA1557S2 AA878366 AA090872 AB033013 AW249107 AA112820 N AA326755 AW552294 C03570 C04358 M074274 A1589543 428092 1 AJ734104 AJ733S23 AA430600 AI824164 AI676005 AW129612 AIB25903 AA773987 AA456229 AI824295 AA454622 AI264049 AJ090237 A1669767 AI306153 W96164 A1298273 AW884073 430168 I? ? 468,507 AA862642 BE263S01 433,707 AW385394 AW385401 A1922683 AA907337 AA1605O4 440,191 3 AJ3 4400 A1193071 AI742483 AW003403 AJ656740 8E467373 5212 AW205103 A1051273 AW103289AJ4 443,402 U7784SAA479373 M26S67AA72ÍS01 715367AA3777W AA339685 BE0742S4AW938712 AA330624 AA3470S8 AA495763 AA479278 AJ204484 AW834745 444,590 AA457456 AA907921 AA579472 F35533 AA722113 T64403 AA653738 F28806AAS95689 AA047S37 AW440532 F36782 A1183767 AA160Ó79 AI148988 A1174482 AJ674395 AA4B1440 AI914985 445625 BE246743 AA436942 AW024744 AA97S476 734S2 T574 2 R4S743 AA317606 A1678000 A1335104 AJ590161 T25141 R50074 448 506 BE613362 AA447862 H72036 AA3936S4 AJ681334 AA932579 AJ302241 AJ936800 AW960628 C06192 AA336107 AA808008 AW615212 BE297403 AI040261 448577 A1560769 A1857497 AW151454 4507B8 AI738410 A1971725 452160 901991 1 453412 AJ0O329O AJ003288 455357 T70192 455,928 BE170313 BE1E8290 457022 BE067468 1 BE057515 BE067467 AA397442 ta an Eos I laughed lis are to human posiíons Stand P 400563 9344011 400747 7329330 40C646 9,188,505 401,097 9,935,518 401,128 8,699,792 s 9,099,093 401,727 Pius 401751 9828651 401772 9966243 402365 9454515 402463 9796896 402865 8077033 402793 6136940 402916 7406502 403023 7670577 403325 9367203 7229907 6094561 405356 2155224 PVA 3611636276 405496 8468968 Pka 406,101 9,124,019 8,576,099 406,535 7,711,477 611 rsto 96ft Would they pray or? cr A i púnase Iam g D79989 U51031 AA984512 AL120358 AI671506 AA526S09 AW243S60 AA939069 BE514362 BE5163S0 AW163444 AW161588 AW236803 BE267205 BE2806S5 BE278833 BE281417 AW377597 BE395951 BE393978 BE39 17S 432118 432499 34857J NWJ16577 AF 16S 92 AA908607 U66623 AJ570393 682S57 AW593957 AI148105 AYfi61068 R19618 433 075 1 XS8248 AA233278 AA346376 AI337018 H85459 AA418378 AA418275 AA232975 AL035861 433,494 AB02S396T04S34 R21715 R46605 Z40657 BE218899 AI457785 EE550988 N80O9O BE549719 AJ332686 N49234 AI290722 R43116 434755 AA746117 AW173260 AW271715 AA837437 AA837368 AA829826 A AYV500856 AA339125 5 R18883 AW45037S A 440242 AA909877 AA87E9598E1713S3 AW510S07 449405 AA001350 AA203114 450739 451320 AI701458 R88265 AA224388 AI084316 T336S2 AI1 T03490 AW205836 A017131 AA443303 Stand 400471 9931670 Mnus 400518 9796703 Plus 400551 9601071 400563 9644011 Plus 400565 400726 Plus 400748 8119053 400772 8131629 Mnus 400333 8705148 Mnus 400836 8954179 400843 9188605 Plus 400845 9188605 400T46 400694 99 58307 Mnus 400933 400965 8085497 Mnus 9966714 401134 7210005 Plus 401180 9438648 Unis 401215 Flus 9600073 Mnus 401454 Mnus 401488 734177S Pks 401507 7534110 401510 7E22346 Mna 401542 8072607 Mnus 401577 9280797 Mnus 401736 3219338 401335 3806091 401960 3249127 402053 6547592 402171 6575908 Mnus 402183 7658390 Mnus 402191 8576073 Mnus Plus 402209 8576119 Mnus 5331553472 Mnus 402338 6957591 Mnus 402,393 Plus 402,453 7,534,025 Plus 402460 9796S84 Mnut 402463 Mnus 9,797,301 Mnus 402,497 9,797,775 Plus 402632 PKs 402651 7960331 402665 8077033 Mnus 402,758 Plus 6763867924 422645 422098 202 429555 434058 423767 423652 422179 193 441356 185 418969 432831 172 172 434518 163 456642 162 421612 456177 409261 414837 401278 406620 4214S5 15? 416693 442S20 143 406S01 416006 45S557 416819 400206 123 122 412574 120 400460 120 428758 115 424707 114i 444359 115 435158 407688 113 450503 112 427448 112 406230 112 432143 112 433573 431974 450461 412738 103 445434 444003 444410 444607 404333 1045 401210 434743 434030 439332 438185 102 102 405371 456741 458130 456377 420023 453216 451721 420233 AA255714 FU22578 SS 414576 A O004O5 4 433 669 AL047B79 proton SS 426912 AL043054 SS 418945 BE245762 A1375424 h 458,040 BE280S62 proton 458357 AA088470 Homo 433234 AA582082 437671 AA536047 425338 H16716 sapiens 447,946 A1555164 ESTs 447205 T1 H99640 EST Hamo throw it 24 429253 Y11739 AA788727 ta A43932 SS 439246 SS 419120 BE271922 f 416487 product 413837 AW163525 AW292S62 TM 410277 R5S621 ta T2D3 W42913 14 AW809762 Homo sapiens 407,754 AAS27348 Homo sapiens RJ141055i 409,877 proton 10S 431629 AU077025 pr 438800 AB037103 6418 saven kxas 9C TM 418900 8E2073 57 K1AA1821 402400 U91616 n contactor heard 433319 AA583232 ESTs 424959 432750 425954 AK000633 447,245 AK0017I3 proton 427,101 ESTs 447544 AA401573 proton sapiens 412841 proton 422,066 AW24927S 418,373 proton 424487 T08754 426571 AA331642 433941 AA620612 ESTs 421717 AF230924 PROIS 450 883 427 351 AW732480 420421 H 43,589 414,513 G receptor 431498 AKD01777 HSJ258551 432593 AW301003 404661 412790 1AA0275 1 426222 BE3917C6 D 231 prown 439,594 WGC10974 409,114 429,049 424,271 305,382 418,741 K83265 S41044 450493 U93718 3 433074 Homo b 444 893 AW249312 420508 baking box B6 409591 AA5329S3 Homo sapiens 456181 L36463 BE2S8278 proton 440104 AA132838 423279 ESTs SS 445087 AW893449 404 036 431 832 AW2768S6 AA613S96 433,886 ESTs ESTs ESTs T78716 SS AW838994 417825 455600 423858 BE061053 AL137326 Homo sapiens C4 BE304S71 redu BE170313 BE500961 H SS SS 438143 412550 235033 1 R524S2 l CAT A 408215 BE614290 AA307674 AA338538 AA503756 AW276647 BE2212S3 A1343640 AI275091? 934,519 406,294 AA626639 BE141331 W178416 BE SE14 12B5 AA070021 AA126205 AA115915 AA081S30 AA12ES05 AA063336 AA064707 409,154 AL03632O AJ651598 AA120S58 405,938 409,950 AW974648AA6521S3 AA07S582 BE261944 AA31Í136 AA134972 ?? 319ß49 AW879032 AA90824S AA38S346 AA377395 AA199630 AVW70250 AA932S39 Al A1143895 AW961629 AA322 410445 82 411219 AW832917 AW832913 A 832 788 A 411 674 A 85670S AW856784 AW856776 412091 412173 412575 AW89760B AW894515 413534 BE146367 413754 BE162732 BE162702 413837 AW163385 BE279279 AW157329 AA584408 A 157252 AW0035I4 T2443S AW157459 A16595S2 AI9232S4 M349063 A 299522 AW654650 AW239S13 132529 A191283S A1341293AJ650609AA279 BE294759 415126 060945061346061568 419120 BE271922 AA234233 AA471354 AA824327 H24470 AA609917 A 780349 AW457553 AW571643 AA469943 AW474826 AA767165 AA326817 AW341739 422155 AA070372 H14246 AW403997 AA297034 AA297092 F11858 A1372597 AA297787 A297072 423345 AA324687AA32S155 AW962038 425858 AW963483 C21461 426571 AA3S1642AA381664 AA381728AA381608 427328 AI804160 428092 429720 M79091 AA773950AA566573AA4 57225 430168 431424 A1222969 AA806S60 AA805251 433319 AA583232AA601715 433,933 AI754389AW295190 AI863355 AW131720 A1674922 A1949042 AI990060 AI623178 AW469497 AA620354 433941 AA62Q612 AA994963 AA994990 434303 434743 AI363410 H00141 AL079911 Z42602 AW452S23 A1223826 AJ633829 AA292122 AW50S595 M131836 AW607273 AA527132 T32315 AA421961 AA278868 AA700 434796 AA812046 AYV974514 AAS4S302 AA700946AA702712AA947620 436163 R84938 AL047151 AA310309 A1569528 49975 437215 438999 AA829050 439246 A AA965226 A1392809 AA206609 AA555262 N50847F27148 ?? 731186 ?? 417728 ?? 003145 440317 442462 442472 BE5618888S60615 BE5S2102 AW806852 445625 BE246743 AW024744 AW242177 AA436942 AA975476 AA317806 T57442 R48743 AI769689 AW189963 AW471273 H21954 73463 445631 A1590161 A1347975 A AW860325 AW130957 AW662527 AAS381S3T6SS6S AI380485 AA410698 AI520726 BE501355 AJ637925 AI524755 AVV593995AI336327 ?? 336,328 447,128 AI357036 AI452509 AI244810 A1553937 S853 H00719 A1765Z59 AW973696 F25787 F35749 A 059537 77127 44S241 BE26S481 AW407710 BE13882 AAOS3597 A1636283 AI557255 BE207794 RS9173 AA292343 AA339460 BE047245 AA730380 AA39 063 AA454 ty μ ??? n in Tate 26 et reios to tha The of 10 Plus Table 26 15 SEQ ID 1 DNA Sequence SEQ ID 3 DNA Sequence Acid Access Number Sequence Eos Sequence of 75 1 11 21 31 41 51 60 120 190 80 240 300 420 480 85 S40 SEQ 4 Protein Sequence Sequence Access Number Eos SEQ ID 5 DNA Sequence Acid Access Number AB051390 Sequence of il ID 6 Sequence of Access Protein of SEQ ID 7 DNA Sequence Access Number of Acid N 54 Sequence of 9 SEQ ID 8 Protein Sequence Access of SEQ ID 9 DNA Sequence Acid Access Number Sequence of STATTAAATT GGTG SEQ ID Access Number Sequence of Q9H8V3 IIIIII SEQ 1 DNA Sequence Acid Access Number 166 Sequence of 21 31 41 if SEQ 12 Access Number Sequence of IIII 5EQ 13 DNA Sequence Acid Access Number Sequence Eos Sequence of SEQ ID 15 DNA Sequence Access Number of Acid Sequence Eos Sequence of 1 11 Si GTGTGGCCAT 60 TTCAAGATAT TCCTTGTCAT C ATTTGTCTr CATGTCGTTC C 120 GATACTGATA ATTCCAGTTT GTCACCACCA CCTGATGTTA 180 AAAAAACTAA AATCACTATA GTAAAAACC TCAATGCTTC CCCCAGAGAA ATATCTGCAA TTTGTCATCT 300 GAGATCATGT TAAAOAAAGC ACTGTTCCCC AGAATCAACA TATAACGAAT 360 GAAT AAACA ATAATACAAT GAATGCATGT GCTGTAATAG CrGCTTTGGA AAGAGTAAAG 480 ATTCGACCAA TGGAACACTG CTG GTCAGGATAC CTCCCCAGAA 5 0 GAGTTGGAAA AGCTTCAGTG TGACCTGCAG TGACCATCCA 600 CG GG CAGCCAATCC ATCCCAGTGG 660 TCCCAGGTCC CCAAAGCTAC CT CAATAGG GGAGATTCAA CCCAGCCTTC CAGTCTGAAA CGAT TC CCCTATGCCC CAAAC TCTCCGGCAC CCCACCTCCT GTGAAAGCCT CATTTTCCTC TCCCACCGTG 900 CACTACCAGC TCCTG CATCGTCAAC 960 ACCAGCAGTA GTGT GCAGA TGGAGAAGGC TCTGTCCTTG 1020 AGCCTAACCT 1080 TG GC GGATGACATT 1140 G3CCTACAGC TTTGGCTCTG 1200 G TGTCAT A GAGTGAATGC CAGTAGTTTC AACACAACTA GGAAACCCAA 1320 TAATTTACCA TTCCAGGGTT 1380 CAGTTCAATT ACCTGCTTTG TTTCAGGATC CTTCCCTGGA GAA 1440 CTGATCAGCT ACGTCATATC GCAAACCTGA CCGTCAGGAA CT 1S00 AACGTGACAG GCACATCAAC ATGAGTTAAC AG GAGATGT 1560 GTATTTTGGG GGTCAGACAA 1620 GTCAAAGACA GGAGATTG AA TGAAACCATC CTGCCTGCTC AAATGATGGC TCTGACGTTC 1740 ATTACATATA TTGGTTGTGG GCTTTCATCA TGTAACCTAC ATAGCTTTTG AAAAGA GAGGGATTAC TCCTCATCCA GC TGCTGAACCT GGATTGCTCT GCATCTCAGT GG TG ATTT CT TTCTCTTGGT CTCATTCACA TAGAAGCATT CCATATGTAC TAATACTTAC 2040 GAAAAT ACATCCTTAA GGGTACCAGC TGTCGTOTG 2100 CCCAGATAAC GATCCTATGG GAAATTCCCC 2160 AA GGTTCAC CGGATGACTT CAGTATTCTA CATTACGGTG 2220 A AACGTCAGCA 22S0 GAATTAAAAA GAAGAAGCAA AGCGAAAAAC CAGTATTCAA 2340 GACCTCAGGA GTATCGCTGG C TAACTTGGGG 2400 CGTGACCTTC 2460 CAAGGATTTT GTGGCCAAAG AAAATG AGGCGGTATC AAAGTTACGG ATTCTGACTG GCTACTAATG GTTTAAAGAA AACCAAGGAG TGT CAG 264 CACTAACTCC TAGTGAATAA ACAGAGAGGA 2760 ACTGGAAAAC TAA GAGAAG 2820 GAAGATT GCGGGGAAGC 2880 SEQ ID 16 Protein sequence Accession Number Sequence Eos January 11 21 31 41 51 60 I RGPPFSSSCJS SQVPKATSPA 240 300 160 420 4S0 540 600 M 660 780 900 960 SEQ ID 17 DNA sequence Accession number of Acid Eos Sequence of 11 21 31 41 CTGTCAGGCA GTTGGCAGAA 60 TTCAAGATAT TCCTTGTCAT CATTTGTCTT CATG TCGTTC TGGTAACATC CCTGGAAGAA 120 GATACTGATA ATTCCAGTTT GTCACCACCA CCTGAGGTTG CCTCAATGAT 180 GTTACTTTAA TTCAAACGAA ACAGOCGTCA AAATATCTOC 0 SEQ ID 19 DNA sequence Accession Number Acid Sequence Eos Sequence III i CAGCTCCCAT 960 ACGATCTCTT 1020 OTCTGCCCCT 1080 GTCCAGACAG CACCAGCAGT TTGAGAACCA AGTGTTGCAG 1140 CTCTGTCCTT TCGCAGGAGA AATGATCAAC 1200 TTCCCCGCCT GACATGCTGG 1560 16 0 1680 40 1800 1860 1920 2040 2160 2280 2340 2400 SEQ ID 20 Sequence of Froteina Sequence Access Number Eos 31 51 III 1 I 60 120 E IMCATAEAQS 180 AALE PCPSSPEEXQ 240 300 360 540 600 660 CISVAVFLHY 780 AVFYITWGY FCTIFLLMVS 840 900 SEQ 21 DNA Sequence Acid Access Number 21 41 l CGGCAGGTG TCTCCACT 60 CTCGOSGTCA CAG ATGTTGGCM AACTGAAGAA 120 CGTTCAAGAT CT TC CTCGAAG TAATTCCAGT TTGTCACCAC CACCTGCTAA ATTATCTGTT 240 GTCAGTTTTG CAAICAGGTT GAAACAACAA GCCTCAATGA 300 AGCTTACTCC CTTCAAACGA AACAGAAAAA ACTAAAATCA CTATAGTAAA AACCTTCAAT 360 GCTTCAGGCG TCAAACCCCA GAGAAATATC TGCAATTTGT CATCTATTTG CAATGACTCA 420 GCAXTTTTTA GAGGTGAGAT CATGTTTCAA TATGATAAAG AAAGCACTOT TCCCCAGAAT 480 CAACATATAA CGAATGGCAC CTTAACTGGA GTCCTGTCTC TAAGTGAATT AAAACGCTCA 540 GAGCTCAACA AAACCCTGCA AACCCTAAGT GAGACTTACT 600 GAGGCCCAAA GCACATTAAA ACAATAAAAC TGAATAATAC AATGAATGCA 660 CTGCTGCTCT TCTGTCAGGA TACCCTGCCC GAAGAGTTGG GAAAGCTTCA 780 CAGGATCCCA CCACGTGGCC CACCATTTTC TTCCAGCCAA 840 TCCATCCCAG TGGTGCCTCG CTTTCCCAGG TCCCCAAAGC TACCTCTTTT 900 GCTGAGCCTC CAGATTATTC ACCTGTGACC CACAATGTTC CCTCTCCAAT 960 CAACCCCTTT CACCCCAGCC TTCAGCTCCC ATAGCTTCCA 1020 CCACAGTCTG AAACGATCTC ATGTCTCCGG 1080 CCTCATTTTC GTGTCTGCCC CTGCGAATCT CAACACTACC 1140 CTGTCCAGAC AGACATCGTC AACACCAGCA TCTTGAGAAC 1200 GGCTCTGTCC TTGGGCAGCC TGGAGCCTAA CCTCGCAGGA 1260 GAAATGATCA ACCAAGTCAG CAGACTCCTT CATTCCCCGC crGACATGCT 1320 GCTCAAAGAT TGCTGAAAGT AGTGGATGAC ATTGGCCTAC AGCTGAACTT G 1380 C TT CTGGC GTGA TCAGAGTGAA TGCCAGTAGT CCTGCAAATC TTCAGGTTTC 1H00 AGAA A GAATAATTTA 1560 ACATGGAG AGCTTCCAGG AACACCTGCT 1620 T GTTTCAGG 1680 GTTGCAAACC TGACCGTCAG GAACTTGACA AGAAACGTGA AAAGCACATC 1740 AACCCGAGCC AGGATGAGTT AACAGTGACA 1800 GGCAGAGGAG CAGA TCTOT 1860 GTAGCCATCT TAGGACATCT 1920 G TGGGCTTTCA 1980 TCAATTTTTC TCT TACATAGCTT 20 0 CCTGGTCTTC ATGCAAGGCC TCTGCATCTC 2160 TT ATTTT GGTCTCATTC ACATGGATGG TACCTGGCCC CGAA AATACATC 2280 TCCTGACTAT AGAT CACCGGATGA CTTCTGCTGG 2400 ATCAACAACA CTACATTACG GTGGTGGGAT ATTTCTGTGT GATATTTTTG 60 CG CGAATTAA AAAGAAGAAQ CAACTGGGAG AACCAGTATT CAAGACCTCA GGAG ATCGC 2580 GAATAACTTG G TT GGGGACCAGT TAACGTGACC 2640 ATC CTTTAATACC CATATT 2700 TGTGTGGCCA AAGAAAATGT CAGGAAGCAA ATCTTTGTTG TGGAAAGTTA 2760 AAAATTCTGA CTGGASTAAA TCCTTACAGT 2880 TCCACCACAC TAGTGAA TAATGATTGC TCAGTACAOS CAAGCGGGAA 2S40 TCTACAGAGA GGAATGGGGT GTTCAGAATG CCTTCACGAT GAAAGGCCGT 3060 AAAGCGGGGA AATGTGATTC AAATCAAAGC ACAGTGTGAA TTAC TTTTA 3180 CACAATGTGA AATC ACTCA TTTTATTCTC AAGCTAATTA AGGGCGATGA AAGAAGAAAC CAAGACATTA CACCATGCTT 3300 TTTAGACATT TCTGATTTGG T AAGAAGOTTG ATACACTAAO AATGACTCCT TAGTGAACTT TCAGCTACCT March 20 TTTGATAACA CAACTGTTGA TAGTTGTGCA TGCCTTTGTT TAAATTCTAG TGACCCATGT 3540 T ACT TACTGTGTAA ATGTATTCCT 3600 TTGTAGAATC ATGGTTGTTT TGTCTCACGT GATAATTCAG 3 GCTCCTTTTG AGGATGTGAA ATACAGAAAC CTCAGTGAAA 3720 TCAAGAAATA ATGATCCCAG CAGACAGTG CACAGTTAGC TCATACAGTS AGATGCCCCC ACTGGGCAGA 3840 AGCCCCACTC ACC TCTTGG 3900 C AATATGAA TACCCATCCC CTGACCSCAT 3960 AATCTG TTCGCXACAG 4020 AGAGGGATGA TCAGGAAAAT IGTGAACGTA GATGAGGTAC 4080 ATACACTGCC AGGAGAGTAG ACIAGGATTC 4140 AAAGS ACAT AAAAATCATA TTGCCGTTCT TTAAA ACGCA 4200 ACTGCATGGT ACATTGTTGA TTGTTATGAC TOGCCCAGCC AGAGCTATAA 4260 TTGTTTTTTA AATGTGTCTT GAAGAATGCA GGGAGTAGCT ATTGGGAACA 4320 ATTGTTGCTA CATGTATCGA GCCTTGATTG 4380 TATACAGGGT CTATCTTGCT ATCTGCT GA GCAGTGCCTC AAGTACATCC 4440 TTATTAGGAA CATTTCAAAC CCCTTTTAGT TAAGTCTTTC ACTAAGGTTC TCTTGCATAT ATTTCAAGTG AATGTTGGAT CTCAGACTAA CCATAGTAAT AATACACATT 4560 CTGACTTGTC TTTGCAATAT ATTTATTTAA TTTATATCtTT 4620 AAAATCAAAA ATGTTAAAAT CAATGAAATA AATTTG AGT TAAGA SEQ ID 22 Sequence of Protelna Access Number of 1 11 41 51 IIIIII PAJXSWSFA 60 120 RSELNKrLOT 180 RVKIRPMEHC CCSVRIPCPS LQC 240 SQSIPWP A EIQPLSPQPS 300 PPPVKASFSS PTVSAPANTO 360 PLAQRLL W 420 480 S40 KGGRGGHSDM ETICTCSHLT 660 AV 720 WVTIILTIS 780 SIQDLRSIAG 840 CCG 960 SEQ ID 23 Sequence DNA Acid Access Number Sequence of 51 660 780 15 960 1020 1080 20 SEQ ID 24 Protein Sequence SEQ ID 27 DNA Sequence Acid Access Number N IIIII Sequence 75 80 85 SEQ 28 Protein Sequence Acc Accident Number that of I I II SEQ 29 DNA Sequence Acid Access Number IIIIII Sequence SEQ ID 30 Sequence of SEQ ID 33 DNA Sequence Acid Access Number Sequence of li i SEQ ID 35 DNA Sequence Acid Access Number Sequence of ID 37 Sequence of DNA Acid Access Number Protein Sequence SEQ ID 39 Acid DNA Access Sequence of Coding SEQ 40 Protein Sequence Access Number of SEQ ID 41 DNA Sequence Acid Access Number Sequence of IIIGII SEQ 42 Sequence of Number SEQ ID 43 Access DNA Sequence Acid Access Number IIIIII Sequence r Protein Sequence IIIIII Access Number DNA Sequence Acid Access Number Sequence of SEQ 46 Protein Sequence Accession Number of SEQ ID 47 Sequence of DNA Acid Access Number N Sequence of SEQ ID 49 DNA Sequence Acid Access Number Sequence of 1 I SEQ ID 50 Protein Sequence Access Number of S EQ ID 51 DNA Sequence Acid Access Number Sequence of SEQ 54 Protein Sequence Accession Number of SEQ ID 55 DNA Sequence Access Number of Acid N Sequence of SEQ ID 57 DNA Sequence Acid Access Number Sequence of SEQ 58 from Pro SEQ ID 59 DNA sequence Acid Access Number Sequence from I 1 IIII SEQ ID 61 DNA sequence Acid Access Number Sequence from SEQ 62 Sequence from Protelna Access Number from SEQ ID 63 DNA Sequence Access Number of Acid Sequence of il SEQ ID 64 Protein Sequence Access Number of II lli SEQ ID DNA Sequence Acid Access Number Sequence of I l I SEQ 67 DNA Sequence Acid Access Number Sequence Eos Sequence of 1 11 31 41 51 lii i SEQ ID 68 Protein Sequence SEQ ID 69 DNA Sequence Acid Access Number Sequence of 1 11 21 31 41 I Protein Sequence DNA Sequence Access Number Acid Access Number Sequence of SEQ ID 72 Sequence Number of SEQ ID 73 DNA Sequence Acid Access Number X Sequence of SEQ ID 74 of de of XP 057014 SEQ ID 75 DNA Sequence Acid Access Number BC010423 Sequence of SEQ 76 Sequence of Access Number of AAH10423 SEQ ID 77 DNA Sequence Acid Access Number SEQ ID 78 Protein Sequence IIIIIII Accession Number TCCCAGAGCC 1020 1140 1200 CCGTCGGGTC CCAGGGAGGG GCAGGGCAAG 1380 1440 1500 1560 AGGAGTGTCA TT CTATCTO 1680 TGTCTGGGCT GGGGGGGGACA TATTTTAACC 1740 ATCTCGATT ACAAAGCAAC AAA CAGCTC AAAACCAG GA? GG 1960 CACTTGGGGG AAACCTTATA 3GAA 2040 2100 AGCTCGAAAC C 2160 C TACATA 2220 GACIGCTGAA TTCCAGATCC AGGAGAGGAG TCCAAQGGGA CAAATAAAGG GAGAOAGAGA GGGAGAGOAA GAAAAGAGAQ AGASAAAAGA G SEQ ID 80 Pro Access Number Sequence 1 11 21 31 41 iil 60 GDVGCGVFEC DALKCX 120 180 300 SEQ ID 81 Sequence DNA Acid Access Number Cluster Cat 1 11 21 31 41 IIIIII 60 TG ACAGACA 120 100 AATACAT CAATGCAGAC TGACCATATT 240 CA GGAAGAAG ACATCCTCAO CCCACCACCC CTTCCCCTCC 300 TCAACIGATA AGCAGTGCAG GCTTTGT 420 AAAGATCTOA AAGAAGACCT AT A TGGGACGTCC 600 660 AAA rr TCCGG OCCCAAAAAC ACCAGAACTA TTACGAAATG CAQ ACC TG SEQ ID 82 DNA sequence Acid Access Number Sequence of 1 11 31 III AIGCCAAATA 60 XGAGCX T GG iGCa 240 GGCAAACGAA G AAAGAAAC TGGACATCAT 360 OAAAGSGAGC 420 GTCTGGACAT AGGGTCAGAQ 480 T 540 CAAAGGAGG3 CGCACGGAGA 600 GGAAGTCC A CXAAG 720 GGTG TTTCCCAGST GGGAGGAGCT A rCGG C 900 960 1020 TGCCCGCTGG GGAGG GGAGGCTAAC 1080 GCGGGCACCA CTCTGGACGO GCCAAAGTCT TCGTGAAGCG GTTTGTGCGG GCCGTGCTGA GCGAGGACTC CCACATACAG CAGGGAGCtG SEQ 83 Sequence Protelna Accession Number IIII SEQ ID 84 DNA sequence Acid Access Number Sequence Eos Sequence of IIIII 2040 SEQ ID 85 Protein Sequence of Secu Eos SEQ 86 DNA Sequence Acid Access Number Sequence Eos Sequence of SEQ ID 87 Protein Sequence Access Number of Sequence Sequence Eos l II SEQ 88 DNA sequence Acc number that of Acid Sequence of SEQ ID 91 Protein Sequence Access Number of 21 31 41 IIIIII SEQ ID 93 Protein Sequence Accession Number of NP 35 IIII 1 I 80 SEQ ID 95 Protein Sequence Accession Number of I SEQ ID 97 Protein Sequence Accession Number of SEQ ID 98 Acid Access DNA Sequence SEQ ID 100 DNA Sequence Acid Access Number Sequence of SEQ ID 101 Access Protein Sequence of SEQ ID 102 DNA Sequence Acid Access Number AK025790 of ID 103 Access Protein Sequence of SEQ 104 DNA Sequence Number Acid Access Sequence Protein Sequence SEQ ID 106 DNA Sequence Access Acid Number Sequence 1968 SEQ ID 108 DNA Sequence Acid Access Number Sequence Sequence Protein SEQ ID 110 DNA Sequence Acid Access Number Sequence Eos SEQ ID 111 Sequence of Protein Accession Number of SEQ ID 112 Sequence of DNA Accession Number of Acid Sequence Eos Sequence of TGCAAATTAT SEQ 113 Sequence of Protein Accession Number of Sequence Eos SEQ ID 114 Sequence of DNA Acid Access Number Sequence Eos Sequence of SEQ ID 115 Sequence of Protein Sequence Access Number Eos SEQ 117 Sequence Access Number Sequence Eos SEQ ID 118 DNA Sequence Acid Access Number Sequence of 119 Protein Sequence Accession Number of I 1 I 1 II SEQ ID 120 DNA Sequence Acid Access Number Sequence of I 1740 1860 1 198 2040 2100 2160 22 2340 3 2580 2700 28 0 SEQ 121 Protein Sequence Number of Protein Sequence Access of 1 21 31 60 G 120 180 240 PPVESEAAQS 300 IEYLSSY 3 TS 780 CTCCCACATG A AGTGC 840 TCGAGCTCTA CTGAAGCCAA AACC GGAT 900 AAG 960 1020 1080 G ATTTAGGGG G AATTCA 1140 AGXTCTTGAA GGGAAGGGCT CGATTCACGA TCAAAAAGGC AGC 1320 T 1380 GAS CTC GAAAAGTCAfl TGTGGAGAGA TTCGC 1S60 GGTTAT 1620 TT AGAAAAT GAAAOCTTCC TTCATAGTTC 1740 TGGCGATGAC AAAGATAATQ AGCGTGAACA TGAACGTGAA GTGAAC3TG AGCGCGGGGA 1800 AG AGAAA ATGTATGGTA AAGAGAAAAT GTACGAATGT XAGGTGTGTG 1920 GAAAATCCAT ACTAGAGGGA AAACAAGG GT AGGAAA 1980 TATTCCTGGT CAGTCCCTTA AAAGGCGTCA GAAÍACTTAC AATAAGGAGA AGCTCTGTGA CTTTACAGAT GGCCGGGATG CCTTCATGCA AAGCTCAGAO CTCAGTGAGC ATCAGAAAAI 2100 TCATTCTCGA AAGAACCTCT TTGAAGGCAG AAATCTGTCA TTCATAGTGG 2160 GCCATTCACT GAATCTCAGA AGAGTCATAC TATAACAAGA CCTCTTGAAA 2220 TTCACCATTA GCTCTAACCC AAATGTCTAC GAGGCAAAAT CATATGAGAG GTCTGTTATT C TCTGTGGA 2340 ASCTCAGAAA AGTCACAGTG TAGCAGOGCC CAGTAAACCA CAGAGTCTAC 2400 CATTCAGAGC TTCGATGCTA TCAACCATCA TACAGTAGGT CTGTTATCCA TAGCTTAOTO GCTTCCAAAjC CTCCAAGAAG 2520 TCACAATGGA AATGAATTGG TGGAATCTAA TGASAAGGGA TC GATAAGCGAC AGAAGATTCC AACCCTTGTO 2640 TAAGAATCGC AACTATGAAG ACTCTGTCAT ACAGAGTGTA 2700 AAGTGTTCCT GGAGAGGGAT OGCOAATTCT CTCTTCCCAO 2760 TGCTAAAAAÜ AAATACAT 2820 SEQ ID 123 Sequence Protein Accession Number January 11 21 41 51 III DGEAAEPIGE SEQ ID 124 Sequence DNA Accession Number Acid N Sequence of 1 IIIII SEQ ID Protein Sequence Accession Number of NP 009127 lii í SEQ ID 126 Acid Access DNA Sequence or N Sequence of lili SE SEQ ID 127 Protein Sequence Accession Number of iiiii SEQ ID 128 DNA Sequence Acid Access Number Sequence Eos Sequence of SEQ ID DNA Sequence Acid Access Number Sequence of ri SEQ ID 131 Sequence of Protein IIIIII Accession Number SEQ ID 132 DNA Sequence Acid Access Number Sequence of ss SEQ 138 Sequence of Protelna Sequence Access Number Eos SEQ ID 139 DNA Sequence Access Number of Arid Sequence of SEQ ID 140 Sequence of SEQ ID 141 Access DNA Sequence SEQ ID 142 Protein Sequence Sequence Access Number of Eos SEQ ID 143 DNA Sequence Acid Access Number X Sequence of SEQ ID 144 Sequence of Protelne Access Number of SEQ ID Sequence of Protein SEQ Access Number 147 DNA Sequence Acid Access Number ID 148 Protein Sequence Accession Number of SEQ ID 149 DNA Sequence Access Acid Number Sequence of TTCCAGGCTC GGCCGCXGCC GGGAGCGCTG ACX ATTGGGAGAT GTACCTCGAA GGGGCCGCAG CAAAACAGAT AACACTGAGG CTTCTGCCGT CCTA TGGAACCTAC TCA CACCAAAGGG 350 ATTTCTCTAC TATTCTTAGT AGCGCCTTCC CAATCACCAA CCGTG3AGGT TCATAACCCA TTCTGAAAGT CATCACTAAG AGCTCATTGT AAAAAAGTTA CGAAAAACAA AAGATTTGGT TGCCAGCATA AT GCATTGAGGA GGGGCTGGGC GGGTGCTGGT TCTTCATCAT CCACGCGTCC AGGGGA AAAAAAAAAA SEQ ID 150 Sequence Protelna access number IIIIII SEQ ID 151 Sequence DNA Accession Number Sequence acid AGCAAGTTTG C CCTATAAATA ATGATGATAA AAAAGAAGQA AGAAGCAGAC AAGAAGAAGA CTATTATAGA TTCTACATCC GGTCTGGCTC CAGGGAAGAG TGATGATTGC AAATAGCCGT AACCTCATCA ACCGG AAAC CAGAGGAATA ACTTCTGGCA GTCTACTGAT AACAGCCTTC TTGG ACCC ACAOCACATT 960 CCATAGCAAG 1080 ACATTATGA SEQ ID 152 Sequence Protein Accession Number 1 11 21 31 51 IIIIII 60120240 TSGSSGQSTD EPSFEPEDED TEFE 360 Ti SEQ ID 153 DNA sequence Acid Access Number N Sequence of 1 11 21 31 41 51 lilil í CAGAGTCACr GSAAAGTCCT 120 AGTCTGTCCT 180 TTGTCCTGAC 240 ACCCAACAAG CAGTGACTTA 300 360 G 420 TATGGAGGA G AC CTGATATCCT CC ACACAG C ATCAATGAAT AAATAAACGA SEQ ID 154 Protein Sequence Accession Number of 1 11 llil SO KA SEQ ID DNA Sequence Acid Access Number Sequence of 1 11 41 IIIIII AATTCGSCAC GAGGGCAGGT SO CCGCAGCTCC 120 AG OGGAGCCACC CGGTGGAGCS 180 CGGGCACCGC 240 GCGTTGC CA GTCGGCCTTC 300 ATCGGCAGCA ATCTGGGAG3 GAACTGCGTG 360 GTO 420 C AA AGGACGA AC 540 CTTCTCGCCG 600 CATTATCCGa ACCCCOTGGT GCCCGAGGCG 660 CTGCTCSTGT AGAAGAAGTA CACGGCCACC AAGGTCGTCT A TCCSCGCC GCAGGGAGAC CCACCACCAC 900 CAACACCACC ACCAC ACCS CGAGCTGGAQ CGCGCACCAO GCCATCCAGC fflGCAGCCTT 960 GCCTCGGAGG CCAGCCCACC CCCAGAAGCC A03AAGCCCC CGCGCTGGAC TGGGGCAGCT 1020 CGGGGCCCAG GGACCAACCT 1080 GCATGGA TGAAACCrCA CCCTTCIGGA QCACGGGGCC TGGGTGACCG CCAATACTTG 1140 CCCCCATGTC GGGACC3GCA 1200 GCCCTGGAAG GGGCACITGA TATTTTTCAA TAAAAGCCTC TCGTTTTAGC SEQ ID 156 Protein Sequence Accession Number 11 21 31 41 51 IIIIII 60 AQCTHCVQDD 120 SEQ ID 157 DNA Sequence Access Number N Acid Sequence ia January 11 31 31 41 IF I 1 IIII ATGCCCCTAG G CrCCTGTG GCTGGGCCTA GCCCTGTTS3 GGGCTCTGCA C 60 CAGGACTCCA GCAAGOTCCC CCAGGGGAAQ TGGTATGTGG AGGGAATGCA AAGACAAAGA CCCGCAAAAG CTACTGGATC AGGACTTTTG TTCCAGGTTG CCAGCCCGGC TGGGCAACAT TAAGAGTTAC C TGGATTAA CGAGTTAC G GAG ACCA ACTACAACCA GCATGCTATG 420 ACCAAGGAGC TGACTTCGGA ACTAAAGGAG AACTTCATCC TGAAA ACCACATCGT CTICCCTGTC AG GTATCGA GA SEQ ID 1S8 Sequence of Protelna Access Number of 1 11 21 31 41 lll SY 120 SEQ 159 DNA Sequence Access Number of Acid Sequence of 11 31 41 ll AGGAATCTGC GCTCGGGTTC CGCAGATGCA ACTGGAAGTC 60 ATCSGGCAGA AC rGGGG COCTCCTCCC 120 CATGAGGATT TCTGGCAACA GGGOAGAGAC 180 CAGGATCATC AGT3CAAGCC TCACTCCCAC CCCTOGCAQG 240 GCTCATCGCC CCCAGATGGC TCCTGACAGC 300 AGCCCACTGC rCACCTGGCa GGAGGGCTGT GGACAGCCAC TGAGTCCTTC 420 CAGCCTCCCC AACAAAGACC ACC3CAATGA CATCATGCTS GTGAAGATGG CATCGCCAGT 480 CTCCATCACC TGSGCTGTGC GACCCCTCAC CCTCTCCTCA 540 GGGGCAGCAC STCCAOCCCC CAGTTACGCC TGCCTCACAC CTTOCGATGC CCATCATTGA GCACCAGAA G TGTGAGAACG CCTACCCCGO CAACATCACA GACACCATG TGTOTGCCAG CGTGCAGGAA GGGGGCAAGG ACTCCTGCCA 720 GGGTGACTCC GGGGGCCCTC TGGTCTGTAA CCAGTCTCTT CAAGGCATTA TCTCCTGGGG CCAGGATCCa TGTGCGATCA CCCGAAAGCC ACGAAAGTCT GCAAATATGT CAGSAGACGA TTAGACTGGA CCCACCCACC ACAGCCCATC 900 ACCCTCCATT TCCACTTGGT GTT TAAGA AACCCTAAGC CAAGACCCTC TACGAACATT CTTTGGGCCT CCTGGACTAC AGGAGATGCT GTCACTTAAT 1020 GGGTTCGAAA TCAGTGAGAC ATTCTGCCTT 1080 CTCTGTTGTA TCCCCAGCCC CAAAGACAGC 1140 TCCTGGCCAT ATATCAAGGT TTCAATAAAT TGAGTG SEQ ID 160 Protein Sequence Accession number of 1 11 21 31 41 SI lii í 60 120 180 QDPCAITRKP 240 It is understood that the examples described above do not in any way serve to limit the true scope of this but rather are presented for all purposes. The sequences of numbers of and patent applications cited herein are hereby incorporated by reference as if each publication or patent application ind were specifically and individually indicated. ividual as incorporated by insufficientOCRQuality